Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 235
Encontrada(s) 3 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Gamma rays as leptonic portals to energetic neutrinos: A new Monte Carlo approach

  • Marco, Gaetano di
  • Alves Batista, Rafael
  • Sánchez Conde, Miguel Ángel
High center-of-mass electromagnetic (EM) interactions could produce decaying heavy leptons and hadrons, leading to neutrino generation. These processes might occur in the most extreme astrophysical scenarios, potentially altering the expected gamma-ray and neutrino fluxes in both the hadronic and the leptonic pictures. For instance, neutrinos could arise from high-redshift EM cascades, triggered by gamma rays beyond 1018 eV scattering background photons, from radio to ultraviolet energy bands. Such energetic gamma rays are predicted in cosmogenic models and in scenarios involving non-standard physics. On astrophysical scales, leptonic production of neutrinos could take place in active galactic nuclei cores, where several-TeV gamma rays interact with the X-ray photons from the hot corona. We explore these scenarios within the CRPropa Monte Carlo code framework, developing dedicated tools to account for leptonic production and decay of heavy leptons and hadrons. In particular, the latter are performed by interfacing with the PYTHIA event generator. With these novel tools, we characterise the spectrum and flavour composition of neutrinos emerging from cosmological EM cascades and from leptonic processes in the core of active galactic nuclei. Finally, we investigate the leptonic production of neutrinos in the context of the IceCube detection of NGC 1068, GDM’s work is supported by FPI Severo Ochoa PRE2022-101820 grant. GDM also thanks the Institut d’Astrophisique de Paris, where part of this work was carried out, for the hospitality. This work was funded by the ‘‘la Caixa’’ Foundation, Spain (ID 100010434) and the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648, fellowship code LCF/BQ/PI21/11830030. The work of GDM and MASC was also supported by the grants PID2021-125331NB-I00 and CEX2020001007-S, both funded by MCIN/AEI/10.13039/501100011033 and by ‘‘ERDF A way of making Europe’’. The authors also acknowledge the MultiDark Network, ref. RED2022-134411-T. RAB acknowledges the support from the Agence Nationale de la Recherche (ANR), project ANR-23-CPJ1-0103-01
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

On the generality of symmetry breaking and dissipative freezing in quantum trajectories

  • Tindall, Joseph
  • Jaksch, Dieter
  • Sánchez Muñoz, Carlos
Recently, several studies involving open quantum systems which possess a strong symmetry have observed that every individual trajectory in the Monte Carlo unravelling of the master equation will dynamically select a specific symmetry sector to ‘freeze’ into in the long-time limit. This phenomenon has been termed ‘dissipative freezing’, and in this paper we argue, by presenting several simple mathematical perspectives on the problem, that it is a general consequence of the presence of a strong symmetry in an open system with only a few exceptions. Using a number of example systems we illustrate these arguments, uncovering an explicit relationship between the spectral properties of the Liouvillian in off-diagonal symmetry sectors and the time it takes for freezing to occur. In the limiting case that eigenmodes with purely imaginary eigenvalues are manifest in these sectors, freezing fails to occur. Such modes indicate the preservation of information and coherences between symmetry sectors of the system and can lead to phenomena such as non-stationarity and synchronisation. The absence of freezing at the level of a single quantum trajectory provides a simple, computationally efficient way of identifying these traceless modes, C.S.M. acknowledges that the project which gave rise to these results received the support of a fellowship from "la Caixa" foundation (ID 100010434) and from European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 847648, with fellowship code LCF/BQ/P120/11760026, and financial support from the Proyecto Sinérgico CAM 2020 Y2020/TCS-6545 (NanoQuCo-CM). DJ and JT acknowledge funding from EPSRC grant EP/P009565/1. DJ also acknowledges funding from the Cluster of Excellence ‘Advanced Imaging of Matter’ of the Deutsche Forschungsgemeinschaft (DFG) - EXC 2056 - project ID 390715994. We are also grateful to Berislav Buˇca for discussions on dissipative freezing and for suggesting the coupled model
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Systematic comparison of atomistic force fields for the mechanical properties of double-stranded DNA

  • Roldán Piñero, Carlos
  • Luengo Márquez, Juan
  • Assenza, Salvatore
  • Pérez Pérez, Rubén
The response of double-stranded DNA to external mechanical stress plays a central role in its interactions with the protein machinery in the cell. Modern atomistic force fields have been shown to provide highly accurate predictions for the fine structural features of the duplex. In contrast, and despite their pivotal function, less attention has been devoted to the accuracy of the prediction of the elastic parameters. Several reports have addressed the flexibility of double-stranded DNA via all-atom molecular dynamics, yet the collected information is insufficient to have a clear understanding of the relative performance of the various force fields. In this work, we fill this gap by performing a systematic study in which several systems, characterized by different sequence contexts, are simulated with the most popular force fields within the AMBER family, bcs1 and OL15, as well as with CHARMM36. Analysis of our results, together with their comparison with previous work focused on bsc0, allows us to unveil the differences in the predicted rigidity between the newest force fields and suggests a roadmap to test their performance against experiments. In the case of the stretch modulus, we reconcile these differences, showing that a single mapping between sequence-dependent conformation and elasticity via the crookedness parameter captures simultaneously the results of all force fields, supporting the key role of crookedness in the mechanical response of double-stranded DNA, The project that gave rise to these results received the support of a fellowship from the “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon research and innovation programme under Marie Skłodowska-Curie grant agreement no. 847648. The fellowship code is LCF/BQ/ PI20/11760019. S.A. acknowledges support from MCIN/AEI/ 10.13039/501100011033 and FSE + through a Ramón y Cajal Fellowship (ref. RYC2022-037744-I). We acknowledge support from the Ministerio de Ciencia e Innovación (MCIN) through the project PID2020-115864RB-I00 and the “María de Maeztu” Programme for Units of Excellence in R&D (grant no. CEX2018-000805-M)
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Permutational symmetry for identical multilevel systems: A second-quantized approach

  • Ferreira da Silva, Rui Emanuel
  • Feist, Johannes
We develop a framework that provides a straightforward approach to fully exploit the permutational symmetry of identical multilevel systems. By taking into account the permutational symmetry, we outline a simple scheme that allows us to map the dynamics of N identical d-level systems to the dynamics of d bosonic modes with N particles, achieving an exponential reduction on the dimensionality of the problem in a simple and straightforward way. In particular, we consider the Lindblad dynamics of several identical multilevel systems interacting with a common subsystem under the action of collective dissipation terms
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Interaction between giant atoms in a one-dimensional structured environment

  • Soro, Ariadna
  • Sánchez Muñoz, Carlos
  • Kockum, Anton Frisk
Giant atoms, quantum emitters that couple to light at multiple discrete points, are emerging as a new paradigm in quantum optics due to their many promising properties, such as decoherence-free interaction. While most previous work has considered giant atoms coupled to open continuous waveguides or a single giant atom coupled to a structured bath, here we study the interaction between two giant atoms mediated by a structured waveguide, e.g., a photonic crystal waveguide. This environment is characterized by a finite energy band and a band gap, which affect atomic dynamics beyond the Markovian regime. Here we show that, inside the band, decoherence free interaction is possible for different atom-cavity detunings, but is degraded from the continuous-waveguide case by time delay and other non-Markovian effects. Outside the band, where atoms interact through the overlap of bound states, we find that giant atoms can interact more strongly and over longer distances than small atoms for some parameters, for instance, when restricting the maximum coupling strength achievable per coupling point. The results presented here may find applications in quantum simulation and quantum gate implementation, Swedish Research Council (Grant No. 2019-03696), Knut and Alice Wallenberg Foundation through the Wallenberg Centre for Quantum Technology, Caixa Foundation (Grant No. 100010434), European Union’s Horizon 2020, Marie Skłodowska-Curie Grant Agreement No. 847648
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Quantum state tomography with conditional generative adversarial networks

Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Unconventional mechanism of virtual-state population through dissipation

  • Vivas-Viaña, Alejandro
  • González-Tudela, Alejandro
  • Muñoz, Carlos Sánchez
Virtual states are a central concept in quantum mechanics. By definition, the probability of finding a quantum system in a virtual state should be vanishingly small at all times. In contrast to this notion, we report a phenomenon occurring in open quantum systems by which virtual states can acquire a sizable population in the long-time limit, even if they are not directly coupled to any dissipative channel. This means that the situation in which the virtual state remains unpopulated can be metastable. We describe this effect by introducing a two-step adiabatic elimination method, which we termed hierarchical adiabatic elimination, that allows one to obtain analytical expressions of the timescale of metastability in general open quantum systems. We show how these results can be relevant for practical questions such as the generation of stable and metastable entangled states in dissipative systems of interacting qubits
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Engineering long-lived vibrational states for an organic molecule

  • Gurlek, Burak
  • Sandoghdar, Vahid
  • Martín Cano, Diego
The optomechanical character of molecules was discovered by Raman about one century ago. Today, molecules are promising contenders for high-performance quantum optomechanical platforms because their small size and large energy-level separations make them intrinsically robust against thermal agitations. Moreover, the precision and throughput of chemical synthesis can ensure a viable route to quantum technological applications. The challenge, however, is that the coupling of molecular vibrations to environmental phonons limits their coherence to picosecond time scales. Here, we improve the optomechanical quality of a molecule by several orders of magnitude through phononic engineering of its surrounding. By dressing a molecule with long-lived high-frequency phonon modes of its nanoscopic environment, we achieve storage and retrieval of photons at millisecond timescales and allow for the emergence of single-photon strong coupling in optomechanics. Our strategy can be extended to the realization of molecular optomechanical networks
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Squeezed lasing

  • Sánchez Muñoz, Carlos
  • Jaksch, Dieter
We introduce the concept of a squeezed laser, in which a squeezed cavity mode develops a macroscopic photonic occupation due to stimulated emission. Above the lasing threshold, the emitted light retains both the spectral purity of a laser and the photon correlations characteristic of quadrature squeezing. Our proposal, implementable in optical setups, relies on a combination of the parametric driving of the cavity and the excitation by a broadband squeezed vacuum to achieve lasing behavior in a squeezed cavity mode. The squeezed laser can find applications that go beyond those of standard lasers thanks to the squeezed character, such as the direct application in Michelson interferometry beyond the standard quantum limit, or its use in atomic metrology
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Phylogenetic signal in primate tooth enamel proteins and its relevance for paleoproteomics

  • Fong-Zazueta, Ricardo|||0000-0003-1212-7837
  • Krueger, Johanna|||0000-0002-2685-718X
  • Alba, David M.|||0000-0002-8886-5580
  • Aymerich Núñez de Arenas, Xènia|||0000-0002-5848-1068
  • Beck, Robin|||0000-0002-7050-7072
  • Cappellini, Enrico|||0000-0001-7885-7811
  • Carrillo-Martin, Guillermo
  • Cirilli, Omar|||0000-0001-8478-1462
  • Clark, Nathan|||0000-0003-0006-8374
  • Cornejo, Omar E.|||0000-0003-4076-4227
  • Farh, Kyle Kai-How|||0000-0001-6947-8537
  • Ferrández-Peral, Luis|||0000-0003-0338-0603
  • Juan, David|||0000-0003-1912-9667
  • Kelley, Joanna|||0000-0002-7731-605X
  • Kuderna, Lukas F. K.|||0000-0002-9992-9295
  • Little, Jordan|||0000-0002-8590-9357
  • Orkin, Joseph|||0000-0001-6922-2072
  • Paterson, Ryan S.|||0000-0003-0260-9947
  • Pawar, Harvinder|||0000-0002-3852-4999
  • Marquès i Bonet, Tomàs|||0000-0002-5597-3075
  • Lizano, Esther|||0000-0003-3304-9807
Ancient tooth enamel, and to some extent dentin and bone, contain characteristic peptides that persist for long periods of time. In particular, peptides from the enamel proteome (enamelome) have been used to reconstruct the phylogenetic relationships of fossil taxa. However, the enamelome is based on only about 10 genes, whose protein products undergo fragmentation in vivo and post mortem. This raises the question as to whether the enamelome alone provides enough information for reliable phylogenetic inference. We address these considerations on a selection of enamel-associated proteins that has been computationally predicted from genomic data from 232 primate species. We created multiple sequence alignments for each protein and estimated the evolutionary rate for each site. We examined which sites overlap with the parts of the protein sequences that are typically isolated from fossils. Based on this, we simulated ancient data with different degrees of sequence fragmentation, followed by phylogenetic analysis. We compared these trees to a reference species tree. Up to a degree of fragmentation that is similar to that of fossil samples from 1-2 million years ago, the phylogenetic placements of most nodes at family level are consistent with the reference species tree. We tested phylogenetic analysis on combinations of different enamel proteins and found that the composition of the proteome can influence deep splits in the phylogeny. With our methods, we provide guidance for researchers on how to evaluate the potential of paleoproteomics for phylogenetic studies before sampling valuable ancient specimens.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Water-hydroxide trapping in cobalt tungstate for proton exchange membrane water electrolysis

  • Ram, Ranit|||0000-0002-7999-5551
  • Xia, Lu
  • Benzidi, Hind|||0000-0002-9705-2389
  • Guha, Anku|||0000-0003-4533-6336
  • Golovanova, Viktoria|||0000-0002-4008-0733
  • Garzón Manjón, Alba|||0000-0003-2954-1102
  • Llorens Rauret, David|||0000-0001-5359-5456
  • Sanz Berman, Pol|||0000-0001-8736-404X
  • Dimitropoulos, Marinos|||0000-0002-1466-4575
  • Mundet, Bernat|||0000-0003-0608-2070
  • Pastor, Ernest|||0000-0001-5334-6855
  • Celorrio, Veronica|||0000-0002-2818-3844
  • Mesa, Camilo A.|||0000-0002-8450-2563
  • Das, Aparna M.|||0000-0001-7250-1291
  • Pinilla-Sánchez, Adrián|||0000-0002-4532-942X
  • Giménez, Sixto|||0000-0002-4522-3174
  • Arbiol i Cobos, Jordi|||0000-0002-0695-1726
  • López, Núria|||0000-0001-9150-5941
  • García de Arquer, F. Pelayo|||0000-0003-2422-6234
The oxygen evolution reaction is the bottleneck to energy-efficient water-based electrolysis for the production of hydrogen and other solar fuels. In proton exchange membrane water electrolysis (PEMWE), precious metals have generally been necessary for the stable catalysis of this reaction. In this work, we report that delamination of cobalt tungstate enables high activity and durability through the stabilization of oxide and water-hydroxide networks of the lattice defects in acid. The resulting catalysts achieve lower overpotentials, a current density of 1.8 amperes per square centimeter at 2 volts, and stable operation up to 1 ampere per square centimeter in a PEMWE system at industrial conditions (80°C) at 1.77 volts; a threefold improvement in activity; and stable operation at 1 ampere per square centimeter over the course of 600 hours.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Symmetric multifield oscillons

  • van Dissel, Fabio|||0000-0003-2347-8931
  • Sfakianakis, Evangelos I.|||0000-0002-1525-2433
Oscillons are long-lived, spatially localized field configurations, which are supported by attractive nonlinearities in the scalar potential. We study oscillons comprised of multiple interacting fields, each having an identical potential with quadratic, quartic and sextic terms. We consider quartic interaction terms of either attractive or repulsive nature. In the two-field case, we construct semianalytical oscillon profiles for different values of the potential parameters and coupling strength using the two-timing small-amplitude formalism. We use analytical and numerical techniques to explore the basin of attraction of stable oscillon solutions and show that, depending on the initial perturbation size, unstable oscillons can either completely disperse or relax to the closest stable configuration. We generalize our analysis to multifield oscillons and show that the governing equations for their shape and stability can be mapped to the ones arising in the two-field case. Finally, we study the emergence of multicomponent oscillons in one and three spatial dimensions, both numerically and through Floquet theory.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Oscillon spectroscopy

  • van Dissel, Fabio|||0000-0003-2347-8931
  • Pujolàs Boix, Oriol|||0000-0003-4263-1110
  • Sfakianakis, Evangelos I.|||0000-0002-1525-2433
The sine-Gordon model in 3+1 dimensions is known to admit two oscillons of different energy and frequency but comparable lifetime. We show that the oscillon spectrum includes more spherically symmetric "states". We identify new high-amplitude oscillons by allowing the field profile to have a number of nodes. For each number of nodes, we find 2 states with a comparable lifetime to the nodeless ones. Oscillons with nodes are, however, unstable to non-spherical perturbations and so their lifetime is significantly reduced. Interestingly, these states are seen to fragment into a collection of nodeless oscillons. The heavy nodeless oscillon is quite remarkable: despite its energy, it is stable against fragmentation. Moreover, it has considerably small oscillation frequency, meaning that it can be interpreted as a rather relativistic bound state.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cosmic birefringence from the Axiverse

  • Gasparotto, Silvia|||0000-0001-7586-1786
  • Sfakianakis, Evangelos I.|||0000-0002-1525-2433
We revisit the evidence for CMB birefringence in the context of a rich Axiverse. Using probability density functions (PDFs) for various axion parameters, such as the mass and axion decay constant, we construct the PDF for the cosmic birefringence angle and investigate its properties. By relating the observed value of the birefringence angle to the mean or standard deviation of the constructed PDF, we constrain the shape of the input PDFs, providing insights into the statistical distribution of the Axiverse. We focus on three different types of axion potentials: cosine, quadratic, and asymptotically linear axion monodromy. Our analysis showcases the potential of cosmic birefringence in constraining the distribution of axion parameters and uncovering possible correlations among them. We additionally offer predictions for "birefringence tomography", anticipating future measurements of birefringence from lower multipoles, and show how it can be used to rule out simpler versions of the Axiverse. Our findings contribute to the ongoing exploration of the Axiverse and its implications for cosmic birefringence.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Assessment of Short-Term Sediment Deposition Patterns Along the Palamós Submarine Canyon (NW Mediterranean) Using 234Th

  • Sierks, Maria
  • Paradis, Sarah|||0000-0002-7035-0538
  • Roca-Martí, Montserrat|||0000-0002-4719-9358
  • Puigcorbé, Viena|||0000-0001-5892-2305
  • Puig, Pedro|||0000-0002-6607-9642
Sedimentary dynamics in the Palamós Canyon are influenced by river inputs and storm resuspension, as well as by bottom trawling on the canyon flanks. In this study, we estimate recent sediment deposition patterns along the canyon axis using the excess activity concentration of the short-lived radiotracer 234Th (half-life of 24.1 days). Sediment cores were obtained at various locations along the canyon axis from a depth of approximately 800 m to 2100 m in June 2023 and August 2024. Excess 234Th (234Thxs) was detected in all sampled sites with variable penetration depths (0.5-3.5 cm). 234Thxs-derived estimations of mixing rates decreased downcanyon from up to 15.6 cm2 y-1 at the canyon head (~800 m) to negligible mixing at the canyon mouth (~2100 m). 234Thxs inventories, a proxy of recent sediment deposition, were high (1800-3490 Bq m-2) at the canyon head and at the upper canyon (~1400 m) close to fishing grounds and decreased downcanyon (82-694 Bq m-2) at the lower canyon (~1800 m) and canyon mouth. Inventories varied 2-fold across years presumably attributed to enhanced riverine and bottom trawling sediment fluxes. Similar 234Th-derived sediment deposition patterns can be found in submarine canyons worldwide, highlighting the value of this radiotracer for sedimentary dynamics studies in such complex environments.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publication Artículo científico (JournalArticle)

Cosmological mirror symmetry and gravitational-wave helicity

  • Calderón Bustillo, Juan
  • Del Río Vega, Adrián
  • Leong, Samson H.W.
  • Sanchís Gual, Nicolás
Our current understanding of the Universe relies on the hypothesis that, when observed at sufficiently large scales, it looks statistically identical regardless of location or direction of observation. Consequently, the Universe should exhibit mirror-reflection symmetry. In this essay, we show that gravitational-wave astronomy provides a unique, observer-independent test of this hypothesis. In particular, we analyze the average circular polarization emitted by an ensemble of binary black hole mergers detected by LIGO–Virgo, which we compute using a novel geometric and chiral observable in general relativity. We discuss current results and future prospects with upcoming detections and technical advancements. Moreover, we show that this circular polarization and the helicity of the remnant black hole are linearly correlated, drawing a conceptual parallel with Wu experiment in particle physics., JCB is funded by a fellowship from “la Caixa” Foundation (ID100010474) and from the European Union’s Horizon2020 research and innovation programme under the Marie Skodowska-Curie grant agreement No 847648. The fellow-ship code is LCF/BQ/PI20/11760016. JCB is also supported by the research grant PID2020-118635GB-I00 from the Spain-Ministerio de Ciencia e Innovación and by its Ramón y Cajal program (grant RYC2022-036203-I). ADR acknowledges support through Atraccion de Talento Cesar Nombela grant No 2023-T1/TEC-29023, funded by Comunidad de Madrid (Spain); as well as financial support via the Spanish Grant PID2023-149560NB-C21, funded by MCIU/AEI/10.13039/501100011033/FEDER, UE. NSG acknowledges support from the Spanish Ministry of Science and Innovation via the Ramón y Cajal programme (grant RYC2022-037424-I), funded by MCIN/AEI/ 10.13039/501100011033 and by ESF Investing in your future. NSG is further sup-ported by the Spanish Agencia Estatal de Investigación (Grant PID2021-125485NB-C21) funded by MCIN/AEI/10.13039/501100011033 and ERDF A way of making Europe, and by the European Union’s Horizon 2020 research and innovation (RISE) programme H2020-MSCA-RISE-2017 Grant No. FunFiCO-777740 and by the European Horizon Europe staff exchange (SE) programme HORIZON-MSCA2021-SE-01 Grant No. NewFunFiCO-101086251.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publication Artículo científico (JournalArticle)

Testing mirror symmetry in the Universe with LIGO-Virgo black-hole mergers

  • Calderón Bustillo, Juan
  • Del Río Vega, Adrián
  • Sanchís Gual, Nicolás
  • Chandra, Koustav
  • Leong, Samson
Certain precessing black-hole mergers produce gravitational waves with net circular polarization, understood as an imbalance between right- and left-handed amplitudes. According to the cosmological principle, such emission must average to zero across all binary mergers in our Universe to preserve mirror-reflection symmetry at very large scales. We present a new independent gravitational-wave test of this hypothesis. Using a novel observable based on the Chern-Pontryagin pseudoscalar, we measure the emission of net circular polarization across 47 black-hole mergers recently analyzed by [T. Islam et al., arXiv:2309.14473.] with a state-of-the art model for precessing black-hole mergers in general relativity. The average value obtained is consistent with zero. Remarkably, however, we find that at least 82% of the analyzed sources must have produced net circular polarization. Of these, GW200129 shows strong evidence for mirror asymmetry, with a Bayes factor of 12.6 or, equivalently, 93.1% probability. We obtain consistent (although stronger) results of 97.5% and 94.3%, respectively, using public results on this event from [M. Hannam et al., Nature (London) 610, 652 (2022).] and performing our own parameter inference. This finding further implies evidence of astrophysical sources that can spontaneously emit circularly polarized photons by quantum effects. Forthcoming black-hole merger detections will enable stronger constraints on large-scale mirror asymmetry and the cosmological principle., JCB is funded by a fellowship from “la Caixa” Foundation (ID100010474) and from the European Union’s Horizon2020 research and innovation programme under the Marie Skodowska-Curie grant agreement No 847648. The fellowship code is LCF/BQ/PI20/11760016. JCB is also supported by the research grant PID2020-118635GB-I00 from the Spain-Ministerio de Ciencia e Innovación and by its Ram´on y Cajal program (grant RYC2022-036203-I). ADR acknowledges support through (i) Maria Zambrano grant ZA21-048 with reference UP2021-044 from the Spanish Ministerio de Universidades, funded within the European Union-Next Generation EU, and (ii) Atraccion de Talento Cesar Nombela grant No 2023-T1/TEC-29023, funded by Comunidad de Madrid (Spain). ADR further acknowledges financial support via the Spanish Grants PID2020-116567GBC21, funded by MCIN/AEI/10.13039/501100011033, and PID2023-149560NB-C21, funded by MCIU /AEI/10.13039/501100011033/FEDER, UE. NSG acknowledges support from the Spanish Ministerio de Universidades, through a Mar´ıa Zambrano grant (ZA21-031) with reference UP2021-044, funded within the European Union-Next Generation EU, and from the Spanish Ministry of Science and Innovation via the Ramón y Cajal programme (grant RYC2022-037424-I), funded by MCIN/AEI/ 10.13039/501100011033 and by “ESF Investing in your future”. NSG is further supported by the Spanish Agencia Estatal de Investigaci ´on (Grant PID2021-125485NB-C21) funded by MCIN/AEI/10.13039/501100011033 and ERDF A way of making Europe, and by the European Union’s Horizon 2020 research and innovation (RISE) programme H2020-MSCA-RISE-2017 Grant No. FunFiCO-777740 and by the European Horizon Europe staff exchange (SE) programme HORIZON-MSCA2021-SE-01 Grant No. NewFunFiCO-101086251. KC acknowledges the support through NSF grant numbers PHY-2207638, AST-2307147, PHY-2308886, and PHY-2309064. We acknowledge the use of IUCAA LDG cluster Sarathi for the computational/numerical work. The authors acknowledge computational resources provided by the CIT cluster of the LIGO Laboratory and supported by National Science Foundation Grants PHY-0757058 and PHY0823459; and the support of the NSF CIT cluster for the provision of computational resources for our parameter inference runs.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A high-quality, long-read genome assembly of the endangered ring-tailed lemur (Lemur catta)

  • Palmada Flores, Marc
  • Orkin, Joseph D.
  • Haase, Bettina
  • Mountcastle, Jacquelyn
  • Bertelsen, Mads F.
  • Fedrigo, Olivier
  • Kuderna, Lukas, 1989-
  • Jarvis, Erich D.
  • Marquès i Bonet, Tomàs, 1975-
Background: The ring-tailed lemur (Lemur catta) is a charismatic strepsirrhine primate endemic to Madagascar. These lemurs are of particular interest, given their status as a flagship species and widespread publicity in the popular media. Unfortunately, a recent population decline has resulted in the census population decreasing to <2,500 individuals in the wild, and the species's classification as an endangered species by the IUCN. As is the case for most strepsirrhine primates, only a limited amount of genomic research has been conducted on L. catta, in part owing to the lack of genomic resources. Results: We generated a new high-quality reference genome assembly for L. catta (mLemCat1) that conforms to the standards of the Vertebrate Genomes Project. This new long-read assembly is composed of Pacific Biosciences continuous long reads (CLR data), Optical Mapping Bionano reads, Arima HiC data, and 10X linked reads. The contiguity and completeness of the assembly are extremely high, with scaffold and contig N50 values of 90.982 and 10.570 Mb, respectively. Additionally, when compared to other high-quality primate assemblies, L. catta has the lowest reported number of Alu elements, which results predominantly from a lack of AluS and AluY elements. Conclusions: mLemCat1 is an excellent genomic resource not only for the ring-tailed lemur community, but also for other members of the Lemuridae family, and is the first very long read assembly for a strepsirrhine., The project that gave rise to these results received the support of 2 fellowships from "la Caixa" Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 847648. The fellowship codes are LCF/BQ/PI20/11760004 and LCF/BQ/DR20/11790032. T.M.B. is supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. 864203), BFU2017-86471-P (MINECO/FEDER, UE), “Unidad de Excelencia María de Maeztu,” funded by the AEI (CEX2018-000792-M), Howard Hughes International Early Career, NIH 1R01HG010898-01A1, and Secretaria d'Universitats i Recerca and CERCA Programme del Departament d'Economia i Coneixement de la Generalitat de Catalunya (GRC 2017 SGR 880).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Associations between objective sleep metrics and brain structure in cognitively unimpaired adults: interactions with sex and Alzheimer's biomarkers

  • Stankeviciute, Laura
  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Holst, Sebastian Camillo
  • Garcés, Pilar
  • Mueggler, Thomas
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Iranzo, Álex
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
INTRODUCTION: Sleep disturbances are prevalent in Alzheimer's disease (AD), probably emerging during its preclinical stage. Poor subjective sleep quality is linked to reduced brain volume and cortical thickness (CTh), but associations with objective sleep measures, particularly regarding sex and AD pathology, remain unclear. METHODS: We characterized 171 cognitively unimpaired adults from the ALzheimer and FAmilies (ALFA) Sleep study using actigraphy, MRI, amyloid beta 42/40, and phosphorylated tau at threonine 181 in cerebrospinal fluid. RESULTS: Lower sleep efficiency, higher wake after sleep onset (WASO), and sleep fragmentation were associated with lower CTh in the medial temporal lobe and other regions linked with AD and sleep disruption, even after adjusting for AD biomarkers. Sex and AD biomarkers modified these associations, with longer WASO showing a stronger correlation with lower CTh in females. DISCUSSION: Disrupted sleep may reduce cortical integrity independently of AD biomarkers, suggesting alternative pathways. Females appear more vulnerable to impaired sleep, and AD pathology may exacerbate AD-related changes in CTh. Highlights: Poor sleep efficiency, increased WASO, and sleep fragmentation are associated with reduced CTh in regions vulnerable to early AD, independently of amyloid and tau pathology. In the presence of AD pathology, this relationship is altered, with A+T+ individuals exhibiting increased CTh associated with sleep disruption. Sex-specific effects suggest females are more vulnerable to sleep-related cortical thinning. These findings highlight the potential of targeting sleep as a secondary prevention strategy to preserve brain integrity and mitigate neurodegenerative processes in AD-vulnerable regions., The ALFA+ study receives funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an anonymous international charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under Grant 2017-SGR-892. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institutes of Health (NIH), USA (Grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and from the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). J.D.G. has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (Grant Agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (Grant Agreement RTI2018‑102261). G.S-B. receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. O.G.R. receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme IJC2020-043417-I).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Association between different diet quality scores and depression risk: the REGICOR population-based cohort study

  • Lugon, Gabriela
  • Hernáez, Álvaro
  • Jacka, Felice N.
  • Marrugat, Jaume, 1954-
  • Ramos, Rafel
  • Garre-Olmo, Josep
  • Elosua Llanos, Roberto
  • Lassale, Camille
Background: Our aim was to determine the association between diet quality and depression incidence in the population-based REGICOR cohort study, Catalonia, Spain. Methods: Prospective observational study using participants' baseline (2003-2006), follow-up (2007-2013) and clinical records data. Five diet quality scores were derived from a food frequency questionnaire (FFQ) at baseline: the relative Mediterranean Diet Score (rMED), the Modified Mediterranean Diet Score (ModMDS), a Dietary Approaches to Stop Hypertension (DASH) score, a Healthful Plant-based Diet Index (HPDI) and the World Health Organization Healthy Diet Indicator (WHO-HDI). Participants using pharmacological antidepressant treatment were excluded as a proxy for presence of depression at baseline. At follow-up, the Patient Health Questionnaire (PHQ-9) was applied to assess depressive symptoms (≥ 10 defining depressive disorder). A secondary outcome was depression diagnosis assessed through clinical records. Logistic regression and Cox proportional hazards models were used. Results: Main analysis included 3046 adults (50.3% women) with a mean age of 54.7 (SD = 11.6) years. After 6-years follow-up, 184 (6.04%) cases of depressive disorder were identified. There was 16% lower odds of depressive disorder per 1SD increase of rMED (OR = 0.84; 95%CI = 0.71-0.98). Secondary outcome analysis (n = 4789) identified 261 (5.45%) incident cases of clinical depression diagnosis over 12 years follow-up, and 19% lower risk of clinical depression was observed with the WHO-HDI (HR = 0.81; 95%CI = 0.70-0.93). Adjusting for BMI did not attenuate the findings. Conclusions: A significant inverse association between diet quality and depression incidence was found in this population-based cohort study, independent of sociodemographic, health and lifestyle. Adherence to a healthy diet could be a complementary intervention for the prevention of depression., This project was funded by the Carlos III Health Institute–European Regional Development Fund (FIS PI12/00232, FIS PI15/00051, FIS PI21/00040, CIBERCV, CIBERESP), and the Government of Catalonia through the Agency for Management of University and Research Grants (PERIS SLT002/16/00088, PERIS STL006/17/00234, 2017SGR222). Camille Lassale was supported by a fellowship from ‘La Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847 648. The fellowship code is LCF/BQ/PR21/11840003.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's disease

  • González Escalante, Armand
  • Milà Alomà, Marta
  • Brum, Wagner S.
  • Ashton, Nicholas J.
  • Ortiz Romero, Paula, 1994-
  • Shekari, Mahnaz
  • Campo, Marta del
  • Anastasi, Federica
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Minguillón, Carolina
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Zetterberg, Henrik
  • Vilor Tejedor, Natàlia, 1988-
  • Blennow, Kaj
  • Suárez-Calvet, Marc
Background: Plasma biomarkers of Alzheimer's disease (AD) change during preclinical stages, indicating potential for detecting amyloid-β (Aβ) pathology in cognitively unimpaired (CU) individuals. Given the need for accurate, scalable biomarkers, we evaluated a fully automated plasma panel to detect and monitor longitudinal Aβ accumulation in CU individuals. Methods: In this longitudinal study, we examined a plasma panel (Aβ42/40, p-tau181, GFAP, NfL, p-tau217 and ApoE4) in CU participants at risk for AD. We assessed the biomarkers' performance to detect Aβ pathology and the cross-sectional and longitudinal relationships between the biomarkers and Aβ accumulation, neurodegeneration and cognition. Findings: We included 400 middle-aged CU participants, of whom 135 (33.8%) were CSF Aβ-positive. All plasma biomarkers differed between Aβ-positive and -negative individuals, with plasma Aβ42/40, p-tau217, p-tau181/Aβ42, and p-tau217/Aβ42 showing the best performance in detecting A+ CU individuals. However, plasma Aβ42/40 was sensitive to random variability. Plasma p-tau217/Aβ42 had the highest performance in detecting PET A+ individuals (AUC = 0.94). All baseline plasma biomarkers were associated with longitudinal increases in Aβ deposition (mean follow-up [SD]: 3.27 ± 0.5). Longitudinal changes in plasma p-tau217 and p-tau217/Aβ42 were associated with concurrent changes in Aβ (both CSF and PET) and soluble tau pathology. Interpretation: In CU individuals, several plasma biomarkers at baseline detect Aβ accumulation and are associated with its short-term change. Plasma p-tau217, and p-tau217/Aβ42 longitudinal changes reflect concurrent Aβ accumulation during this period. These findings help enrich studies in CU individuals at risk of progressing to AD. Funding: ERC-2020-STG (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (SLD077/21/000001); PI19/00155; PI22/00456, LCF/BQ/PR21/11840004., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure Plasma and CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. We thank the collaborators of the ALFA Study: Alba Cañas, Albina Polo, Ana Fernández-Arcos, Annabella Beteta, Anna Brugulat-Serrat, Anna Soteras, Blanca Rodríguez-Fernández, Carme Deulofeu, Ferran Lugo, Irene Cumplido-Mayoral, Jordi Huguet, Laura Hernández, Maria Emilio, Patricia Genius, Paula Marne, Sandra Pradas, Sherezade Fuentes, and Wiesje Pelkmans. MMA receives funding from the Alzheimer’s Association Research Fellowship Program (AARF-23-1141384). FA receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. GSB is supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+). OGR’s institution is supported by Roche Pharmaceuticals and Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer’s Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency (grant RYC2022-038136-I, cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). Additionally, NVT is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative. KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022–2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, Stockholm, Sweden. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155” and “PI22/00456”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study

  • Cumplido-Mayoral, Irene
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Anastasi, Federica
  • Milà Alomà, Marta
  • López-Martos, David
  • Akinci, Muge
  • Falcón, Carles
  • Shekari, Mahnaz
  • Cacciaglia, Raffaele
  • Arenaza Urquijo, Eider M.
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
  • ALFA Study
Background: Neuroimaging-based brain-age delta has been shown to be a mediator linking cardiovascular risk factors to cognitive function. We aimed to assess the mediating role of brain-age delta in the association between modifiable risk factors of dementia and longitudinal cognitive decline in middle-aged and older individuals who are asymptomatic, stratified by Alzheimer's disease pathology. We also explored whether the mediation effect is specific to cognitive domain. Methods: In this cohort study, we included participants from the ALFA+ cohort aged between 45 years and 65 years who were cognitively unimpaired and who had available structural MRI, cerebrospinal fluid β-amyloid (Aβ)42 and Aβ40 measurements obtained within 1 year of each other, modifiable risk factors assessment, and cognitive evaluation over 3 years. Participants were recruited from the Barcelonaβeta Brain Research Center (Barcelona, Spain). Included individuals underwent a first assessment between Oct 25, 2016, and Jan 28, 2020, and a follow-up cognitive assessment 3·28 (SD 0·27) years later. We computed brain-age delta and composites of different cognitive function domains (preclinical Alzheimer's cognitive composite [PACC], attention, executive function, episodic memory, visual processing, and language). We used partial least squares path modelling to explore mediation effects in the associations between modifiable risk factors (including cardiovascular, mental health, mood, metabolic or endocrine history, and alcohol use) and changes in cognitive composites. To assess the role of Alzheimer's disease pathology, we computed separate models for Aβ-negative and Aβ-positive individuals. Findings: Of the 419 participants enrolled in ALFA+, 302 met our inclusion criteria, of which 108 participants were classified as Aβ-positive and 194 as Aβ-negative. In Aβ-positive individuals, brain-age delta partially mediated (percent mediation proportion 15·73% [95% CI 14·22-16·66]) the association between modifiable risk factors and decline in overall cognition (across cognitive domains). Brain-age delta fully mediated (mediation proportion 28·03% [26·25-29·21]) the effect of modifiable risk factors on the PACC, wherein increased values for risk factors correlated with an older brain-age delta, and, consequently, an older brain-age delta was linked to greater PACC decline. This effect appears to be primarily driven by memory decline. Mediation was not significant in Aβ-negative individuals (3·52% [0·072-4·17]) on PACC, although path coefficients were not significantly different from those in the Aβ-positive group. Interpretation: Our findings suggest that brain-age delta captures the association between modifiable risk factors and longitudinal cognitive decline in middle-aged and older people. In asymptomatic middle-aged and older individuals who are Aβ-positive, the pathology might be the strongest driver of cognitive decline, whereas the effect of risk factors is smaller. Our results highlight the potential of brain-age delta as an objective outcome measure for preventive lifestyle interventions targeting cognitive decline. Funding: La Caixa Foundation, the TriBEKa Imaging Platform, and the Universities and Research Secretariat of the Catalan Government. Translation: For the Spanish translation of the abstract see Supplementary Materials section., This publication is part of the ALFA study. We thank the ALFA project participants and relatives, without whom this research would not have been possible. We thank Kaj Blennow and Henrik Zetterberg for performing the measurements of cerebrospinal fluid Aβ42:Aβ40 ratio. We thank Roche Diagnostics International for providing the kits to measure cerebrospinal fluid biomarkers. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to evaluate biomarkers associated with key pathological events characteristic of Alzheimer's disease and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from La Caixa Foundation (100010434; LCF/PR/GN17/50300004) and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government (2021 SGR 009132017-SGR-892). MS-C receives funding from the European Research Council under the EU Horizon 2020 research and innovation programme (948677; project PI19/00155), funded by Instituto de Salud Carlos III and co-funded by the EU, and from a fellowship from La Caixa Foundation (100010434) and from the EU Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (847648; LCF/BQ/PR21/11840004). DL-M is supported by Instituto de Salud Carlos III (PI19/00117; co-funded by European Regional Development Fund, European Social Fund A Way to Make Europe, and Investing in your Future). EMA-U is supported by the Spanish Ministry of Science and Innovation State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund and the Spanish Ministry of Science and Innovation (PID2019-111514RA-I00). VV has been supported by the Spanish Research Agency (PID2020-116907RB-I00 of the call MCIN/AEI/10.13039/501100011033). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU and European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative Joint Undertaking AMYPAD (115952), European Institute of Innovation and Technology Digital (2021), and from Ministerio de Ciencia y Universidades (RTI2018-102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency (PID2020-119556RA-I00). OG-R receives funding from the Alzheimer's Association Research Fellowship (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology

  • Vila-Castelar, Clara
  • Akinci, Muge
  • Palpatzis, Eleni
  • Aguilar Dominguez, Pablo
  • Operto, Grégory
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Falcón, Carles
  • Fauria, Karine
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Glial reactivity may contribute to sex/gender differences in Alzheimer's disease (AD) pathophysiology. Here, we investigated the differential effect of cerebrospinal fluid (CSF) glial markers on AD pathology and neurodegeneration by sex/gender among cognitively unimpaired older adults at increased risk of developing AD. We included 397 participants from the ALFA+ cohort with CSF Aβ42/40, p-tau181, sTREM2, YKL40, and GFAP, magnetic resonance imaging-based hippocampal volume (n = 299), and amyloid burden (centiloids) measured with [18F] flutemetamol positron emission tomography (n = 341). We ran multiple linear regression models to assess the association between glial markers, AD pathology and hippocampal volumes and their interaction with sex/gender, using False Discovery Rate to correct for multiple comparisons. Glial markers significantly contributed to explain amyloid burden, tau pathology, and hippocampal volumes, beyond age and/or primary AD pathology in a sex/gender-specific manner. Compared to men, women showed increased amyloid burden (centiloids) and CSF p-tau181 with increasing levels of sTREM2 and YKL40, and YKL40 and GFAP, respectively. Compared to women, men with greater tau burden showed lower hippocampal volumes as CSF YKL40 levels increased. Overall, our findings suggest that glial reactivity may contribute to sex/gender differences in AD progression, mostly, downstream amyloid. Further research identifying sex/gender-specific temporal dynamics in AD development is warranted to inform clinical trials., This publication is part of the ALFA study (ALzheimer and FAmilies). The authors would like to express their sincerest gratitude to the ALFA project participants, without whom this research would have not been possible. Collaborators of the ALFA study are: Federica Anastasi, Annabella Beteta, Anna Brugulat-Serrat, Raffaele Cacciaglia, Irene Cumplido-Mayoral, Alba Cañas, Marta del Campo, Carme Deulofeu, Ruth Dominguez, Maria Emilio, Ana Fernández-Arcos, Sherezade Fuentes, Patricia Genius, Armand González-Escalante, Laura Hernández, Felipe Hernández-Villamizar, Jordi Huguet, David López-Martos, Ferran Lugo, Paula Marne, Tania Menchón, Carolina Minguillon, Paula Ortiz, Wiesje Pelkmans, Albina Polo, Sandra Pradas, Blanca Rodríguez-Fernandez, Gonzalo Sánchez-Benavides, Mahnaz Shekari, Anna Soteras, Laura Stankeviciute, Marc Vilanova and Natalia Vilor-Tejedor. The authors would like to thank Jordi Huguet (Barcelonaβeta Brain Research Center, Barcelona) and Robin de Flores (INSERM, Caen, France) for their contributions to hippocampal subfield segmentation with Automated Segmentation of Hippocampal Subfields (ASHS). The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. Elecsys β-amyloid (1–42) CSF, Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation - State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research J(PND2022-138). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). CV-C is supported by a grant from the National Institute on Aging (K99AG073452).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

sTREM2 is associated with amyloid-related p-tau increases and glucose hypermetabolism in Alzheimer's disease

  • Biel, Davina
  • Suárez-Calvet, Marc
  • Hager, Paul
  • Rubinski, Anna
  • Dewenter, Anna
  • Steward, Anna
  • Roemer, Sebastian
  • Ewers, Michael
  • Haass, Christian
  • Brendel, Matthias
  • Franzmeier, Nicolai
  • Alzheimer’s Disease Neuroimaging Initiative
Microglial activation occurs early in Alzheimer's disease (AD) and previous studies reported both detrimental and protective effects of microglia on AD progression. Here, we used CSF sTREM2 to investigate disease stage‐dependent drivers of microglial activation and to determine downstream consequences on AD progression. We included 402 patients with measures of earliest beta‐amyloid (CSF Aβ1‐42) and late‐stage fibrillary Aβ pathology (amyloid‐PET centiloid), as well as sTREM2, p‐tau181, and FDG‐PET. To determine disease stage, we stratified participants into early Aβ‐accumulators (Aβ CSF+/PET−; n = 70) or late Aβ‐accumulators (Aβ CSF+/PET+; n = 201) plus 131 controls. In early Aβ‐accumulators, higher centiloid was associated with cross‐sectional/longitudinal sTREM2 and p‐tau181 increases. Further, higher sTREM2 mediated the association between centiloid and cross‐sectional/longitudinal p‐tau181 increases and higher sTREM2 was associated with FDG‐PET hypermetabolism. In late Aβ‐accumulators, we found no association between centiloid and sTREM2 but a cross‐sectional association between higher sTREM2, higher p‐tau181 and glucose hypometabolism. Our findings suggest that a TREM2‐related microglial response follows earliest Aβ fibrillization, manifests in inflammatory glucose hypermetabolism and may facilitate subsequent p‐tau181 increases in earliest AD., The study was funded by grants from the LMU (FöFoLe,1032, awarded to NF;FöFoLe,1119, awarded to DB), the Hertie foundation for clinical neurosciences(awarded to NF), and the SyNergy excellence cluster (EXC2145/ID390857198).MSC receives funding from the European Research Council (ERC) under theEuropean Union’s Horizon2020research and innovation programme (Grantagreement No.948677), the Instituto de Salud Carlos III (PI19/00155), and froma fellowship from“la Caixa”Foundation (ID100010434) and from theEuropean Union’s Horizon2020research and innovation programme underthe Marie Skłodowska-Curie grant agreement No.847648(LCF/BQ/PR21/11840004). We thank the ADNI participants and their families who made thisstudy possible. Open Access funding enabled and organized by Projekt DEAL.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms

  • Stankeviciute, Laura
  • Blackman, Jonathan
  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Sánchez Benavides, Gonzalo
  • Suárez-Calvet, Marc
  • Iranzo, Álex
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Coulthard, Elizabeth
  • Grau, Oriol (Grau Rivera)
Sleep disturbances are prevalent in Alzheimer's disease (AD), affecting individuals during its early stages. We investigated associations between subjective sleep measures and cerebrospinal fluid (CSF) biomarkers of AD in adults with mild cognitive symptoms from the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study, considering the influence of memory performance. A total of 442 participants aged >50 years with a Clinical Dementia Rating (CDR) score of 0.5 completed the Pittsburgh Sleep Quality Index questionnaire and underwent neuropsychological assessment, magnetic resonance imaging acquisition, and CSF sampling. We analysed the relationship of sleep quality with CSF AD biomarkers and cognitive performance in separated multivariate linear regression models, adjusting for covariates. Poorer cross-sectional sleep quality was associated with lower CSF levels of phosphorylated tau and total tau alongside better immediate and delayed memory performance. After adjustment for delayed memory scores, associations between CSF biomarkers and sleep quality became non-significant, and further analysis revealed that memory performance mediated this relationship. In post hoc analyses, poorer subjective sleep quality was associated with lesser hippocampal atrophy, with memory performance also mediating this association. In conclusion, worse subjective sleep quality is associated with less altered AD biomarkers in adults with mild cognitive symptoms (CDR score 0.5). These results could be explained by a systematic recall bias affecting subjective sleep assessment in individuals with incipient memory impairment. Caution should therefore be exercised when interpreting subjective sleep quality measures in memory-impaired populations, emphasising the importance of complementing subjective measures with objective assessments., Data used in the preparation of this article were obtained from the Longitudinal Cohort Study (LCS), delivered by the European Prevention of Alzheimer's Disease (EPAD) Consortium. As such investigators within the EPAD-LCS and EPAD Consortium contributed to the design and implementation of EPAD and/or provided data but did not participate in the analysis or writing of this report. A complete list of EPAD Investigators can be found at: https://ep-ad.org/wp-content/uploads/2020/12/202010_List-of-epadistas.pdf. The EPAD-LCS was launched in 2015 as a public–private partnership, led by Chief Investigator Professor Craig Ritchie MB BS. This work used data and/or samples from the EPAD project which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement number 115736 and an Alzheimer's Association Grant (SG21-818099-EPAD).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic

  • Anastasi, Federica
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Torres-Torronteras, Javier
  • González Escalante, Armand
  • Contador, José
  • García Escobar, Greta
  • Manero, Rosa María
  • Navalpotro-Gómez, Irene
  • Jiménez-Moyano, Esther
  • Grau, Oriol (Grau Rivera)
  • Campo, Marta del
  • Puig-Pijoan, Albert
  • Suárez-Calvet, Marc
Introduction: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. Methods: In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ pathology status. Results: Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior area under the curves. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers. Discussion: Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in detecting AD in a memory clinic setting. Highlights: Plasma p-tau biomarkers demonstrated higher diagnostic performance and larger effect sizes than t-tau and Aβ42/40 assays in detecting Alzheimer's disease. Among the p-tau biomarkers, p-tau217 assays consistently outperformed the others, providing superior classification of Aβ pathology status across different phosphorylation sites. p-tau217 assays showed the strongest correlation between plasma and CSF levels, indicating its potential as a reliable surrogate for CSF biomarkers. Several plasma p-tau biomarkers can be used in a specialized memory clinic to accurately detect Alzheimer's disease., Federica Anastasi receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. Henrik Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155″ and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts

  • Lantero Rodríguez, Juan
  • Vrillon, Agathe
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Snellman, Anniina
  • Montoliu-Gaya, Laia
  • Brum, Wagner S.
  • Cognat, Emmanuel
  • Dumurgier, Julien
  • Puig-Pijoan, Albert
  • Navalpotro-Gómez, Irene
  • García-Escobar, Greta
  • Karikari, Thomas K.
  • Vanmechelen, Eugeen
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Suárez-Calvet, Marc
  • Paquet, Claire
  • Blennow, Kaj
Background Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer’s disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient landscape found in clinical settings. Therefore, in this multicentre study, we investigated the performance of CSF p-tau235 to detect symptomatic AD in clinical settings and compared it with CSF p-tau181, p-tau217 and p-tau231. Methods CSF p-tau235 was measured using an in-house single molecule array (Simoa) assay in two independent memory clinic cohorts: Paris cohort (Lariboisière Fernand-Widal University Hospital Paris, France; n=212) and BIODEGMAR cohort (Hospital del Mar, Barcelona, Spain; n=175). Patients were classified by the syndromic diagnosis (cognitively unimpaired [CU], mild cognitive impairment [MCI] or dementia) and their biological diagnosis (amyloid-beta [Aβ]+ or Aβ ). Both cohorts included detailed cognitive assessments and CSF biomarker measurements (clinically validated core AD biomarkers [Lumipulse CSF Aβ1–42/40 ratio, p-tau181 and t-tau] and in-house developed Simoa CSF p-tau181, p-tau217 and p-tau231). Results High CSF p-tau235 levels were strongly associated with CSF amyloidosis regardless of the clinical diagnosis, being significantly increased in MCI Aβ+ and dementia Aβ+ when compared with all other Aβ− groups (Paris cohort: P ˂0.0001 for all; BIODEGMAR cohort: P ˂0.05 for all). CSF p-tau235 was pronouncedly increased in the A+T+ profile group compared with A−T− and A+T− groups (P ˂0.0001 for all). Moreover, CSF p-tau235 demonstrated high diagnostic accuracies identifying CSF amyloidosis in symptomatic cases (AUCs=0.86 to 0.96) and discriminating AT groups (AUCs=0.79 to 0.98). Overall, CSF p-tau235 showed similar performances to CSF p-tau181 and CSF p-tau231 when discriminating CSF amyloidosis in various scenarios, but lower than CSF p-tau217. Finally, CSF p-tau235 associated with global cognition and memory domain in both cohorts. Conclusions CSF p-tau235 was increased with the presence of CSF amyloidosis in two independent memory clinic cohorts. CSF p-tau235 accurately identified AD in both MCI and dementia patients. Overall, the diagnostic performance of CSF p-tau235 was comparable to that of other CSF p-tau measurements, indicating its suitability to support a biomarker-based AD diagnosis in clinical settings., Open access funding provided by University of Gothenburg. This study was funded by the Swedish Research Council (#2017-00915 and #2022-00732), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236) and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). AV is supported by Fondation Ophtalmologique Adolphe de Rothschild and Fondation Vaincre Alzheimer. AES was supported by the Paulo Foundation, the Orion Research Foundation sr, and currently holds a postdoctoral fellowship from the Academy of Finland (#341059). TKK was funded by the Swedish Research Council (Vetenskapsrådet #2021-03244), the Alzheimer’s Association Research Fellowship (#AARF-21-850325), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms stiftelsen and the Emil och Wera Cornells stiftelsen. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694) and the UK Dementia Research Institute at UCL (UKDRI-1003). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Characterization of the common genetic variation in the spanish population of Navarre

  • Maillo, Alberto
  • Beltran, Sergi
  • Gómez Cabrero, David
Large-scale genomic studies have significantly increased our knowledge of genetic variability across populations. Regional genetic profiling is essential for distinguishing common benign variants from disease-causing ones. To this end, we conducted a comprehensive characterization of exonic variants in the population of Navarre (Spain), utilizing whole genome sequencing data from 358 unrelated individuals of Spanish origin. Our analysis revealed 61,410 biallelic single nucleotide variants (SNV) within the Navarrese cohort, with 35% classified as common (MAF > 1%). By comparing allele frequency data from 1000 Genome Project (excluding the Iberian cohort of Spain, IBS), Genome Aggregation Database, and a Spanish cohort (including IBS individuals and data from Medical Genome Project), we identified 1069 SNVs common in Navarre but rare (MAF ≤ 1%) in all other populations. We further corroborated this observation with a second regional cohort of 239 unrelated exomes, which confirmed 676 of the 1069 SNVs as common in Navarre. In conclusion, this study highlights the importance of population-specific characterization of genetic variation to improve allele frequency filtering in sequencing data analysis to identify disease-causing variants., NAGEN1000 and pharmaNAGEN were supported by Navarra Gov (Dirección General de Industria, Energia y Proyectos Estrategicos S3). GRANTS_NUMBERS: 0011-1411-2017-000032, 0011-1411-2018-000047. M.A.-R has a Postdoctoral Junior Leader—INCOMMING Fellowship from “la Caixa” Foundation (ID: 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska Curie grant agreement No. 847648 (fellowship code: LCF/BQ/PI21/11830009).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit

  • Johnson, Sterling C.
  • Suárez-Calvet, Marc
  • Suridjan, Ivonne
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Jonaitis, Erin
  • Michna, Agatha
  • Carboni, Margherita
  • Bittner, Tobias
  • Rabe, Christina
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
Background: Alzheimer's disease (AD) is a complex and heterogeneous disease, which requires reliable biomarkers for diagnosis and monitoring disease activity. Preanalytical protocol and technical variability associated with biomarker immunoassays makes comparability of biomarker data across multiple cohorts difficult. This study aimed to compare cerebrospinal fluid (CSF) biomarker results across independent cohorts, including participants spanning the AD continuum. Methods: Measured on the NeuroToolKit (NTK) prototype panel of immunoassays, 12 CSF biomarkers were evaluated from three cohorts (ALFA+, Wisconsin, and Abby/Blaze). A correction factor was applied to biomarkers found to be affected by preanalytical procedures (amyloid-β1-42, amyloid-β1-40, and alpha-synuclein), and results between cohorts for each disease stage were compared. The relationship between CSF biomarker concentration and cognitive scores was evaluated. Results: Biomarker distributions were comparable across cohorts following correction. Correlations of biomarker values were consistent across cohorts, regardless of disease stage. Disease stage differentiation was highest for neurofilament light (NfL), phosphorylated tau, and total tau, regardless of the cohort. Correlation between biomarker concentration and cognitive scores was comparable across cohorts, and strongest for NfL, chitinase-3-like protein-1 (YKL40), and glial fibrillary acidic protein. Discussion: The precision of the NTK enables merging of biomarker datasets, after correction for preanalytical confounders. Assessment of multiple cohorts is crucial to increase power in future studies into AD pathogenesis., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). For the Wisconsin studies, CSF assay kits were provided by Roche Diagnostics GmbH. Data were collected under the following grants from the NIH National Institute of Aging: R01 AG027161, R01 AG037639, R01AG054059 UF1AG051216, P50 AG033514, and P30 AG062715. Support was also provided by the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427 (Clinical and Translational Sciences). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie (grant agreement No. 847648; LCF/BQ/PR21/11840004). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation; Stiftelsen för Gamla Tjänarinnor; Hjärnfonden, Sweden (#FO2019-0228); the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE); and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); the National Institute of Health (NIH), USA (grant #1R01AG068398-01); and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease

  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • Salvadó, Gemma
  • Ortiz Romero, Paula, 1994-
  • González Escalante, Armand
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's disease are needed to facilitate the initial screening process of participants in disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient Aβ pathology, but a comprehensive comparison with other putative blood biomarkers is lacking. In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40) were significantly changed in preclinical Alzheimer's disease. However, plasma p-tau231 reached abnormal levels with the lowest Aβ burden. Plasma p-tau231 and p-tau217 had the strongest association with Aβ positron emission tomography (PET) retention in early accumulating regions and associated with longitudinal increases in Aβ PET uptake in individuals without overt Aβ pathology at baseline. In summary, plasma p-tau231 and p-tau217 better capture the earliest cerebral Aβ changes, before overt Aβ plaque pathology is present, and are promising blood biomarkers to enrich a preclinical population for Alzheimer's disease clinical trials., The research leading to these results received funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/10300004 and the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). E.V. was supported by Flanders Innovation and Entrepreneurship (VLAIO grant no. 140105). C.M. received funding within the context of EURO-FINGERS, a EU Joint Programme–Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (grant no. 2018-02532), the European Research Council (ERC, grant no. 681712), Swedish State Support for Clinical Research (grant no. ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (grant no. 201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (grant nos. ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C), the Olav Thon Foundation, the Erling–Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (grant no. FO2019-0228), the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 860197 (MIRIADE) and the UK Dementia Research Institute at University College London (UCL). J.D.G. is supported by the Spanish Ministry of Economy and Competitiveness (RYC-2013-13054) and received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant no. 115952) and from Ministerio de Ciencia, Innovación y Universidades (grant no. RTI2018-102261). M.S.C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948677), the Instituto de Salud Carlos III (PI19/00155), and from the ERC under the EU’s ‘la Caixa’ Foundation (ID 100010434) and from the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (no. 847648, LCF/BQ/PR21/11840004). K.B. is supported by the Swedish Research Council (grant no. 2017-00915), the ADDF, USA (grant no. RDAPB-201809-2016615), the Swedish Alzheimer Foundation (grant no. AF-742881) (grant nos. AF-930351, AF-939721 and AF-968270), Hjärnfonden, Sweden (grant nos. FO2017-0243 and ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (grant nos. ALFGBG-715986 and ALFGBG-965240), the EU Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the National Institutes of Health (grant no. 1R01AG068398-01) and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The diversity of primates: from biomedicine to conservation genomics

  • Orkin, Joseph D.
  • Kuderna, Lukas, 1989-
  • Marquès i Bonet, Tomàs, 1975-
Until now, the field of primate genomics has focused on two major themes: understanding human evolution and advancing biomedical research. We propose that it is now time for a third theme to receive attention: conservation genomics. As a result of anthropogenic effects, the majority of primate species have become threatened with extinction. A more robust primate conservation genomics will allow for genetically informed population management. Thanks to a steady decline in the cost of sequencing, it has now become feasible to sequence whole primate genomes at the population level. Furthermore, technological advances in noninvasive genomic methods have made it possible to acquire genome-scale data from noninvasive biomaterials. Here, we review recent advances in the analysis of primate diversity, with a focus on genomic data sets across the radiation., J.D.O is supported by the Beatriu de Pinós postdoctoral programme of the Government of Catalonia's Secretariat for Universities and Research of the Ministry of Economy and Knowledge. The project that gave rise to these results received the support of a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648. L.F.K.K is supported by an FPI fellowship associated to BFU2014-55090-P (MINECO/FEDER, UE) and by an EMBO short-term fellowship STF-8286. TMB is supported by funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 864203), BFU2017-86471-P (MINECO/FEDER, UE), “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M, Obra Social "La Caixa" and Secretaria d’Universitats i Recerca and CERCA Programme del Departament d’Economia i Coneixement de la Generalitat de Catalunya (GRC 2017 SGR 880)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Omega-3 blood biomarkers relate to brain glucose uptake in individuals at risk of Alzheimer's disease dementia

  • Lázaro, Iolanda
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Fauria, Karine
  • Minguillón, Carolina
  • Shekari, Mahnaz
  • Falcón, Carles
  • Garcia Prat, Marina
  • Huguet, Jordi
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Sala Vila, Aleix
  • ALFA Study
Introduction: Brain glucose hypometabolism is a preclinical feature of Alzheimer's disease (AD). Dietary omega-3 fatty acids promote brain glucose metabolism, but clinical research is incipient. Circulating omega-3s objectively reflect their dietary intake. Methods: This was a cross-sectional study in 320 cognitively unimpaired participants at increased risk of AD dementia. Using lipidomics, we determined blood docosahexaenoic (DHA) and alpha-linolenic (ALA) acid levels (omega-3s from marine and plant origin, respectively). We assessed brain glucose metabolism using [18-F]-fluorodeoxyglucose (FDG) positron emission tomography (PET). Results: Blood ALA directly related to FDG uptake in brain areas known to be affected in AD. Stronger associations were observed in apolipoprotein E ε4 carriers and homozygotes. For DHA, significant direct associations were restricted to amyloid beta-positive tau-positive participants. Discussion: Blood omega-3 directly relate to preserved glucose metabolism in AD-vulnerable brain regions in individuals at increased risk of AD dementia. This adds to the benefits of omega-3 supplementation in the preclinical stage of AD dementia. Highlights: Blood omega-3s were related to brain glucose uptake in participants at risk of Alzheimer's disease (AD) dementia.Complementary associations were observed for omega-3 from marine and plant sources.Foods rich in omega-3 might be useful in early features of AD., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. MSC receives funding from the European Research Council (ERC) under the European Unionʼs Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155,” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Unionʼs Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648(LCF/BQ/PR21/11840004). This work was supported by funding from Instituto de Salud Carlos III (PI22/00071) and by a grant from the California Walnut Commission, Folsom, CA, US (to AS-V). The funding agencies had no input in the study design, data collection, analyses, or writing and submission of the manuscript.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Identification of constrained sequence elements across 239 primate genomes

  • Kuderna, Lukas, 1989-
  • Valenzuela, Alejandro
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Marquès i Bonet, Tomàs, 1975-
  • Kai-How Farh, Kyle
Noncoding DNA is central to our understanding of human gene regulation and complex diseases1,2, and measuring the evolutionary sequence constraint can establish the functional relevance of putative regulatory elements in the human genome3-9. Identifying the genomic elements that have become constrained specifically in primates has been hampered by the faster evolution of noncoding DNA compared to protein-coding DNA10, the relatively short timescales separating primate species11, and the previously limited availability of whole-genome sequences12. Here we construct a whole-genome alignment of 239 species, representing nearly half of all extant species in the primate order. Using this resource, we identified human regulatory elements that are under selective constraint across primates and other mammals at a 5% false discovery rate. We detected 111,318 DNase I hypersensitivity sites and 267,410 transcription factor binding sites that are constrained specifically in primates but not across other placental mammals and validate their cis-regulatory effects on gene expression. These regulatory elements are enriched for human genetic variants that affect gene expression and complex traits and diseases. Our results highlight the important role of recent evolution in regulatory sequence elements differentiating primates, including humans, from other placental mammals., The authors thank H. Chang, O. Ryder, S. Reilly and E. Karlsson for helpful discussions. Funding: M.C.J., D.d.V., I. Goodhead, R.M.D.B. and J.P.B. were supported by a UKRI NERC standard grant (NE/T000341/1). H.C. and M.H. were supported by NHGRI U24HG002371. M.K. was supported by la Caixa Foundation (ID 100010434), fellowship code LCF/BQ/PR19/11700002, and by the Vienna Science and Technology Fund (WWTF) and the City of Vienna through project VRG20-001. J.D.O. was supported by la Caixa Foundation (ID 100010434) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648. The fellowship code is LCF/BQ/PI20/11760004. F.E.S. was supported by Brazilian National Council for Scientific and Technological Development (CNPq) (Processes 303286/2014-8, 303579/2014-5, 200502/2015-8, 302140/2020-4, 300365/2021-7, 301407/2021-5 and 301925/2021-6), by the Fonds de la Recherche Scientifique - FNRS (#40017464), and by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 801505. Fieldwork for samples collected in the Brazilian Amazon was funded by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq/SISBIOTA Program #563348/2010-0), Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM/SISBIOTA #2317/2011), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES AUX # 3261/2013) to I.F. Samples from Amazônia, Brazil were accessed under SisGen no. A8F3D55. Sampling of non-human primates in Tanzania was funded by the German Research Foundation (KN1097/3-1 to S. Knauf and RO3055/2-1 to CR). No animals in Tanzania were sampled purposely for this study. Details of the original study on Treponema pallidum infection can be requested from S. Knauf. This research was funded by the Vietnamese Ministry of Science and Technology’s Program 562 (grant no. ĐTĐL.CN-64/19). A.N. is supported by AEI-PGC2018-101927-BI00 704 (FEDER/UE), FEDER (Fondo Europeo de Desarrollo Regional)/FSE (Fondo Social Europeo), Unidad de Excelencia María de Maeztu, funded by the AEI (CEX2018-000792-M) and Secretaria d’Universitats i Recerca and CERCA Programme del Departament d’Economia i Coneixement de la Generalitat de Catalunya (GRC 2017 SGR 880). A.D.M. was supported by the National Sciences and Engineering Research Council of Canada and Canada Research Chairs program. Aotus azarae samples from Argentina were obtained with grant support to E.F.-D. from the Zoological Society of San Diego, Wenner-Gren Foundation, the L. S. B. Leakey Foundation, the National Geographic Society, the US National Science Foundation (NSF-BCS-0621020, 1232349, 1503753, 1848954; NSF-RAPID-1219368, NSF-FAIN-1952072; NSF-DDIG-1540255; NSF-REU 0837921, 0924352, 1026991), and the US National Institute on Aging (NIA- P30 AG012836-19, NICHD R24 HD-044964-11). J.H.S. was supported in part by the NIH under award number P40OD024628 - SPF Baboon Research Resource. K.G. was supported by the Swedish Research Council VR (2020-03398). We thank C. Escudé and B. Bed’Homme, and L. Cacheux and J.-P. Gautier for providing guenon cell culture and tissue samples. This research is supported by the National Research Foundation Singapore under its National Precision Medicine Programme (NPM) Phase II Funding (MOH-000588 to P.T. and W.K.L.) and administered by the Singapore Ministry of Health’s National Medical Research Council. The authors thank the Veterinary and Zoology staff at Wildlife Reserves Singapore for their help in obtaining the tissue samples, and the Lee Kong Chian Natural History Museum for storage and provision of the tissue samples. T.M.B. is supported by funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 864203), PID2021-126004NB-100 (MICIIN/FEDER, UE) and Secretaria d’Universitats i Recerca and CERCA Programme del Departament d’Economia i Coneixement de la Generalitat de Catalunya (GRC 2021 SGR 00177). K.L.-T. is a recipient of Distinguished Professor award from the Swedish Research Council and the Knut and Wallenberg Foundation.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Blood DNA methylation signature of diet quality and association with cardiometabolic traits

  • Domínguez Barragán, Jorge
  • Fernández Sanlés, Alba, 1988-
  • Hernáez, Álvaro
  • Llauradó-Pont, Joana
  • Marrugat, Jaume, 1954-
  • Robinson, Oliver
  • Tzoulaki, Ioanna
  • Elosua Llanos, Roberto
  • Lassale, Camille
Aims: Diet quality might influence cardiometabolic health through epigenetic changes, but this has been little investigated in adults. Our aims were to identify cytosine-phosphate-guanine (CpG) dinucleotides associated with diet quality by conducting an epigenome-wide association study (EWAS) based on blood DNA methylation (DNAm) and to assess how diet-related CpGs associate with inherited susceptibility to cardiometabolic traits: body mass index (BMI), systolic blood pressure (SBP), triglycerides, type 2 diabetes (T2D), and coronary heart disease (CHD). Methods and results: Meta-EWAS including 5274 participants in four cohorts from Spain, the USA, and the UK. We derived three dietary scores (exposures) to measure adherence to a Mediterranean diet, to a healthy plant-based diet, and to the Dietary Approaches to Stop Hypertension. Blood DNAm (outcome) was assessed with the Infinium arrays Human Methylation 450K BeadChip and MethylationEPIC BeadChip. For each diet score, we performed linear EWAS adjusted for age, sex, blood cells, smoking and technical variables, and BMI in a second set of models. We also conducted Mendelian randomization analyses to assess the potential causal relationship between diet-related CpGs and cardiometabolic traits. We found 18 differentially methylated CpGs associated with dietary scores (P < 1.08 × 10-7; Bonferroni correction), of which 12 were previously associated with cardiometabolic traits. Enrichment analysis revealed overrepresentation of diet-associated genes in pathways involved in inflammation and cardiovascular disease. Mendelian randomization analyses suggested that genetically determined methylation levels corresponding to lower diet quality at cg02079413 (SNORA54), cg02107842 (MAST4), and cg23761815 (SLC29A3) were causally associated with higher BMI and at cg05399785 (WDR8) with greater SBP, and methylation levels associated with higher diet quality at cg00711496 (PRMT1) with lower BMI, T2D risk, and CHD risk and at cg0557921 (AHRR) with lower CHD risk. Conclusion: Diet quality in adults was related to differential methylation in blood at 18 CpGs, some of which related to cardiometabolic health., C.L. was supported by a fellowship from "la Caixa" Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement no. 847 648. The fellowship code is LCF/BQ/PR21/11840003. The REGICOR study was funded by the Carlos III Health Institute and European Regional Development Fund (FIS PI12/00232; FIS PI15/00051, CIBERCV, CIBERESP) and the Government of Catalonia through the Agency for Management of University and Research Grants (AGAUR: PERIS SLT002/16/00088, 2017SGR222). A.F.-S. was supported by the British Heart Foundation (AA/18/1/34219) and the Medical Research Council (UK MRC) (MC_UU_00011/6). O.R. was supported by a UKRI Future Leaders Fellowship (MR/S03532X/1). The Framingham Heart Study (FHS) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (contract no. N01-HC-25195 and HHSN268201500001I). The Women’s Health Initiative (WHI) programme is funded by the NHLBI (contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221). This manuscript was not prepared in collaboration with investigators of the FHS/WHI, has not been reviewed and/or approved by the FHS/WHI, and does not necessarily reflect the opinions or views of the FHS and WHI investigators or the NHLBI. The funding bodies had no role in the study design, collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The landscape of tolerated genetic variation in humans and primates

  • Gao, Hong
  • Kuderna, Lukas, 1989-
  • Kuhlwilm, Martin
  • Orkin, Joseph D.
  • Águeda, Lidia
  • Blanc, Julie
  • Gut, Marta
  • Juan, David
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Gut, Ivo Glynne
  • Marquès i Bonet, Tomàs, 1975-
  • Kai-How Farh, Kyle
Personalized genome sequencing has revealed millions of genetic differences between individuals, but our understanding of their clinical relevance remains largely incomplete. To systematically decipher the effects of human genetic variants, we obtained whole-genome sequencing data for 809 individuals from 233 primate species and identified 4.3 million common protein-altering variants with orthologs in humans. We show that these variants can be inferred to have nondeleterious effects in humans based on their presence at high allele frequencies in other primate populations. We use this resource to classify 6% of all possible human protein-altering variants as likely benign and impute the pathogenicity of the remaining 94% of variants with deep learning, achieving state-of-the-art accuracy for diagnosing pathogenic variants in patients with genetic diseases., L.F.K.K. was supported by an EMBO STF 8286 (to L.F.K.K.). R.R. was supported by an NIH training grant NIH T32 GM007748. M.K. was supported by “la Caixa” Foundation (ID 100010434 to M.K.), fellowship code LCF/BQ/PR19/11700002 (to M.K.), and the Vienna Science and Technology Fund (WWTF) [10.47379/VRG20001] (to M.K.). J.D.O. was supported by “la Caixa” Foundation (ID 100010434) and the European Union’s Horizon 2020 research and innovation programme under the Marie SkŽodowska-Curie grant agreement 847648. The fellowship code is LCF/BQ/PI20/11760004. F.E.S. has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie SkŽodowska-Curie grant agreement No 801505. F.E.S. also received funds from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (Process nos.: 303286/2014-8, 303579/2014-5, 200502/2015-8, 302140/2020-4, 300365/2021-7, 301407/2021-5, 301925/2021-6,; the International Primatological Society (Conservation grant), The Rufford Foundation (14861-1, 23117-2, 38786-B), the Margot Marsh Biodiversity Foundation (SMA-CCO-G0023, SMA-CCOG0037), and Primate Conservation Inc. (#1713 and #1689). The Mamirauá Institute for Sustainable Development received funds from the Gordon and Betty Moore Foundation (grant 5344 to J.V.A. and F.E.S.) Fieldwork for samples collected in the Brazilian Amazon was funded by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq/SISBIOTA Program 563348/2010-0 to I.P.F.), Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM/SISBIOTA 2317/2011 to I.P.F.), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES AUX 3261/2013) to I.P.F. Sampling of nonhuman primates in Tanzania was funded by the German Research Foundation (KN1097/3-1 to S.K. and RO3055/2-1 to C.R.) and by the US National Science Foundation (BNS83-03506 to J.P.C.) No animals in Tanzania were sampled purposely for this study. Details of the original study on Treponema pallidum infection can be requested from S.K. Sampling of baboons in Zambia was funded by US NSF grant BCS-1029451 to J.P.C., C.J.J., and J.R. The research reported in this manuscript was also funded by the Vietnamese Ministry of Science and Technology’s Program 562 (grant ĐTĐL.CN-64/19). A.N.C. is supported by I+D+i project PID2021-127792NB-I00 funded by MCIN/AEI/10.13039/501100011033 (FEDER Una manera de hacer Europa)” and by “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M) and Departament de Recerca i Universitats de la Generalitat de Catalunya (GRC 2021 SGR 0467). A.D.M. was supported by the National Sciences and Engineering Research Council of Canada and Canada Research Chairs program. The authors thank the Veterinary and Zoology staff at Wildlife Reserves Singapore for their help in obtaining the tissue samples, as well as the Lee Kong Chian Natural History Museum for storage and provision of the tissue samples. We thank H. Doddapaneni, D. M. Muzny, and M. C. Gingras for their support of sequencing at the Baylor College of Medicine Human Genome Sequencing Center. We greatly appreciate the support of R. Gibbs, director of HGSC, for this project and thank the Baylor College of Medicine for internal funding. T.M.B. is supported by funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement 864203 to T.M.B.), PID2021-126004NB-100 (MICIIN/FEDER, UE) and Secretaria d’Universitats i Recerca and CERCA Programme del Departament d’Economia i Coneixement de la Generalitat de Catalunya (GRC 2021 SGR 00177). H.L.R. receives funding from Illumina, Inc to support rare disease gene discovery and diagnosis. M.C.J, D.d.V. I.G., R.M.D.B., and J.P.B. were supported by a UKRI NERC standard grant (NE/T000341/1). We thank P. Karanth (IISc) and H. N. Kumara (SACON) for collecting and providing us with some of the samples from India. S.M.A. was supported by a BINC fellowship from the Department of Biotechnology (DBT), India. We acknowledge the support provided by the Council of Scientific and Industrial Research (CSIR), India, to G.U. for the sequencing at the Centre for Cellular and Molecular Biology (CCMB), India. We acknowledge the Duke Lemur Center for collecting primate samples. This is Duke Lemur Center publication #1560. Samples from Amazônia, Brazil, were accessed under SisGen no. A8F3D55. Aotus azarae samples from Argentina were obtained with grant support to E.F.D. from the Zoological Society of San Diego, the Wenner-Gren Foundation, the L.S.B. Leakey Foundation, the National Geographic Society, the US National Science Foundation (NSF-BCS-0621020, 1232349, 1503753, 1848954; NSF-RAPID-1219368, NSF-FAIN-1952072; NSF-DDIG-1540255; NSF-REU 0837921, 0924352, 1026991) and the US National Institute on Aging (NIA- P30 AG012836-19, NICHD R24 HD-044964-11). E.F.D. thanks the Ministry of Production and the Environment of Formosa Province in Argentina for the research presented here. J.H.S. was supported in part by the NIH under award number P40OD024628 - SPF Baboon Research Resource. This research is supported by the National Research Foundation Singapore under its National Precision Medicine Programme (NPM) Phase II Funding (MOH-000588 to P.T. and W.K.L.) and administered by the Singapore Ministry of Health’s National Medical Research Council. J.R. is also a Core Scientist at the Wisconsin National Primate Research Center, Univ. of Wisconsin, Madison. K.G. was supported by the Swedish Research Council VR (2020-03398). We acknowledge the institutional support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and institutional cofinancing with the European Regional Development Fund (MINECO/FEDER, BIO2015-71792-P). We also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d’Empresa i Coneixement and the CERCA Programme to the institute. The research reported in this manuscript was also funded by the Vietnamese Ministry of Science and Technology’s Program 562 (grant no. ĐTĐL.CN-64/19) to M.D.L.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Use of traditional medicine and control of hypertension in 12 African countries

  • Lassale, Camille
  • Jouven, Xavier
Background: use of traditional medicine (TM) is widespread in sub-Saharan Africa as a treatment option for a wide range of disease. We aimed to describe main characteristics of TM users and estimate the association of TM use with control of hypertension. Methods: we used data on 2128 hypertensive patients of a cross-sectional study (convenience sampling), who attended cardiology departments of 12 sub-Saharan African countries (Benin, Cameroon, Congo, Democratic Republic of the Congo, Gabon, Guinea, Côte d'Ivoire, Mauritania, Mozambique, Niger, Senegal, Togo). To model association of TM use with odds of uncontrolled, severe and complicated hypertension, we used multivariable mixed logistic regressions, and to model the association with blood pressure (systolic (SBP) and diastolic (DBP)) we used mixed linear models. All models were adjusted for age, sex, wealth, adherence to hypertension conventional treatment and country (random effect). Results: a total of 512 (24%) participants reported using TM, varying across countries from 10% in the Congo to 48% in Guinea. TM users were more likely to be men, living in rural area, poorly adhere to prescribed medication (frequently due to its cost). Use of TM was associated with a 3.87 (95% CI 1.52 to 6.22)/1.75 (0.34 to 3.16) mm Hg higher SBP/DBP compared with no use; and with greater odds of severe hypertension (OR=1.34; 95% CI 1.04 to 1.74) and of any hypertension complication (OR=1.27; 95% CI 1.01 to 1.60), mainly driven by renal complication (OR=1.57; 95% CI 1.07 to 2.29) after adjustment for measured confounders. Conclusions: the use of TM was associated with higher blood pressure, more severe hypertension and more complications in Sub-Saharan African countries. The widespread use of TM needs to be acknowledged and worked out to integrate TM safely within the conventional healthcare., Camille Lassale is supported by a fellowship from 'La Caixa' Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847 648. The fellowship code is LCF/BQ/PR21/11840003. Bamba Gaye is supported by a Lefoulon Delalande grant and a Fondation Bettencourt Schueller Price. The EIGHT study is supported by INSERM (Institut national de la Santé et de la Recherche Médicale), AP-HP (Assistance Publique Hôpitaux de Paris), Paris Descartes University.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Trajectories of antidepressant use and 6-year change in body weight: a prospective population-based cohort study

  • Lassale, Camille
  • Lugon, Gabriela
  • Hernáez, Álvaro
  • Frank, Philipp
  • Marrugat, Jaume, 1954-
  • Ramos, Rafel
  • Garre-Olmo, Josep
  • Elosua Llanos, Roberto
Background: Antidepressant drug treatment may be associated with weight gain, but long-term studies are lacking. Methods: We included 3,127 adults (1,701 women) from the REGICOR study, aged 55.6 (SD = 11.6) years on average in 2003-2006, living in the northeast of Spain. They had data at two time points (baseline and a median of 6.3 years later) on self-reported antidepressant use, body weight and height, and on baseline smoking, physical activity, diet quality, education, civil status, and depressive symptoms assessed with the Patient Health Questionnaire (PHQ-9) at follow-up. We defined four trajectories of antidepressant use as follows: never use, new use at follow-up, initial use discontinued, repeated use at both time points. We used multivariable linear models to estimate the association of these trajectories with the percentage of weight change. In people without obesity at baseline (n = 2,404), we also estimated the association with obesity incidence at follow-up. Results: The average 6-year weight gain was 0.53 kg (1.01% body weight), and 24.5% of the participants gained >5% of body weight. The majority (83.6%) of participants did not report any use of antidepressants, 6.2% initiated during follow-up, 5.1% discontinued it, and 5.1% reported their use at both time points. In multivariable analyses, compared to never users, all trajectories were associated with greater weight gain: +1.78% (0.57, 2.98) for initial use discontinued, +2.08% (0.97, 3.19) for new use at follow-up, and +1.98% (95% CI: 0.75, 3.20) for repeated use. In non-obese participants at baseline (n = 2,404), the odds ratio for becoming obese was 2.06 (1.03, 3.96) for repeated use and non-statistically significant for the other trajectories. Conclusions: In a population-based adult cohort, repeated use of antidepressants was strongly associated with weight gain. New and discontinued use was associated with weight gain, but non-significantly to obesity incidence. Given the global obesity epidemic and the widespread use of antidepressants, weight management and metabolic monitoring should be encouraged and integrated into depression follow-up guidelines alongside antidepressant prescriptions., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was funded by the Carlos III Health Institute CIBERCV (CB16/11/00246). CL is supported by a Ramon y Cajal Fellowship RYC2020-029599 funded by MICIU/AEI/10.13039/501100011033 and the European Social Fund “Invest in your future”. She was supported by a fellowship from “La Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 847 648. The fellowship code is LCF/BQ/PR21/11840003. The REGICOR study was funded by the Carlos III Health Institute–European Regional Development Fund (FIS PI12/00232; FIS PI15/00051, CIBERCV, CIBERESP), and the Government of Catalonia through the Agency for Management of University and Research Grants (PERIS SLT002/16/00088, 2017SGR222). The funding bodies had no role in the study design, collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?

  • Akinci, Muge
  • Sánchez Benavides, Gonzalo
  • Brugulat Serrat, Anna, 1986-
  • Peña-Gómez, Cleofé
  • Palpatzis, Eleni
  • Shekari, Mahnaz
  • Deulofeu, Carme
  • Fuentes-Julian, Sherezade
  • Salvadó, Gemma
  • González de Echávarri, José Maria
  • Suárez-Calvet, Marc
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Background: the COVID-19 pandemic may worsen the mental health of people reporting subjective cognitive decline (SCD) and therefore their clinical prognosis. We aimed to investigate the association between the intensity of SCD and anxious/depressive symptoms during confinement and the underlying mechanisms. Methods: two hundred fifty cognitively unimpaired participants completed the Hospital Anxiety and Depression Scale (HADS) and SCD-Questionnaire (SCD-Q) and underwent amyloid-β positron emission tomography imaging with [18F] flutemetamol (N = 205) on average 2.4 (± 0.8) years before the COVID-19 confinement. During the confinement, participants completed the HADS, Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), and an ad hoc questionnaire on worries (access to primary products, self-protection materials, economic situation) and lifestyle changes (sleep duration, sleep quality, eating habits). We investigated stress-related measurements, worries, and lifestyle changes in relation to SCD. We then conducted an analysis of covariance to investigate the association of SCD-Q with HADS scores during the confinement while controlling for pre-confinement anxiety/depression scores and demographics. Furthermore, we introduced amyloid-β positivity, PSS, and BRS in the models and performed mediation analyses to explore the mechanisms explaining the association between SCD and anxiety/depression. Results: in the whole sample, the average SCD-Q score was 4.1 (± 4.4); 70 (28%) participants were classified as SCD, and 26 (12.7%) were amyloid-β-positive. During the confinement, participants reporting SCD showed higher PSS (p = 0.035) but not BRS scores (p = 0.65) than those that did not report SCD. No differences in worries or lifestyle changes were observed. Higher SCD-Q scores showed an association with greater anxiety/depression scores irrespective of pre-confinement anxiety/depression levels (p = 0.002). This association was not significant after introducing amyloid-β positivity and stress-related variables in the model (p = 0.069). Amyloid-β positivity and PSS were associated with greater HADS irrespective of pre-confinement anxiety/depression scores (p = 0.023; p < 0.001). The association of SCD-Q with HADS was mediated by PSS (p = 0.01). Conclusions: higher intensity of SCD, amyloid-β positivity, and stress perception showed independent associations with anxious/depressive symptoms during the COVID-19 confinement irrespective of pre-confinement anxiety/depression levels. The association of SCD intensity with anxiety/depression was mediated by stress perception, suggesting stress regulation as a potential intervention to reduce affective symptomatology in the SCD population in the face of stressors., This research was supported by Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMAU. EMAU holds a “Ramón y Cajal” fellowship (RYC2018-026053-I). EMAU holds a grant from the Ministry of Science and Innovation (PID2019-111514RA-I00). The research leading to these results has received funding from the “la Caixa” Foundation (LCF/PR/GN17/10300004), the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project. Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2017-SGR-892. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant Agreement No. 948677) and the Instituto de Salud Carlos III (PI19/00155) and a fellowship from “la Caixa” Foundation (ID 100010434) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Proteomic polygenic risk scores of age-related plasma protein levels reveal a role for Metalloproteinase inhibitor 2 (TIMP2) in cognitive performance

  • Anastasi, Federica
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Yang, Chengran
  • Gorijala, Priyanka
  • Timsina, Jigyasha
  • Hernández-Villamizar, Felipe
  • Lorenzini, Luigi
  • Campo, Marta del
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Cruchaga, Carlos
  • Suárez-Calvet, Marc
  • Vilor Tejedor, Natàlia, 1988-
Several studies in mice have identified blood proteins that influence brain aging, yet translating these findings into humans remains challenging. To address this gap, we conducted a systematic review that identified 12 proteins reported to have an aging or rejuvenating effect in murine brains. Using protein quantitative trait loci data, we computed proteomic polygenic risk scores (protPRSs) capturing the lifelong genetic predisposition to higher or lower plasma protein levels and their regulation. We first validated the prediction accuracy of these protPRSs in two independent cohorts: 10 protPRSs in the Knight-ADRC and 7 protPRSs in the ALFA+ cohort significantly predicted their corresponding protein levels, although effect sizes were modest. We then examined their association with cognitive performance in cognitively unimpaired individuals at risk of Alzheimer's disease of the ALFA+ cohort. Among the protPRSs tested, the metalloproteinase inhibitor 2 (TIMP2) protPRS was significantly associated with better global cognition and episodic memory. These associations were consistent across stratifications by sex, APOE-ε4, and amyloid-β status, although some did not survive multiple testing corrections. TIMP2 protPRS correlated with measured TIMP2 levels, but actual plasma concentrations were not significantly related to cognition. This finding aligns with murine evidence of TIMP2's brain-rejuvenating role. By leveraging genetic predisposition to protein abundance and regulation, protPRSs may provide complementary insight into long-term biological processes not captured by single protein measurements. Our results support TIMP2 as a candidate for further investigation in the context of brain aging and cognitive decline., This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/)and the Departments of Neurology and Psychiatry at Washington University School of Medicine. MS-C receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project "PI19/00155" and "PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from "la Caixa" Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). NV-T was supported by the Spanish Ministry of Science and Innovation - State Research Agency (IJC2020-043216-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU»/PRTR and currently receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). Additionally, NV-T is supported in part by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals

  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • Milà Alomà, Marta
  • Vilor Tejedor, Natàlia, 1988-
  • Operto, Grégory
  • Falcón, Carles
  • Grau, Oriol (Grau Rivera)
  • Arenaza Urquijo, Eider M.
  • Minguillón, Carolina
  • Fauria, Karine
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
Purpose: To determine whether the APOE-ε4 allele modulates the relationship between regional β-amyloid (Aβ) accumulation and cognitive change in middle-aged cognitively unimpaired (CU) participants. Methods: The 352 CU participants (mean aged 61.1 [4.7] years) included completed two cognitive assessments (average interval 3.34 years), underwent [18F]flutemetamol Aβ positron emission tomography (PET), T1w magnetic resonance imaging (MRI), as well as APOE genotyping. Global and regional Aβ PET positivity was assessed across five regions-of-interest by visual reading (VR) and regional Centiloids. Linear regression models were developed to examine the interaction between regional and global Aβ PET positivity and APOE-ε4 status on longitudinal cognitive change assessed with the Preclinical Alzheimer's Cognitive Composite (PACC), episodic memory, and executive function, after controlling for age, sex, education, cognitive baseline scores, and hippocampal volume. Results: In total, 57 participants (16.2%) were VR+ of whom 41 (71.9%) were APOE-ε4 carriers. No significant APOE-ε4*global Aβ PET interactions were associated with cognitive change for any cognitive test. However, APOE-ε4 carriers who were VR+ in temporal areas (n = 19 [9.81%], p = 0.04) and in the striatum (n = 8 [4.14%], p = 0.01) exhibited a higher decline in the PACC. The temporal areas findings were replicated when regional PET positivity was determined with Centiloid values. Regionally, VR+ in the striatum was associated with higher memory decline. As for executive function, interactions between APOE-ε4 and regional VR+ were found in temporal and parietal regions, and in the striatum. Conclusion: CU APOE-ε4 carriers with a positive Aβ PET VR in regions known to accumulate amyloid at later stages of the Alzheimer's disease (AD) continuum exhibited a steeper cognitive decline. This work supports the contention that regional VR of Aβ PET might convey prognostic information about future cognitive decline in individuals at higher risk of developing AD. Clinicaltrials: gov Identifier: NCT02485730. Registered 20 June 2015 https://clinicaltrials.gov/ct2/show/NCT02485730 and ClinicalTrials.gov Identifier:NCT02685969. Registered 19 February 2016 https://clinicaltrials.gov/ct2/show/NCT02685969 ., The research leading to these results has received funding from “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2021 SGR 00913. NV-T is funded by a postdoctoral grant, Juan de la Cierva Programme (FJC2018-038085-I), Ministry of Science and Innovation-Spanish State Research Agency. Her research has received additional support of “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan 2016–2020 Grant SLT002/16/00201). OG-R is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I) and receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568). EA-U is supported by Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), a “Ramón y Cajal” fellowship (RYC2018-026053-I) and by a grant of the Ministry of Science and Innovation (PID2019-111514RA-I00). MS-C receives funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). JD-G holds a “Ramón y Cajal” fellowship (RYC-2013-13054).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer's disease and neurodegeneration stratified by sex

  • Cumplido-Mayoral, Irene
  • Operto, Grégory
  • Falcón, Carles
  • Shekari, Mahnaz
  • Cacciaglia, Raffaele
  • Milà Alomà, Marta
  • Minguillón, Carolina
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • OASIS study
Brain-age can be inferred from structural neuroimaging and compared to chronological age (brain-age delta) as a marker of biological brain aging. Accelerated aging has been found in neurodegenerative disorders like Alzheimer's disease (AD), but its validation against markers of neurodegeneration and AD is lacking. Here, imaging-derived measures from the UK Biobank dataset (N=22,661) were used to predict brain-age in 2,314 cognitively unimpaired (CU) individuals at higher risk of AD and mild cognitive impaired (MCI) patients from four independent cohorts with available biomarker data: ALFA+, ADNI, EPAD, and OASIS. Brain-age delta was associated with abnormal amyloid-β, more advanced stages (AT) of AD pathology and APOE-ε4 status. Brain-age delta was positively associated with plasma neurofilament light, a marker of neurodegeneration, and sex differences in the brain effects of this marker were found. These results validate brain-age delta as a non-invasive marker of biological brain aging in non-demented individuals with abnormal levels of biomarkers of AD and axonal injury., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892 and the Spanish Research Agency (AEI) under project PID2020-116907RB-I00 of the call MCIN/ AEI /10.13039/501100011033. FB is supported by the NIHR biomedical research center at UCLH. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study

  • Tristão Pereira, Catarina
  • Fuster, Valentín
  • Oliva, Belén
  • Moreno Arciniegas, Andrea
  • Garcia-Lunar, Ines
  • Perez-Herreras, Cristina
  • Schöll, Michael
  • Suárez-Calvet, Marc
  • Moro, Maria Angeles
  • Garcia-Alvarez, Ana
  • Fernández Ortiz, Antonio
  • Sánchez González, Javier
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Ibáñez, Borja
  • Gispert, Juan Domingo
  • Cortes-Canteli, Marta
Background: Cardiovascular disease and dementia often coexist at advanced stages. Yet, longitudinal studies examining the interplay between atherosclerosis and its risk factors on brain health in midlife are scarce. We aimed to characterise the longitudinal associations between cerebral glucose metabolism, subclinical atherosclerosis, and cardiovascular risk factors in middle-aged asymptomatic individuals. Methods: The Progression of Early Subclinical Atherosclerosis (PESA) study is a Spanish longitudinal observational cohort study of 4184 asymptomatic individuals aged 40-54 years (NCT01410318). Participants with subclinical atherosclerosis underwent longitudinal cerebral [18F]fluorodeoxyglucose ([18F]FDG)-PET, and annual percentage change in [18F]FDG uptake was assessed (primary outcome). Cardiovascular risk was quantified with SCORE2 and subclinical atherosclerosis with three-dimensional vascular ultrasound (exposures). Multivariate regression and linear mixed effects models were used to assess associations between outcomes and exposures. Additionally, blood-based biomarkers of neuropathology were quantified and mediation analyses were performed. Secondary analyses were corrected for multiple comparisons using the false discovery rate (FDR) approach. Findings: This longitudinal study included a PESA subcohort of 370 participants (median age at baseline 49·8 years [IQR 46·1-52·2]; 309 [84%] men, 61 [16%] women; median follow-up 4·7 years [IQR 4·2-5·2]). Baseline scans took place between March 6, 2013, and Jan 21, 2015, and follow-up scans between Nov 24, 2017, and Aug 7, 2019. Persistent high risk of cardiovascular disease was associated with an accelerated decline of cortical [18F]FDG uptake compared with low risk (β=-0·008 [95% CI -0·013 to -0·002]; pFDR=0·040), with plasma neurofilament light chain, a marker of neurodegeneration, mediating this association by 20% (β=0·198 [0·008 to 0·740]; pFDR=0·050). Moreover, progression of subclinical carotid atherosclerosis was associated with an additional decline in [18F]FDG uptake in Alzheimer's disease brain regions, not explained by cardiovascular risk (β=-0·269 [95% CI -0·509 to -0·027]; p=0·029). Interpretation: Middle-aged asymptomatic individuals with persistent high risk of cardiovascular disease and subclinical carotid atherosclerosis already present brain metabolic decline, suggesting that maintenance of cardiovascular health during midlife could contribute to reductions in neurodegenerative disease burden later in life. Funding: Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III, Santander Bank, Pro-CNIC Foundation, BrightFocus Foundation, BBVA Foundation, "la Caixa" Foundation., We thank the PESA participants and the imaging, administrative, and medical PESA teams. The PESA study is equally co-funded by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and Santander Bank (Madrid, Spain) and also receives funding from the Instituto de Salud Carlos III (ISCIII), Madrid, Spain (PI15/02019), the European Regional Development Fund (ERDF—A Way to Build Europe), and the European Social Fund (ESF—Investing in Your Future). CNIC is a Severo Ochoa Center of Excellence (CEX2020-001041-S) and is supported by the ISCIII, the Spanish Ministry for Science and Innovation, and the Pro-CNIC Foundation. CT-P was supported by a “la Caixa” Foundation fellowship (ID 100010434, LCF/BQ/DI19/11730052). MC-C was supported by a Miguel Servet type II research contract (ISCIII, CPII21/00007) and the Fondo de Investigación Sanitaria (ISCIII, PI20/00819). We acknowledge the Sephardic Foundation on Aging and other donors of the Alzheimer's Disease Research (grant number A2022034S), a programme of the BrightFocus Foundation, for support of this research. This work was also partially produced with the support of a 2021 Leonardo Grant for Researchers and Cultural Creators from the BBVA Foundation awarded to MC-C (the Foundation takes no responsibility for the opinions, statements, and contents of this project, which are entirely the responsibility of its authors). BI was supported by the European Research Council (ERC-2018-CoG 819775-MATRIX). MS is supported by the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine; KAW2014.0363), the Swedish Research Council (2017-02869, 2021-02678, 2021-06545), the Swedish state under the agreement between the Swedish Government and the County Councils, the ALF-agreement (ALFGBG-813971, ALFGBG-965326), the Swedish Brain Foundation (FO2021-0311), and the Swedish Alzheimer Foundation (AF-740191). MS-C receives funding from the European Research Council (grant agreement number 948677), project “PI19/00155”, funded by ISCIII and co-funded by the EU, and a fellowship from “la Caixa” Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 847648 (LCF/BQ/PR21/11840004). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018), the EU's Horizon Europe research and innovation programme under grant agreement number 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation, USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the EU's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 860197 (MIRIADE), the EU Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915, #2022-00732), the Swedish state under the agreement between the Swedish Government and the County Councils, the ALF-agreement (#ALFGBG-715986, #ALFGBG-965240), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270), Hjärnfonden, Sweden (#FO2017-0243, #ALZ2022-0006), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer's Association 2022–2025 grant (SG-23-1038904 QC).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform

  • Palmqvist, Sebastian
  • Anastasi, Federica
  • Puig-Pijoan, Albert
  • Fernández-Lebrero, Aida
  • Contador, José
  • Suárez-Calvet, Marc
  • Hansson, Oskar
Global implementation of blood tests for Alzheimer's disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden (n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181. Plasma p-tau217 detected AD pathology with areas under the receiver operating characteristic curves of 0.93-0.96. In secondary care, the accuracies were 89-91%, the positive predictive values 89-95% and the negative predictive values 77-90%. In primary care, the accuracy was 85%, the positive predictive values 82% and the negative predictive values 88%. Accuracy was lower in participants aged ≥80 years (83%), but was unaffected by chronic kidney disease, diabetes, sex, APOE genotype or cognitive stage. Using a two-cutoff approach, accuracies increased to 92-94% in secondary and primary care, excluding 12-17% with intermediate results. Using the plasma p-tau217:Aβ42 ratio did not improve accuracy but reduced intermediate test results (≤10%). Compared with a high-performing mass-spectrometry-based assay for percentage p-tau217, accuracies were comparable in secondary care. However, percentage p-tau217 had higher accuracy in primary care and was unaffected by age. In conclusion, this fully automated p-tau217 test demonstrates high accuracy for identifying AD pathology. A two-cutoff approach might be necessary to optimize performance across diverse settings and subpopulations., We would like to express our gratitude to the participants, and relatives, in all studies, without whom this research would have not been possible. In addition, we thank B. Arslan for analyzing plasma Aβ in the Gothenburg cohort. The BioFINDER group was supported by the National Institute of Aging (grant no. R01AG083740 to O.H., S.P., R.O. and S.J.), Alzheimer’s Association (grant nos. SG-23-1061717 and ZEN24-1069572 to O.H.), GHR Foundation (O.H. and S.P.), European Research Council (ERC, grant no. ADG-101096455 to O.H.), Swedish Research Council (grant nos. 2023-00356 to O.H., 2021-02219 to N.M.-C. and 2018-02052 to S.P.), ERA PerMed (grant no. ERAPERMED2021-184 to O.H.), the Knut and Alice Wallenberg Foundation (grant no. 2022-0231 to O.H.), the European Union’s (EU’s) Horizon Europe research and innovation program under grant agreement no. 101053962 (to O.H.), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University (to O.H.), the Swedish Alzheimer Foundation (grant nos. AF-1011949 and AF-994075 to S.P., AF-994229 to N.M.-C. and AF-981132 to S.P.), the Swedish Brain Foundation (grant nos. FO2023-0163 to N.M.-C., FO2024-0284 and FO2022-0204 to S.P. and FO2021-0293 to O.H.), the family Rönström’s Foundation (grant nos. FRS-0003 to N.M.-C. and FRS-0004 and FRS-0011 to S.P.), the Berg Family Foundation (O.H.), the Parkinson Foundation of Sweden (grant no. 1412/22 to O.H.), the Cure Alzheimer’s fund (O.H.), the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (O.H.), the Skåne University Hospital Foundation (grant no. 2020-O000028 to S.P.), EU Joint Programme Neurodegenerative Diseases (grant no. 2019-03401 to N.M.-C.), WASP and DDLS Joint call for research projects (grant no. WASP/DDLS22-066 to N.M.-C.), Regionalt Forskningsstöd (grant no. 2022-1346 to S.P.) and the Swedish Federal Government under the ALF-agreement (grant nos. 2022-Projekt0107 to N.M.-C., 2022-Projekt0080 to O.H. and 2018-Projekt0226 to S.P.). The precursor of [18F]flutemetamol was sponsored by GE Healthcare. For the Gothenburg group, S.K. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (nos. ALFGBG-1005471, ALFGBG-965923, ALFGBG-81392 and ALFGBG-771071), the Alzheimerfonden (grant nos. AF-842471, AF-737641, AF-929959 and AF-939825), the Swedish Research Council (grant nos. 2019-02075 and 2019-02075_15), Stiftelsen Psykiatriska Forskningsfonden and the Swedish Brain Foundation (grant no. FO2024-0097). A.D. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant no. ALFGBG-984092). H.Z. is a Wallenberg Scholar and a distinguished professor at the Swedish Research Council. K.B. is supported by the Swedish Research Council (grant nos. 2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (grant nos. AF-930351, AF-939721, AF-968270 and AF-994551), Hjärnfonden, Sweden (grant nos. ALZ2022-0006, FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant nos. ALFGBG-965240 and ALFGBG-1006418), the Alzheimer’s Association 2022–2025 (grant no. SG-23-1038904 QC), the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden and an anonymous philanthropist and donor. The Barcelona group thanks P. Ortiz-Romero, M. de Diego, E. Jiménez, J. Torres and M. del Campo for technical support. F.A. received funding from grant no. JDC2022-049347-I, funded by the MCIU/AEI/10.13039/501100011033 and the EU NextGeneration EU/PRTR. M.S.-C. received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001; project PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)). For the Brescia group, A. Pilotto has beensupported by grants of Airalzh Foundation AGYR2021) Life-BIO grant, the LIMPE-DISMOV Foundation Segala Grant 2021, the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209 and PNRR-Health PNRR-MAD-2022-12376110. V.Q. was supported by the H2020 IMI IDEA-FAST (grant no. ID853981). C.T. was supported by the PRIN 2021 RePlast (grant no. 20202THZAW). A. Padovani has been supported by grants of the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209, RF-2019 RF-2019-12369272 and PNRR-Health PNRR-MAD-2022-12376110. The funders had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review or approval of the paper and decision to submit the paper for publication.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups

  • Jiang, Yuanbing
  • Ortiz Romero, Paula, 1994-
  • Puig-Pijoan, Albert
  • Fernández-Lebrero, Aida
  • Contador, José
  • Suárez-Calvet, Marc
  • Ip, Nancy Y.
Introduction: Existing blood-based biomarkers for Alzheimer's disease (AD) mainly focus on its pathological features. However, studies on blood-based biomarkers associated with other biological processes for a comprehensive evaluation of AD status are limited. Methods: We developed a blood-based, multiplex biomarker assay for AD that measures the levels of 21 proteins involved in multiple biological pathways. We evaluated the assay's performance for classifying AD and indicating AD-related endophenotypes in three independent cohorts from Chinese or European-descent populations. Results: The 21-protein assay accurately classified AD (area under the receiver operating characteristic curve [AUC] = 0.9407 to 0.9867) and mild cognitive impairment (MCI; AUC = 0.8434 to 0.8945) while also indicating brain amyloid pathology. Moreover, the assay simultaneously evaluated the changes of five biological processes in individuals and revealed the ethnic-specific dysregulations of biological processes upon AD progression. Discussion: This study demonstrated the utility of a blood-based, multi-pathway biomarker assay for early screening and staging of AD, providing insights for patient stratification and precision medicine. Highlights: The authors developed a blood-based biomarker assay for Alzheimer's disease. The 21-protein assay classifies AD/MCI and indicates brain amyloid pathology. The 21-protein assay can simultaneously assess activities of five biological processes. Ethnic-specific dysregulations of biological processes in AD were revealed., This study was supported in part by the National Key R&D Program of China (2021YFE0203000); the Areas of Excellence Scheme of the University Grants Committee (AoE/M-604/16); the Research Grants Council of Hong Kong (the Collaborative Research Fund [C6027-19GF] and the Theme-Based Research Scheme [T13-605/18 W]); the Innovation and Technology Commission (InnoHK; ITCPD/17-9, INNOHK18SC01, ITS/207/18FP, MRP/042/18X, and MRP/097/20X); Chow Tai Fook Charity Foundation (CTFCF18SC01); the Guangdong Provincial Key S&T Program Grant (2018B030336001); the Guangdong Provincial Fund for Basic and Applied Basic Research (2019B1515130004); and the Fundamental Research Program of Shenzhen Virtual University Park (2021Szvup137). Yuanbing Jiang is a recipient of the Hong Kong Postdoctoral Fellowship Award from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. HKUST PDFS2324-6S04). Marc Suárez-Calvet received funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement No. 948677); Project “PI19/00155,” co-funded by Instituto de Salud Carlos III (ISCIII) and the European Union; and a fellowship from “La Caixa” Foundation (ID 100010434); and a fellowship from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement (No. 847648; LCF/BQ/PR21/11840004). Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe Research and Innovation Programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Neuroimaging-derived biological brain age and its associations with glial reactivity and synaptic dysfunction cerebrospinal fluid biomarkers

  • Cumplido-Mayoral, Irene
  • Sánchez Benavides, Gonzalo
  • Vilor Tejedor, Natàlia, 1988-
  • López-Martos, David
  • Brugulat Serrat, Anna, 1986-
  • Milà Alomà, Marta
  • Falcón, Carles
  • Cacciaglia, Raffaele
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
  • ALFA Study
  • ADNI
Magnetic resonance Imaging (MRI)-derived brain-age prediction is a promising biomarker of biological brain aging. Accelerated brain aging has been found in Alzheimer's disease (AD) and other neurodegenerative diseases. However, no previous studies have investigated the relationship between specific pathophysiological pathways in AD and biological brain aging. Here, we studied whether glial reactivity and synaptic dysfunction are associated with biological brain aging in the earliest stages of the Alzheimer's continuum, and if these mechanisms are differently associated with AD-related cortical atrophy. We further evaluated their effects on cognitive decline. We included 380 cognitively unimpaired individuals from the ALFA+ study, for which we computed their brain-age deltas by subtracting chronological age from their brain age predicted by machine learning algorithms. We studied the cross-sectional linear associations between brain-age delta and cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction (neurogranin, GAP43, synaptotagmin-1, SNAP25, and α-synuclein), glial reactivity (sTREM2, YKL-40, GFAP, and S100b) and inflammation (interleukin-6). We also studied the cross-sectional linear associations between AD signature and these CSF biomarkers, We further evaluated the mechanisms linking baseline brain-age delta and longitudinal cognitive decline by performing mediation analyses. To reproduce our findings on an independent cohort, we included 152 cognitively unimpaired and 310 mild cognitive impaired (MCI) individuals from the ADNI study. We found that higher CSF sTREM2 was associated with a younger brain-age after adjusting for AD pathology, both in ALFA+ cognitively unimpaired and in ADNI MCI individuals. Furthermore, we found that CSF sTREM2 fully mediated the link between older brain-age and cognitive decline in ALFA+. In summary, we showed that the protective microglial state reflected by higher CSF sTREM2 has a beneficial impact on biological brain aging that may partly explains the variability in cognitive decline in early AD stages, independently of AD pathology., The study was approved by the Independent Ethics Committee “Parc de Salut Mar,” Barcelona, and all participants gave written informed consent. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 009132017-SGR-892. MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (FEDER); and from a fellowship from ”la Caixa” Foundation (ID 100010434) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). DLM is supported by the project PI19/00117, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (FEDER). VV has been supported by the project PID2020-116907RB-I00, funded by the Ministry of Science and Innovation - State Research Agency, MCIN/ AEI /10.13039/501100011033. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+). OGR receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III co-funded by the European Union (FEDER) (PI19/00117) and from Ministry of Science and Innovation - State Research Agency MCIN/ AEI /10.13039/501100011033 co-funded by the the European Union «NextGenerationEU»/PRTR (IJC2020-043417-I). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033, co-funded by the the European Union «NextGenerationEU»/PRTR (IJC2020-043216-I). In addition, NV-T receives funding from the Alzheimer’s Disease Data Initiative (ADDI) through the William H. Gates Sr. Fellowship program, and the PID2022-143106OA-I00 project, funded by MCIN/AEI /10.13039/501100011033 and co-funded by the European Union (FEDER). RC is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2021-125433OA-100 (co-funded by the European Union (FEDER)) and a Ramón y Cajal contract (RYC2021-031128-I, co-funded by the European Union «NextGenerationEU»/PRTR).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Sociodemographic determinants of change in cardiovascular health in middle adulthood in a bi-racial cohort

  • Lassale, Camille
  • Cené, Crystal W.
  • Asselin, Anouk
  • Sims, Mario
  • Jouven, Xavier
  • Gaye, Bamba
Background and aims: Cardiovascular health (CVH), as many other aspects of health, is socially patterned. However, little is known about the socioeconomic determinants of following a more or less favourable pattern of CVH change at midlife. Methods: We used data on 11,049 participants in the Atherosclerosis Risk in Communities (ARIC) study, a prospective, population-based, bi-racial cohort that included participants aged 44-66 years in 1987-1989, who attended a second visit 6 years later. At both visits, CVH was assessed with the American Heart Association's Life's Simple 7 (LS7) score ranging 0-14, based on 7 metrics: cholesterol, blood glucose, blood pressure, smoking, body mass index, physical activity, and diet. An LS7 score ≥8 was considered ideal, <8 was considered poor. Multivariable logistic regression models were used. In a first sample (N = 4416) of participants who started with a poor CVH, we modelled odds of improvement (Poor-Ideal vs. Poor-Poor). In a second sample (N = 6633) with baseline ideal CVH, we modelled odds of deterioration (Ideal-Poor vs. Ideal-Ideal). The determinants considered were baseline age, sex, race, educational level, income and working status. Results: The majority (8,347, 75.5%) of participants remained in the same CVH category at both waves: 28.7% poor-poor, and 46.8% ideal-ideal. The remaining 24.5% were evenly split between improving (11.2%) and deteriorating (13.2%). Compared to poor-poor CVH, older participants displayed higher odds of improving to ideal CVH (OR>58yvs < 50y = 1.41; 95% CI:1.17, 1.69), whereas Black race (vs White, OR = 0.68; 0.57, 0.80), low education (vs high, OR = 0.65; 0.53, 0.79) and low income (vs high, OR = 0.71; 0.57, 0.87)) were associated with lower odds of improvement. Compared to ideal-ideal CVH, Black participants (OR = 1.59; 1.33, 1.89), with low education (OR = 1.98; 1.64, 2.39), low income (OR = 1.57; 1.30, 1.88), and non-working (vs currently working, OR = 1.27; 1.06, 1.51) had greater odds of deterioration to poor CVH. Conclusions: We identified vulnerable groups at higher risk of worsening their CVH over time: Black people, with low income, low education, and who are unemployed. Efforts to reduce income and educational gaps and address structural racism, which shapes the distribution of health-promoting and health-harming resources, are paramount to reduce inequities in CVH., Camille Lassale is supported by a fellowship from “La Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847648. The fellowship code is LCF/BQ/PR21/11840003. Bamba Gaye is supported by a FRM (Fondation pour la Recherche Médicale) grant and a Fondation Bettencourt Schueller Price. The ARIC study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institute of Health, Department of Health and Human Services, under contract numbers (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, and HHSN268201700005I).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression

  • Pelkmans, Wiesje
  • Shekari, Mahnaz
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • González Escalante, Armand
  • Kollmorgen, Gwendlyn
  • Carboni, Margherita
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
Introduction: We studied how biomarkers of reactive astrogliosis mediate the pathogenic cascade in the earliest Alzheimer's disease (AD) stages. Methods: We performed path analysis on data from 384 cognitively unimpaired individuals from the ALzheimer and FAmilies (ALFA)+ study using structural equation modeling to quantify the relationships between biomarkers of reactive astrogliosis and the AD pathological cascade. Results: Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/40 was associated with Aβ aggregation on positron emission tomography (PET) and with CSF p-tau181 , which was in turn directly associated with CSF neurofilament light (NfL). Plasma glial fibrillary acidic protein (GFAP) mediated the relationship between CSF Aβ42/40 and Aβ-PET, and CSF YKL-40 partly explained the association between Aβ-PET, p-tau181 , and NfL. Discussion: Our results suggest that reactive astrogliosis, as indicated by different fluid biomarkers, influences the pathogenic cascade during the preclinical stage of AD. While plasma GFAP mediates the early association between soluble and insoluble Aβ, CSF YKL-40 mediates the latter association between Aβ and downstream Aβ-induced tau pathology and tau-induced neuronal injury. Highlights: Lower CSF Aβ42/40 was directly linked to higher plasma GFAP concentrations. Plasma GFAP partially explained the relationship between soluble Aβ and insoluble Aβ. CSF YKL-40 mediated Aβ-induced tau phosphorylation and tau-induced neuronal injury., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan government under grant no. 2017-SGR-892. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe research and innovation program under grant agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the county councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Programme for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institute of Health (NIH), USA (grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). JDG is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

  • Warmenhoven, Noëlle
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • López-Martos, David
  • Ortiz Romero, Paula, 1994-
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Palpatzis, Eleni
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Introduction: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). Methods: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. Results: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL-40 were positively associated with executive functioning in amyloid negative (Aβ-) individuals. Discussion: Our results suggest that a TREM2-mediated microglial response may be associated with better longitudinal cognitive performance. Highlights: Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance. The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology. Targeting microglial reactivity may be a therapeutic strategy for AD prevention., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to thank the collaborators of the ALFA study. Additionally, the authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa17519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet Contract), so-funded by the European Union (FSE+). DLM is supported by the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). CM received funding within the context of EURO-FINGERS, a EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). JDG has received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), Innovative Health Initiative PROMINENT (grant agreement 101112145), EIT Digital (Grant 2021), and from the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project RTI2018102261. EAU has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00), the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and the European Union Joint Program for Neurodegenerative Disorders (JPND2022-138, AC22/00060). EAU is also supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#201700915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB2018092016615); the Swedish Alzheimer Foundation (#AF742881); Hjärnfonden, Sweden (#FO20170243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALFagreement (#ALFGBG715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019466236); the National Institute of Health (NIH), USA (grant #1R01AG06839801); and the Alzheimer's Association 2021 Zenith Award (ZEN21848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship funded by “la Caixa” Foundation (ID 100010434), and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 co-funded by the European Union (FEDER), and from Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I, co-funded by the European Union “Next GenerationEU”/PRTR. NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJDC2020-043216-I, co-funded by the European Union “Next GenerationEU”/PRTR) and project PID2022-143106OA-I00, co-funded by the European Union (FEDER). In addition, NVT receives funding from the Alzheimer's Disease Data Initiative (ADDI) through the Williams H. Gates Sr. Fellowship Program and the Ajuntament de Barcelona in collaboration with “la Caixa” Foundation though the project 23S06083-001.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The potential dual role of tau phosphorylation: plasma phosphorylated-tau217 in newborns and Alzheimer’s disease

  • González Ortiz, Fernando
  • Vávra, Jakub
  • Payne, Emma
  • Kirsebom, Bjørn-Eivind
  • Sjöbom, Ulrika
  • Santos, Cristiano
  • Júlvez Calvo, Jordi
  • Kramer, Kaitlin
  • Zalcberg, David
  • Montoliu-Gaya, Laia
  • Turton, Michael
  • Harrison, Peter
  • Hellström, Ann
  • Zetterberg, Henrik
  • Fladby, Tormod
  • Sanders, Robert D.
  • Blennow, Kaj
Tau phosphorylation plays an important role in brain physiology and pathology. During foetal development, it supports microtubule dynamics and neuroplasticity, whereas in Alzheimer’s disease (AD), it drives pathological tau aggregation and tangle formation. In this multicentre study (n = 462), we measured plasma phosphorylated-tau217 in healthy newborns, premature infants, patients with AD and healthy controls across various age groups. Plasma phosphorylated-tau217 levels were significantly higher in newborns compared to healthy individuals of any age group and even exceeded levels observed in patients with AD. In newborns, plasma phosphorylated-tau217 levels inversely correlated with perinatal factors such as gestational age. Longitudinal analysis of preterm infants demonstrated a decline in serum phosphorylated-tau217 levels over the first months of life, approaching levels observed in young adults. In contrast, elevated plasma phosphorylated-tau217 in older individuals was associated with AD pathology. Our findings corroborate the crucial role of tau phosphorylation in early brain development. However, in AD, tau phosphorylation transitions into a pathological mechanism. The high levels of blood-based phosphorylated-tau217 observed at birth and subsequent clearance might indicate distinct regulatory mechanisms that prevent tau aggregation in early life. Further studies are needed to explore the shared mechanisms of tau phosphorylation in newborns and AD., K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270 and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006 and #FO2024-0048-TK-130), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark and Familjen Rönströms Stiftelse, Stockholm, Sweden. The project was funded by the Norwegian Research Council, JPND/PMI-AD (NRC 311993), the National Institute of Health (R01 AG083874-01). F.G.-O. was funded by the Anna Lisa and Brother Björnsson’s Foundation and Emil och Maria Palms Foundation. M.S.-C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 948677), Project ‘PI19/00155’, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). B.-E.K. was supported by a grant from Helse-Nord (HNF1540-20). H.Z. is a Wallenberg scholar and a distinguished professor at the Swedish Research Council and receives funding from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement no. 101053962 and Swedish State Support for Clinical Research (#ALFGBG-71320).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging

  • Imam, Farhad
  • Anastasi, Federica
  • Suárez-Calvet, Marc
  • Vilor Tejedor, Natàlia, 1988-
  • Global Neurodegeneration Proteomics Consortium (GNPC)
More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. Despite this growing burden, there are currently no cures, and treatment options remain limited due to disease heterogeneity, prolonged preclinical and prodromal phases, poor understanding of disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is crucial for improving early detection, prognosis, staging and subtyping of these conditions. High-dimensional molecular studies in biofluids ('omics') offer promise for scalable biomarker discovery, but challenges in assembling large, diverse datasets hinder progress. To address this, the Global Neurodegeneration Proteomics Consortium (GNPC)-a public-private partnership-established one of the world's largest harmonized proteomic datasets. It includes approximately 250 million unique protein measurements from multiple platforms from more than 35,000 biofluid samples (plasma, serum and cerebrospinal fluid) contributed by 23 partners, alongside associated clinical data spanning Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). This dataset is accessible to GNPC members via the Alzheimer's Disease Data Initiative's AD Workbench, a secure cloud-based environment, and will be available to the wider research community on 15 July 2025. Here we present summary analyses of the plasma proteome revealing disease-specific differential protein abundance and transdiagnostic proteomic signatures of clinical severity. Furthermore, we describe a robust plasma proteomic signature of APOE ε4 carriership, reproducible across AD, PD, FTD and ALS, as well as distinct patterns of organ aging across these conditions. This work demonstrates the power of international collaboration, data sharing and open science to accelerate discovery in neurodegeneration research., We thank all GNPC V1 consortium members who helped support the creation of the V1 harmonized dataset. We thank the participants, their families as well as the cohorts, institutions and their dedicated staff who helped create this consortium. Funding for the majority of biosample analyses was provided by Gates Ventures and Johnson & Johnson. Funding for cohort creation, participant biosample collection and additional biosample analysis was provided by the following sources. ALLFTD data collection and dissemination was supported by the ALLFTD Consortium (U19: AG063911, funded by the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS)) and the former ARTFL & LEFFTDS Consortia (ARTFL: U54 NS092089, funded by NINDS and the National Center for Advancing Translational Sciences; LEFFTDS: U01 AG045390, funded by the NIA and the NINDS). Additional funding support was provided by the National Institutes of Health (NIH)-NIA for Frontotemporal Dementia: Genes, Images, and Emotions: P01 AG019724 and the UCSF Alzheimer’s Disease Research Center: P30 AG062422. Samples from the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the NIA, were used in this study. The ALLFTD proteomic data included in this paper were funded by a grant from Gates Ventures. Alzheimer and Families (ALFA) was supported by funding from the MCIN/AEI/10.13039/501100011033/FEDER, European Union, through the PID2023-153312OB-I00 project; the CaixaResearch Institute under the project titled DETEC-PK; and the RYC2023-043831-I grant, funded by MCIN/AEI/10.13039/501100011033 and the FSE+. Additional researchers receive funding from the JDC2022-049347-I grant, funded by MCIU/AEI/10.13039/501100011033, the European Union NextGenerationEU/PRTR, the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I co-funded by the European Union FSE+, grant PID2022-143106OA-I00 co-funded by the European Union FEDER), the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project SLD077/21/000001, Project ‘PI19/00155’ and ‘PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). The ALFA proteomic data included in this paper were funded by a grant from Gates Ventures. Stichting Alzheimer Nederland and Stichting VUmc provided funds for supporting Alzheimer Center Amsterdam infrastructure. Additionally, ZonMw Memorabel program project ‘PRODIA’, as part of the Deltaplan Dementie, and 2bike4alzheimer (Alzheimer Nederland) are acknowledged for funding this study for the generation of proteomics data for Amsterdam UMC. The baseline ABC-PD study (study period 2014–2017) was funded by a pre-competitive grant from Janssen Research and Development, a division of Janssen Pharmaceutica N.V. The follow-up study (study period 2018–2020) was funded by a grant from the Michael J. Fox Foundation for Parkinson’s Research (grant no. 15227). Neither study sponsor was involved in collection, analysis and interpretation of data, writing of the report or decision to submit the manuscript for publication. Janssen Research and Development was only involved in study design of the baseline visit. Answer ALS was supported by NEALS Biofluid Repository, and Answer ALS collected, annotated and granted permission to use ALS biofluid samples. The proteomic data included in this paper were funded by a grant from Gates Ventures. The Baltimore Longitudinal Study of Aging (BLSA) was supported by the Intramural Research Program (IRP) of the NIH-NIA. Banner Health was supported by Arizona ADRC and Arizona APOE grants from the NIA (P30 AG019610 and R01 AG069453), the state of Arizona, the Banner Alzheimer’s Foundation, the Sun Health Foundation, the Michael J. Fox Foundation and Gates Ventures. Work at Lund University was supported by the NIA (R01AG083740), the ERC (ADG-101096455), the Alzheimer’s Association (ZEN24-1069572 and SG-23-1061717), the GHR Foundation, the Swedish Research Council (2022-00775 and 2021-02219), ERA PerMed (ERAPERMED2021-184), the Knut and Alice Wallenberg Foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s Disease) at Lund University, the Swedish Alzheimer Foundation (AF-980907 and AF-994229), the Swedish Brain Foundation (FO2021-0293 and FO2023-0163), the Parkinson Foundation of Sweden (1412/22), the Cure Alzheimer’s Fund, the Rönström Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Skåne University Hospital Foundation (2020-O000028), the WASP and DDLS joint call for research projects (WASP/DDLS22-066), the Lilly Research Award Program, Regionalt Forskningsstöd (2022-1259) and the Swedish federal government under the ALF agreement (2022-Projekt0080 and 2022-Projekt0107). Additionally, this work was supported by the SciLifeLab & Wallenberg Data Driven Life Science Program (grant no. KAW 2020.0239), the Swedish Research Council (2024-03642), the NIA (U01 AG079847-02) and Gates Ventures. The CHARIOT-PRO study was funded by Johnson & Johnson, Merck, Takeda and Gates Ventures, and analysis was supported by the UKRI Future Leaders Fellowship (MR/S03532X/1 and MR/Y02012X/1) and the NIHR ARC Dementia Fellowship. The Emory ADRC participation was supported by the Emory Goizueta Alzheimer’s Research Disease Center (P50AG025688) and grants from Gates Ventures for the generation of proteomics data, and data collection was supported through funding by NIA grants R01AG053960, R01AG057911, R01AG061800, RF1AG057471, RF1AG057470, R01AG061800, R01AG057911 and R01AG057339. The Kansas ADRC participation was supported by the NIH (P30 AG072973, P30 AG072974 and R01 AG064227) and further supported by the Neil & Norma Hill Foundation, the Annemarie & Arturo Gandioli-Fumagalli Foundation, the Perpetual Foundation, the John Williams Endowment and the Hillcrest Foundation. The proteomic data included in this paper were funded by a grant from Gates Ventures. The Knight ADRC participation was supported by grants from the NIH (R01AG044546, RF1AG053303, RF1AG058501 and U01AG058922), the Michael J. Fox Foundation, the Alzheimer’s Association Zenith Fellows Award (ZEN-22-848604), Gates Ventures and an anonymous foundation. The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444, P01AG03991 and P01AG026276. Additionally, this work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (https://neurogenomics.wustl.edu/) and the Departments of Neurology and Psychiatry at Washington University School of Medicine. The Whitehall II study was supported by the Wellcome Trust (221854/Z/20/Z), the UK Medical Research Council (Y014154, R024227, S011676 and K013351) and the NIA (R01AG056477 and R01AG062553).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays

  • Ashton, Nicholas J.
  • Puig-Pijoan, Albert
  • Milà Alomà, Marta
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Minguillón, Carolina
  • Navalpotro-Gómez, Irene
  • Grau, Oriol (Grau Rivera)
  • Manero, Rosa María
  • Puente Periz, Victor Manuel
  • Torre Fornell, Rafael de la
  • Roquer, Jaume
  • Suárez-Calvet, Marc
Introduction: Direct comparisons of the main blood phosphorylated tau immunoassays in memory clinic populations are needed to understand possible differences. Methods: In the BIODEGMAR study, 197 participants presenting with cognitive complaints were classified into an Alzheimer's disease (AD) or a non-AD cerebrospinal fluid (CSF) profile group, according to their amyloid beta 42/ phosphorylated tau (Aβ42/p-tau) ratio. We performed a head-to-head comparison of nine plasma and nine CSF tau immunoassays and determined their accuracy to discriminate abnormal CSF Aβ42/p-tau ratio. Results: All studied plasma tau biomarkers were significantly higher in the AD CSF profile group compared to the non-AD CSF profile group and significantly discriminated abnormal CSF Aβ42/p-tau ratio. For plasma p-tau biomarkers, the higher discrimination accuracy was shown by Janssen p-tau217 (r = 0.76; area under the curve [AUC] = 0.96), ADx p-tau181 (r = 0.73; AUC = 0.94), and Lilly p-tau217 (r = 0.73; AUC = 0.94). Discussion: Several plasma p-tau biomarkers can be used in a specialized memory clinic as a stand-alone biomarker to detect biologically-defined AD. Highlights: Patients with an Alzheimer's disease cerebrospinal fluid (AD CSF) profile have higher plasma phosphorylated tau (p-tau) levels than the non-AD CSF profile group. All plasma p-tau biomarkers significantly discriminate patients with an AD CSF profile from the non-AD CSF profile group. Janssen p-tau217, ADx p-tau181, and Lilly p-tau217 in plasma show the highest accuracy to detect biologically defined AD. Janssen p-tau217, ADx p-tau181, Lilly p-tau217, Lilly p-tau181, and UGot p-tau231 in plasma show performances that are comparable to their CSF counterparts., The authors would like to express their most sincere gratitude to the BIODEGMAR participants and relatives without whom this research would have not been possible. The authors thank Anna Boronat Rigol, Rachael Burchfield, and Nicholas Kyle Proctor for technical support. They also thank all the staff at University of Gothenburg, Department of Neurology at Hospital del Mar, and Barcelonaβeta Brain Research Center, who supported this project. Thomas K. Karikari was funded by the Swedish Research Council (Vetenskåpradet), the Alzheimer's Association Research Fellowship (#AARF-21-850325), the BrightFocus Foundation (#A2020812F), the International Society for Neurochemistry's Career Development Grant, the Swedish Alzheimer Foundation (Alzheimerfonden; #AF-930627), the Swedish Brain Foundation (Hjärnfonden; #FO2020-0240), the Swedish Dementia Foundation (Demensförbundet), the Swedish Parkinson Foundation (Parkinsonfonden), Gamla Tjänarinnor Foundation, the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Foundation, the Agneta Prytz-Folkes & Gösta Folkes Foundation (#2020-00124), the Gun and Bertil Stohnes Foundation, and the Anna Lisa and Brother Björnsson's Foundation. Oriol Grau-Rivera is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I), and receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568) and the Instituto de Salud Carlos III (PI19/00117). Irene Navalpotro-Gómez receives funding from the Spanish Instituto de Salud Carlos III (ISCIII-FEDER, PI21/00194). Jaume Roquer receives funding from the Spanish Instituto de Salud Carlos III (ISCIII-FEDER, PI21/00194). Jeff L. Dage is supported by the National Institutes of Health (U24AG021886, P30AG072976, and U01AG057195), Roche Diagnostics (RD005665), as well as the Stark Neurosciences Research Institute at Indiana University School of Medicine. Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer's Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), European Union Joint Program for Neurodegenerative Disorders (JPND2021-00694), and the UK Dementia Research Institute at UCL. Kaj Blennow is supported by the Swedish Research Council (#2017-00915), ADDF, USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), and the NIH, USA (grant #1R01AG068398-01). Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease

  • González Ortiz, Fernando
  • González Escalante, Armand
  • Ortiz Romero, Paula, 1994-
  • Minguillón, Carolina
  • Contador, José
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Introduction: Detection of Alzheimer's disease (AD) pathophysiology among individuals with mild cognitive changes and those experiencing subjective cognitive decline (SCD) remains challenging. Plasma phosphorylated tau 217 (p-tau217) is one of the most promising of the emerging biomarkers for AD. However, accessible methods are limited. Methods: We employed a novel p-tau217 immunoassay (University of Gothenburg [UGOT] p-tau217) in four independent cohorts (n = 308) including a cerebrospinal fluid (CSF) biomarker-classified cohort (Discovery), two cohorts consisting mostly of cognitively unimpaired (CU) and mild cognitively impaired (MCI) participants (MYHAT and Pittsburgh), and a population-based cohort of individuals with SCD (Barcelonaβeta Brain Research Center's Alzheimer's At-Risk Cohort [β-AARC]). Results: UGOT p-tau217 showed high accuracy (area under the curve [AUC] = 0.80-0.91) identifying amyloid beta (Aβ) pathology, determined either by Aβ positron emission tomography or CSF Aβ42/40 ratio. In individuals experiencing SCD, UGOT p-tau217 showed high accuracy identifying those with a positive CSF Aβ42/40 ratio (AUC = 0.91). Discussion: UGOT p-tau217 can be an easily accessible and efficient way to screen and monitor patients with suspected AD pathophysiology, even in the early stages of the continuum., This publication is part of the BBRC's β-AARC study, the MYHAT study, and the Pittsburgh study. The authors would like to express their most sincere gratitude to the project participants, without whom this research would have not been possible. The authors would like to thank Altoida for kindly supporting the CSF AD core biomarker characterisation of β-AARC study participants. F.G.-O. was funded by the Anna Lisa and Brother Björnsson's Foundation and Emil och Maria Palms Foundation. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation ə under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation ə under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer's Association 2022-2025 Grant (SG-23-1038904 QC). M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). T.K.K. was supported by grants 1 R01 AG083874-01 and 1U24AG082930 from the National Institutes of Health (NIH), the Swedish Research Council (Vetenskåpradet; 2021-03244), the Alzheimer's Association (AARF-21-850325), the Swedish Alzheimer Foundation (Alzheimerfonden), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Stiftelsen, and the Emil och Wera Cornells stiftelsen. M.G. and the MYHAT study were funded by the NIH (grants AG052521 and R37 AG023651). The other Pittsburgh cohorts were financed by the NIH (grants P30 AG066468, P01AG025204, RF1AG025516, RF1AG052525, R01AG052446, and R01AG052446).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The CSF p-tau/ß-amyloid 42 ratio correlates with brain structure and fibrillary ß-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease

  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • Salvadó, Gemma
  • Milà Alomà, Marta
  • Falcón, Carles
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Grau, Oriol (Grau Rivera)
  • Molinuevo, José Luis
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Quevenco, Frances-Catherine
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
CSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features both in patients and in cognitively unimpaired individuals. The CSF p-tau/Aβ42 ratio, a biomarker combining information from both pathophysiological processes, has emerged as a promising tool for monitoring disease progression, even at pre-clinical stages. Here, we studied the association between the CSF p-tau/Aβ42 ratio with downstream markers of pre-clinical Alzheimer's disease progression including brain structure, glucose metabolism, fibrillary Aβ deposition and cognitive performance in 234 cognitively unimpaired individuals, who underwent cognitive testing, a lumbar puncture, MRI, 18F-fluorodeoxyglucose and 18F-flutemetamol PET scanning. We evaluated both main effects and interactions with Alzheimer's disease risk factors, such as older age, female sex and the apoliporoptein E (APOE)-ɛ4 allele, in a priori defined regions of interest and further examined the associations on the whole-brain using voxel-wise regressions. In addition, as the association between CSF Alzheimer's disease biomarkers and brain structure and function may be non-linear, we tested the interaction between the CSF p-tau/Aβ42 ratio and stages of pre-clinical Alzheimer's disease defined using the amyloid (A) and tau (T) classification. We found significantly positive associations between CSF p-tau/Aβ42 and both cortical Aβ deposition and regional grey matter volume while no effect was observed for brain metabolism. A significant interaction with age indicated that, for the same level of CSF p-tau/Aβ42, older individuals displayed both increased Aβ deposition and lower grey matter volume, in widespread cortical areas. In addition, we found that women compared with men had a greater Aβ fibrillary accumulation in midline cortical areas and inferior temporal regions, for the same level of the CSF biomarker. The impact of CSF p-tau/Aβ42 on grey matter volume was modulated by AT stages, with A+T+ individuals displaying significantly less positive associations in areas of early atrophy in the Alzheimer's continuum. Finally, we found that sex and APOE-ɛ4 modulated the association between the CSF biomarker and episodic memory as well as abstract reasoning, respectively. Our data indicate that the CSF p-tau/Aβ42 ratio is strongly associated with multiple downstream neuropathological events in cognitively unimpaired individuals and may thus serve as a potent biomarker to investigate the earliest changes in pre-clinical Alzheimer's disease. Given that its impact on both Aβ deposition and grey matter volume is modulated by specific risk factors, our results highlight the need to take into account such predisposing variables in both clinical practice and prevention trials., The research leading to these results has received funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. R.C. receives funding from ‘Ministerio de Ciencia, Innovación y Universidades—Agencia Estatal de Investigación’ MCIN/AEI/10.13039/501100011033/FEDER, EU, through project PID2021-125433OA-100 and support from grant RYC2021-031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/Plan de Recuperación, Transformación y Resiliencia (PRTR). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Union’s Horizon Europe research and innovation programme under grant agreement no. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694) and the UK Dementia Research Institute at University College London (UCL) (UKDRI-1003). K.B. is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the Avtal om Läkarutbildning och Forskning (ALF) agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Programme for Neurodegenerative Disorders (JPND2019-466-236), the National Institutes of Health (NIH), USA, (grant #1R01AG068398-01), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495) and the Alzheimer’s Association 2022–25 Grant (SG-23-1038904 QC). M.S.-C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 948677), Project ‘PI19/00155’, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). O.G.-R. is supported by the ‘Ministerio de Ciencia, Innovación y Universidades' (IJC2020-043417-I) and receives funding from the Alzheimer’s Association (2019-AARF-644568) and the Instituto de Salud Carlos III (PI19/00117).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer's prevention research cohort

  • Canals-Gispert, Lidia
  • Cañas-Martínez, Alba
  • Huesa, Gema
  • Suárez-Calvet, Marc
  • Milà Alomà, Marta
  • Arenaza Urquijo, Eider M.
  • Cirillo, Davide
  • Schumacher Dimech, Annemarie
  • Iulita, Maria Florencia
  • Novakova Martinkova, Julie
  • Tartaglia, Maria Carmela
  • Quevenco, Frances-Catherine
  • Santuccione Chadha, Antonella
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Ferretti, Maria Teresa
  • Fauria, Karine
  • Brugulat Serrat, Anna, 1986-
  • ALFA Study
Background: Although there is growing evidence of the association between gender and early diagnosis of preclinical Alzheimer's disease, little attention has been given to the enrolment ratio of men and women in clinical trials and data reporting. Methods: This study aims to analyze gender differences in sociodemographic factors associated with the willingness to participate in clinical trials and undergo specific procedures in the context of an Alzheimer's disease prevention research cohort. 2544 cognitively unimpaired participants from the ALFA parent cohort (age 45-75 years) of the Barcelonaβeta Brain Research Center were contacted through a structured phone call to determine their willingness to participate in Alzheimer's disease clinical trials and undergo trial-related procedures (magnetic resonance imaging, lumbar puncture, positron emission tomography, and cognitive assessment). Sociodemographic data on education, occupational attainment, civil and caregiver status were gathered. Stepwise logistic regression models were performed in order to study the interaction between gender and sociodemographic factors in the willingness to participate in clinical trials and to undergo clinical trial-related procedures. Results: 1,606 out of the 2,544 participants were women (63.1%). Women were significantly younger and had lower educational attainment compared with men. In addition, women were more likely to be caregivers, single and unemployed. Women showed a significantly lower willingness than men to participate in a clinical trial (p = 0.003) and to undergo a lumbar puncture (p < 0.001). Single women were less willing to participate in clinical trials than single men (p = 0.041). Regarding clinical trial-related procedures, women with higher years of education were significantly less willing to undergo a lumbar puncture (p = 0.031). Conclusion: We found gender differences regarding the sociodemographic factors that predict the willingness to participate in clinical trials and to undergo clinical trial-related procedures. Our results highlight the urgent need to design recruitment strategies accounting for gender-related factors, particularly those related to marital status and education., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/10300004. JNM is supported by project nr. LX22NPO5107 (MEYS): Financed by EU – Next Generation EU. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) "A way to make Europe"), and receives the support of a fellowship from”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). EMAU receives funding from the Alzheimer’s Association (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and from the Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI) MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2019-111514RA-I00 and RYC2018-026053-I, co-funded by the European Social Fund (FSE)). GSB receives funding from the Ministry of Science and Innovation/Spanish Research Agency (PID2020-119556RA-I00 funded by MCIN/AEI/https://doi.org/10.13039/501100011033/FEDER, UE). ABS receives funding from the Global Brain Health Institute (GBHI), Alzheimer's Association, Alzheimer's Society (GBHI ALZ UK-21–737797).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Diagnostic performance of plasma Aß42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: an international multi-center study

  • Doecke, James D.
  • González Escalante, Armand
  • Contador, José
  • Suárez-Calvet, Marc
  • Fernández-Lebrero, Aida
  • Puig-Pijoan, Albert
  • Ortiz Romero, Paula, 1994-
  • Jiménez-Moyano, Esther
  • Minguillón, Carolina
  • Campo, Marta del
  • Teunissen, Charlotte E.
Introduction: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aß42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. Methods: Plasma samples (n = 1298) were collected from six international centers. Aß40, Aß42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut-off models. Results: p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aß- dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre-defined cut-offs. Discussion: p-tau181 was the best single plasma marker for detecting AD at any stage. Specific cut-offs are needed to maximize diagnostic performances. Highlights: Phosphorylated tau (p-tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co-pathology in frontotemporal dementia (FTD), p-tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD., O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens. L.G. participated on advisory boards for, and received writing honoraria and travel grants from, Almirall, Biogen, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, and Teva. Work at Lund University was supported by the European Research Council (ADG-101096455), Alzheimer's Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation (AF-980907), Swedish Brain Foundation (FO2021-0293), Parkinson foundation of Sweden (1412/22), Cure Alzheimer's fund, Rönström Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259), and Swedish federal government under the ALF agreement (2022-Projekt0080). The ALFA+ Study has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. M.S.-C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and ‘‘PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). Research of C.E.T. is supported by the European Commission (Marie Curie International Training Network), grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking [JU], grant No. 101034344) and JPND (bPRIDE), European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (22HLT07 NEuroBioStand), CANTATE project funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. C.T. is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). C.T. is recipient of TAP-dementia, a ZonMw funded project (#10510032120003) in the context of the Dutch National Dementia Strategy.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

  • López-Martos, David
  • Suárez-Calvet, Marc
  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • González Escalante, Armand
  • Brugulat Serrat, Anna, 1986-
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Alzheimer's disease (AD) diagnostic guidelines emphasize subjective cognitive decline (SCD) preceding mild cognitive impairment (MCI), implicitly assuming awareness of cognitive decline (ACD) is preserved in preclinical AD. This study aimed to characterize a discrete clinical profile consistent with subtle amnestic anosognosia: decreased ACD, evaluating its association with multimodal core AD biomarkers in cognitively unimpaired (CU) individuals. We analyzed data from CU individuals with baseline CSF biomarkers and 3-year longitudinal neuropsychological assessment (ALFA+ cohort). Decreased ACD was defined by concurrent decline in episodic memory and cognitive awareness using robust longitudinal references (Free and Cued Selective Reminding Test, Memory Binding Test, Wechsler Memory Scale, and Subjective Cognitive Decline Questionnaire). Biomarker outcomes included plasma p-tau181, p-tau181/Aβ42, p-tau217; CSF p-tau181, Aβ42/40, p-tau181/Aβ42, p-tau217; Aβ ([¹⁸F]flutemetamol) and tau PET ([¹⁸F]RO948). Associations of ACD with AD biomarkers were evaluated using linear regression models. Sensitivity analysis was restricted to individuals with memory decline. 350 CU individuals were included (mean age 61 years; 60% female; mean education 14 years; 35% CSF Aβ-positive). Memory decline was identified in 61 (17%) individuals, of whom 25 (41%) exhibited concurrent awareness decline; meeting criteria for decreased ACD. This group demonstrated higher levels of AD pathology compared to the remaining sample. Among fluid biomarkers, CSF p-tau217 showed the strongest association. Neuroimaging revealed elevated frontoparietal Aβ PET, alongside temporal, insular, and frontal tau PET deposition. Sensitivity analysis confirmed that, although less pronounced, this pattern persists at the same threshold of memory decline. This study suggests that assessment of ACD may provide a crucial extension of current AD clinical frameworks., The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa−17–519007). RC received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU, through the project PID2021–125433OA−100 and from the grant RYC2021–031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; MS-C received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); AB-S received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF−23–1145154; HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023–00356, #2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG−71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF−21–831376-C, #ADSF−21–831381-C, #ADSF−21–831377-C, and #ADSF−24–1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022–0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021–00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI−1003), and an anonymous donor; KB is supported by the Swedish Research Council (#2017–00915 and #2022–00732), the Swedish Alzheimer Foundation (#AF−930351, #AF−939721, #AF−968270, and #AF−994551), Hjärnfonden, Sweden (#ALZ2022–0006, #FO2024–0048-TK−130 and FO2024–0048-HK−24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG−965240 and #ALFGBG−1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019–466–236), the Alzheimer’s Association 2021 Zenith Award (ZEN−21–848495), the Alzheimer’s Association 2022–2025 Grant (SG−23–1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous philanthropist and donor; JDG was supported by the Spanish Ministry of Science and Innovation (RYC‑2013–13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018–102261); OG-R received support from the grant IJC2020–043417-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, and receives funding from Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116", co-funded by the European Union/FEDER, and through the project "CB16/10/00417"; GS-B receives support from the grant CP23/00039 (Miguel Servet), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE + , and receives funding from the MCIN/AEI/10.13039/501100011033 through the project PID2020–119556RA-I00 and through the project PID2024–163071OB-I00, funded by MICIU/AEI/10.13039/501100011033 and by the European Union FEDER.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Genetic architecture and mechanisms of host-microbiome interactions from a multi-cohort analysis of outbred laboratory rats

  • Tonnelé, Hélène
  • Morillo Sanz Dias, Felipe
  • García Calleja, Jorge
  • Bosch Fusté, Elena
  • Baud, Amelie
The intestinal microbiome influences health and disease. Its composition is affected by host genetics and environmental exposures. Understanding host genetic effects is critical but challenging in humans, due to the difficulty of detecting, mapping and interpreting them. To address this, we analyse host genetic effects in four cohorts of outbred laboratory rats exposed to distinct but controlled environments. We show that polygenic host genetic effects are consistent across cohort environments. We identify three replicated microbiome-associated loci, one of which involves the sialyltransferase gene St6galnac1 and Paraprevotella. We find a similar association in a human cohort, between ST6GAL1 and Paraprevotella, both of which have been linked with immune and infectious diseases. Moreover, we find indirect (i.e. social) genetic effects on microbiome phenotypes, which substantially increase the total genetic variance. Finally, we identify a novel mechanism whereby indirect genetic effects can contribute to 'missing heritability', This work was supported by a Seed grant from the Centre for Microbiome Innovation, a Sir Henry Wellcome fellowship from the Wellcome Trust (105941/Z/14/Z to A.B.), a fellowship from La Caixa Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska Curie grant agreement No 847648 (LCF/BQ/PI21/11830006 to A.B.), a PRE2021-097413 contract funded by MCIN/AEI/10.13039/501100011033 and FSE+ to H.T., and two NIH/NIDA grants: P50DA037844 and U01DA051234, both to A.A.P. We acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), the Generalitat de Catalunya through the CERCA programme and to the EMBL partnership. This publication includes genotype data generated at the UC San Diego IGM Genomics Center utilising an Illumina NovaSeq 6000 and NovaSeq X Plus that were purchased with funding from a National Institutes of Health SIG grant (S10OD026929). We thank the following members of the Knight lab: Greg Humphrey, MacKenzie Bryant, Karenina Saunders, Caitriona Brennan, and Rodolfo Saldo Bentiez for help processing the gut microbiome samples, and Gail Ackermann for help with metadata and processing. We thank the Rat Genome Database (RGD) team, particularly Jeffrey De Pons, for adapting some features of the Variant Visualizer to help our analyses
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-ß pathology

  • Kac, Przemysław R.
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Ashton, Nicholas J.
  • Shekari, Mahnaz
  • Ortiz Romero, Paula, 1994-
  • Turton, Michael
  • Harrison, Peter
  • Zetterberg, Henrik
  • Gispert, Juan Domingo
  • Karikari, Thomas K.
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Plasma phosphorylated-tau (p-tau) biomarkers show high performance as first-in-line tests in the evaluation of patients with cognitive symptoms and have also found utility in clinical trials for anti-amyloid drug therapies for Alzheimer¿s disease (AD). Plasma p-tau212 is a novel blood biomarker that can discriminate cognitively unimpaired (CU) and subjective cognitive decline patients from mild cognitive impairment (MCI)-AD and AD dementia patients in clinical cohorts. Using Simoa technology, we evaluated plasma p-tau212 for its ability to detect emerging amyloid-beta (Aß) pathology in CU individuals with brain amyloidosis from CSF Aß42/40 ratio (n = 317) or Aß PET scans (n = 277). We benchmarked plasma p-tau212 against p-tau181, p-tau217, and p-tau231 by comparing their accuracies and fold changes for detecting brain amyloidosis. Our results showed that all the plasma p-tau biomarkers are increased in the CU CSF Aß + participants, with the highest median fold change observed for plasma p-tau212. Discrimination performance of the biomarkers to differentiate amyloid PET-positive from amyloid PET-negative participants differed between plasma p-tau biomarkers, being higher for plasma p-tau217 and p-tau212 compared to plasma p-tau181 and p-tau231. Furthermore, plasma p-tau212 was elevated in participants with low Aß burden (CSF Aß-positive, amyloid PET-negative), supporting its potential as a cost-effective, easily implemented biomarker for trial recruitment in early stages. Its further increase in Aß PET-positive participants suggests additional utility for monitoring anti-amyloid therapies., Open access funding provided by University of Gothenburg. Demensförbundet, Anna-Lisa och Bror Björnssons Stiftelse, Alzheimer’s Association, AARF-23-1141384,Marta Milà-Alomà, (#ADSF-21-831376-C,Henrik Zetterberg, #ADSF-21-831381-C, Henrik Zetterberg,#ADSF-21-831377-C, Henrik Zetterberg, #ADSF-24-1284328-C, Henrik Zetterberg, ZEN-21-848495, Kaj Blennow, #AARF-21-850325, Thomas K. Karikari, Vetenskapsrådet, #2023-00356, Henrik Zetterberg, #2022-01018, Henrik Zetterberg, #2019-02397, Henrik Zetterberg, #ALFGBG-71320, Henrik Zetterberg, #2017-00915,Kaj Blennow, (#ALFGBG-715986, Kaj Blennow, #ALFGBG-965240, Kaj Blennow, 2021-03244, Thomas K. Karikari, HORIZON EUROPE Reforming and enhancing the European Research and Innovation system, 101053962, Henrik Zetterberg, 948677, Marc Suárez-Calvet, Alzheimer’s Drug Discovery Foundation, 201809-2016862, Henrik Zetterberg, #RDAPB-201809-2016615, Kaj Blennow, European Partnership on Metrology, NEuroBioStand,Henrik Zetterberg, #22HLT07, Henrik Zetterberg, the Bluefield Project, Cure Alzheimer’s Fund, Olav Thon Stiftelsen, Familjen Erling-Perssons Stiftelse, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, #FO2022-0270, Henrik Zetterberg, #FO2017-0243,Kaj Blennow, #ALZ2022-0006, Kaj Blennow, HORIZON EUROPE Marie Sklodowska-Curie Actions, 860197 (MIRIADE), Henrik Zetterberg, No 847648 LCF/BQ/PR21/11840004, Marc Suárez-Calvet, EU Joint Programme – Neurodegenerative Disease Research, JPND2021-00694, Henrik Zetterberg, University College London Hospitals Biomedical Research Centre, UK Dementia Research Institute, UKDRI-1003, Henrik Zetterberg, Departament de Salut, Generalitat de Catalunya, SLD077/21/000001,Marc Suárez-Calvet, PI19/00155,Marc Suárez-Calvet, PI22/00456, Marc Suárez-Calvet,’la Caixa’ Foundation, ID 100010434, Marc Suárez-Calvet, Instituto de Salud Carlos III, Alzheimerfonden, #AF-930351, Kaj Blennow, #AF-939721,Kaj Blennow, #AF-968270, Kaj Blennow, European Union Joint Program for Neurodegenerative Disorders, JPND2019-466-236, Kaj Blennow, National Institute of Health (NIH), #1R01AG068398-01, Kaj Blennow, 1 RF1 AG052525-01A1, Thomas K. Karikari, 5 P30 AG066468-04, Thomas K. Karikari, 5 R01 AG053952-05, Thomas K. Karikari, 3 R01 MH121619-04S1, Thomas K. Karikari, 5 R37 AG023651-18, Thomas K. Karikari, 2 RF1 AG025516-12A1, Thomas K. Karikari, 5 R01 AG073267-02, Thomas K. Karikari, 2 R01 MH108509-06, Thomas K. Karikari, 5 R01 AG075336-02,Thomas K. Karikari, 5 R01 AG072641-02, Thomas K. Karikari, 2 P01 AG025204-16, Thomas K. Karikari, WaAina (Ann) llströms and Mary-Ann Sjöbloms stiftelsen, Emil och Wera Cornells Stiftelse.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer's disease

  • López-Martos, David
  • Cacciaglia, Raffaele
  • Suárez-Calvet, Marc
  • Salvadó, Gemma
  • Shekari, Mahnaz
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Brugulat Serrat, Anna, 1986-
  • Minguillón, Carolina
  • Tonietto, Matteo
  • Borroni, Edilio
  • Klein, Gregory
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
  • ALFA Study
Background The objective of this study was to provide a multimodal biomarker characterization of amnestic objective subtle cognitive decline (obj-SCD) in aging and preclinical Alzheimer's disease (AD). Methods Prospective observational study; data from the Alzheimer's and Families+ (ALFAs+) cohort, including cognitively unimpaired (CU) individuals with available baseline CSF biomarkers (normal or AD continuum profiles) and longitudinal neuropsychological assessment (2 time points, 3-year follow-up). Amnestic obj-SCD was defined using robust longitudinal neuropsychological references with multivariate base rate thresholds of significant decline (Free and Cued Selective Reminding Test, Memory Binding Test, Wechsler Memory Scale IV: Logical Memory). Study outcomes included plasma p-tau217, NfL, and GFAP; CSF p-tau181/Aß42, NfL, and GFAP; Aß and tau PET; and MRI Grey Matter volume (GMv). The associations of amnestic obj-SCD with fluid (plasma and CSF) and neuroimaging biomarkers (PET and GMv) were evaluated using mixed-effects and voxel-wise linear regression models, respectively. Results 350 CU individuals were included (mean age 61 years; 60% female; mean education 14 years; 35% CSF Aß-positive). Amnestic obj-SCD was identified in 10% of the sample, associated with greater AD pathology (higher plasma p-tau217, CSF p-tau181/Aß42, global Aß PET, medial temporal tau PET), neurodegeneration (higher plasma and CSF NfL, reduced GMv in cingulate cortex, longitudinal GMv reductions in hippocampus) and inflammation (higher plasma and CSF GFAP, longitudinal GMv increases in neocortical brain regions). Discussion These findings highlight the need for standardized clinical staging criteria to enhance early detection and risk stratification in aging and preclinical AD., The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). R.C. received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU,through the project PID2021-125433OA-100 and from the grant RYC2021-031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; M.S.-C. received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); A.B.-S. received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF-23-1145154; H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003), and an anonymous donor; K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous filantropist and donor; J.D.G. was supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261); O.G.-R. was supported by the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva program IJC2020-043417-I), funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116" and co-funded by the European Union/FEDER. OG-R also receives funding from F. Hoffmann-La Roche Ltd, and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U; G.S.-B. was supported by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE+, supported by MCIN/AEI/10.13039/501100011033, through the project PID2020-119556RA-I00 and grant CP23/00039.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Physical activity changes during midlife link to brain integrity and amyloid burden

  • Akinci, Muge
  • Aguilar Dominguez, Pablo
  • Palpatzis, Eleni
  • Shekari, Mahnaz
  • Garcia Prat, Marina
  • Deulofeu, Carme
  • Fauria, Karine
  • García Aymerich, Judith
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Introduction: Evidence suggests that midlife physical activity may reduce Alzheimer's disease (AD) risk. In at-risk individuals, we investigated midlife physical activity changes in relation to AD-related pathologies. Methods: We included 337 cognitively unimpaired adults with baseline and follow-up physical activity evaluations within 4.07 ± 0.84 years. We performed multiple regressions considering follow-up amyloid-PET burden and MRI-based medial temporal lobe cortical thickness as outcomes. Independent variables encompassed changes in adherence to World Health Organization (WHO)-recommended physical activity levels, activity amounts, and sedentary behavior (no activity reported). Results: Remaining sedentary was associated with lower cortical thickness compared to doing limited physical activity, maintaining adherence, or becoming adherent to WHO recommendations. Becoming adherent to recommendations was linked to lower amyloid burden compared to becoming non-adherent. Increased activity amounts showed a dose-dependent association with lower amyloid burden. Discussion: Increasing physical activity and new adherence to WHO recommendations could be key objectives for preventive strategies during midlife. Clinical trial registration information: Registered at Clinicaltrials.gov (identifier: NCT02485730). Highlights: Boosting physical activity in midlife may have beneficial effects in preclinical AD. Physical activity increases relate to lower Aβ burden in a dose-dependent manner. Remaining sedentary links to lower cortical thickness in AD-vulnerable structures. New adherence to WHO-recommended physical activity levels may enhance brain health., This work was supported by ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Support has also been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. EMA-U has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID). EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF) and EU Joint Programme-Neurodegenerative Disease Research (JPND2022-138). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). We acknowledge support from the grant CEX2018-000806-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Blood pressure and Alzheimer's disease biomarkers in cognitively unimpaired adults: a multicenter study

  • Osset-Malla, Mariona
  • Martínez-Velasco, Aitana
  • Sánchez Benavides, Gonzalo
  • Buongiorno, Mariateresa
  • Sierra, Alejandro de la
  • Shekari, Mahnaz
  • Minguillón, Carolina
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Vállez García, David
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Grau-Rivera, Oriol
  • ALFA Study
BACKGROUND: Hypertension is a modifiable risk factor for dementia, potentially influencing Alzheimer's disease (AD) pathology. Understanding this relationship is essential for developing interventions to reduce dementia risk. OBJECTIVES: We investigated cross-sectional and longitudinal associations between blood pressure and AD biomarkers in cerebrospinal fluid (CSF) and amyloid (Aß) positron emission tomography (PET) in cognitively unimpaired adults. DESIGN: Prospective observational study. SETTING: We analyzed data from cognitively unimpaired participants from three observational prospective European studies: ALFA+ (NCT02485730), EPAD-LCS (NCT02804789), and AMYPAD PNHS (EudraCT: 2018-002,277-22). MEASUREMENTS: ALFA+ participants had either CSF biomarkers (CSF Aß42, Aß40, p-tau181, t-tau) and/or Aß PET data. EPAD participants had CSF biomarkers (CSF Aß42, p-tau181, t-tau), and AMYPAD participants had Aß PET data. All participants had available data about diabetes, use of hypertensive medication, and waist-to-hip ratio. Multivariable linear regression models were used to analyze cross-sectional associations between systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) with CSF biomarkers or Aß PET (Centiloid units, CL); longitudinal associations were tested by means of delta CL scores between baseline and follow-up to assess Aß PET changes over time. RESULTS: We included 405 participants from ALFA+ (mean age 61.1 years; 60 % female), 1104 from EPAD (mean age 64.8 years; 59.1 % female), and 340 from AMYPAD (mean age 71.8 years; 60 % female). In ALFA+, DBP was negatively associated with CSF Aß40 (p = 0.016) and p-tau181 (p = 0.050), while there was a non-significant trend towards a positive association between SBP and CL over time (p = 0.058). In EPAD, DBP was negatively associated with CSF Aß42 (p < 0.001) and p-tau181 (p = 0.014), while PP was positively associated with CSF Aß42 (p = 0.024). In AMYPAD, SBP (p = 0.002) and PP (p = 0.003) were positively associated with CL at baseline, with a similar non-significant trend being found for DBP (p = 0.089). Higher DBP (p = 0.042) was significantly associated to increased CL over time, with a similar non-significant trend being found for SBP (p = 0.072). We did not find significant associations between blood pressure and longitudinal changes in CSF biomarkers. CONCLUSIONS: Elevated blood pressure was associated with increased Aß PET accumulation in cognitively unimpaired individuals. Further research is warranted to elucidate potential mechanisms underlying the negative associations between DBP and CSF biomarkers, which do not reflect the typical AD molecular signature. These findings highlight the relevance of high blood pressure as a potential risk factor for cognitive decline., The research leading to these results has received funding from “la Caixa” Foundation (ID 100,010,434), under agreement LCF/PR/GN17/50,300,004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519,007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00,913. OGR has received funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644,568) and Instituto de Salud Carlos III (PI19/00,117) and receives funding from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020–043,417-I). OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020–043,417-I/MCIN/AEI/10.13039/501,100,011,033) and the European Union laquoNextGenerationEUraquo/PRTR. GSB receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020–119556RA-I00. MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948,677); ERA PerMed (ERAPERMED2021–184); Project "PI19/00,155″ and “PI22/00,456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100,010,434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847,648 (LCF/BQ/PR21/11,840,004). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023–00,356; #2022–01,018 and #2019–02,397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101,053,962, Swedish State Support for Clinical Research (#ALFGBG-71,320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809–2016,862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21–831,376-C, #ADSF-21–831,381-C, #ADSF-21–831,377-C, and #ADSF-24–1284,328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022–0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860,197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021–00,694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017–00,915 and #2022–00,732), the Swedish Alzheimer Foundation (#AF-930,351, #AF-939,721 and #AF-968,270), Hjärnfonden, Sweden (#FO2017–0243 and #ALZ2022–0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715,986 and #ALFGBG-965,240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019–466–236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21–848,495), and the Alzheimer’s Association 2022–2025 Grant (SG-23–1038,904 QC). This work used data and/or samples from the EPAD project which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement n° 115,736 and an Alzheimer’s Association Grant (SG-21–818,099-EPAD). This work also used data from AMYPAD PNHS that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115,952. This Joint Undertaking received support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Awareness of episodic memory and meta-cognitive profiles: associations with cerebrospinal fluid biomarkers at the preclinical stage of the Alzheimer's continuum

  • López-Martos, David
  • Suárez-Calvet, Marc
  • Milà Alomà, Marta
  • Gispert, Juan Domingo
  • Minguillón, Carolina
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
Introduction: The lack of cognitive awareness, anosognosia, is a clinical deficit in Alzheimer's disease (AD) dementia. However, an increased awareness of cognitive function, hypernosognosia, may serve as a marker in the preclinical stage. Subjective cognitive decline (SCD) might correspond to the initial symptom in the dynamic trajectory of awareness, but SCD might be absent along with low awareness of actual cognitive performance in the preclinical stage. We hypothesized that distinct meta-cognitive profiles, both hypernosognosia and anosognosia, might be identified in preclinical-AD. This research evaluated the association between cerebrospinal fluid (CSF) AD biomarkers and the awareness of episodic memory, further exploring dyadic (participant-partner) SCD reports, in the preclinical Alzheimer's continuum. Methods: We analyzed 314 cognitively unimpaired (CU) middle-aged individuals (mean age: 60, SD: 4) from the ALFA+ cohort study. Episodic memory was evaluated with the delayed recall from the Memory Binding Test (MBT). Awareness of episodic memory, meta-memory, was defined as the normalized discrepancy between objective and subjective performance. SCD was defined using self-report, and dyadic SCD profiles incorporated the study partner's report using parallel SCD-Questionnaires. The relationship between CSF Aβ42/40 and CSF p-tau181 with meta-memory was evaluated with multivariable regression models. The role of SCD and the dyadic contingency was explored with the corresponding stratified analysis. Results: CSF Aβ42/40 was non-linearly associated with meta-memory, showing an increased awareness up to Aβ-positivity and a decreased awareness beyond this threshold. In the non-SCD subset, the non-linear association between CSF Aβ42/40 and meta-memory persisted. In the SCD subset, higher Aβ-pathology was linearly associated with increased awareness. Individuals presenting only study partner's SCD, defined as unaware decliners, exhibited higher levels of CSF p-tau181 correlated with lower meta-memory performance. Discussion: These results suggested that distinct meta-cognitive profiles can be identified in preclinical-AD. While most individuals might experience an increased awareness associated with the entrance in the AD continuum, hypernosognosia, some might be already losing insight and stepping into the anosognosic trajectory. This research reinforced that an early anosognosic profile, although at increased risk of AD-related decline, might be currently overlooked considering actual diagnostic criteria, and therefore its medical attention delayed., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The design and execution of the study were independent of any influence from funding sources. This includes data collection, analysis, interpretation, manuscript preparation, review, and approval. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. DL-M was supported by Instituto de Salud Carlos III through the project PI19/00117 (Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/”Investing in your future”). MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). JG receives funding from the European Comission Innovative Health Initiative (Grant Agreement: 101112145), the BrightFocus Foundation (Grant Reference ID: A2022034S), and La Marató de TV3 (Project: 202318 30-31-32). HZ was a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB was supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC). OG-R was supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. GS-B was supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma phosphorylated tau 217 to identify preclinical Alzheimer disease

  • Salvadó, Gemma
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Hansson, Oskar
Importance: Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective: To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, setting, and participants: This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures: Plasma p-tau217 levels measured by immunoassay. Main outcome and measures: Aβ status, determined by CSF or Aβ PET biomarkers. Results: Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P = .12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P < .001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P < .001). Conclusions and relevance: The findings highlight the potential of plasma p-tau217 as a stand-alone test-or when used in a sequential 2-step approach alongside PET or CSF testing-as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments., Work at the authors’ research center (Lund University) was supported by the National Institute of Aging (R01AG083740), European Research Council (ADG-101096455), Alzheimer’s Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775 and 2018-02052, 2021-02219), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg Foundation (2022-0231), Strategic Research Area MultiPark (multidisciplinary research in Parkinson’s disease) at Lund University, Swedish Alzheimer Foundation (AF-980907, AF-994229), Swedish Brain Foundation (FO2021-0293, FO2023-0163), Parkinson Foundation of Sweden (1412/22), Cure Alzheimer’s Fund, Rönström Family Foundation, Berg Family Foundation, Greta och Johan Kock Foundation, WASP and DDLS joint call for research projects (WASP/DDLS22-066), Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259), Bundy Academy at Lund University (2025-2026-2024-2428) and the Swedish federal government under the ALF agreement (2022-Projekt0080, 2022-Projekt0107). Dr Salvadó received funding from the European Union’s Horizon 2020 Research and Innovation Program under Marie Skłodowska-Curie action grant agreement number 101061836, an Alzheimer’s Association Research Fellowship (AARF-22-972612), the Brightfocus Foundation (A2024007F), the Alzheimerfonden (AF-980942, AF-994514, AF-1012218), Greta och Johan Kocks research grants and travel grants from the Strategic Research Area MultiPark (multidisciplinary research in Parkinson’s disease) at Lund University. This study was also funded by the Instituto de Salud Carlos III (Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España) through the projects INT21/00073, PI20/01473 and PI23/01786 to Dr Fortea) and the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Program 1, partly jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una Manera de Hacer Europa, and cofunded by the European Regional Development Fund/European Social Fund. This work was also supported by National Institutes of Health grants R01 AG056850; R21 AG056974, R01 AG061566, R01 AG081394, and R61AG066543 to Dr Fortea. It was also supported by Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to Dr Fortea) and Horizon 2020–Research and Innovation Framework Programme from the European Union (H2020-SC1-BHC-2018-2020 to Dr Fortea). Dr Suárez-Calvet received funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III and cofunded by the European Union; and from a fellowship from la Caixa Foundation (100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). The Translational Biomarkers in Aging and Dementia cohort is supported by the Weston Brain Institute, Canadian Institutes of Health Research (MOP-11-51-31; RFN 152985, 159815 and 162303), Canadian Consortium of Neurodegeneration and Aging (MOP-11-51-31-team 1), the Alzheimer’s Association (NIRG-12-92090 and NIRP-12-259245), Brain Canada Foundation (CFI Project 34874; 33397), the Fonds de Recherche du Québec–Santé (Chercheur Boursier, 2020-VICO-279314) and the Colin J. Adair Charitable Foundation. The Wisconsin Registry for Alzheimer's Prevention cohort was supported by R01AG027161, R01AG021155 and P30AG062715 from SC Johnson. The Australian Imaging Biomarkers and Lifestyle Study of Ageing study is funded by the Commonwealth Scientific and Industrial Research Organization, and the National Health and Medical Research Council. The Sant Pau Initiative on Neurodegeneration cohort received funding from the Fondo de Investigaciones Sanitario, Instituto de Salud Carlos III (PI21/00791, PI14/01126, PI17/01019, PI20/01473, PI13/01532, PI16/01825, PI18/00335, PI19/00882, PI18/00435, PI22/00611, INT19/00016, INT23/00048, PI17/01896, and AC19/00103), and the Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas program, jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa. The Sant Pau Initiative on Neurodegeneration cohort was also supported by the National Institutes of Health (grants 1R01AG056850-01A1; R21AG056974; and R01AG061566), by Generalitat de Catalunya (2017-SGR-547, SLT006/17/125, SLT006/17/119, SLT002/16/408), Marató TV3 Foundation grants 20141210, 044412 and 20142610, a grant from the Fundació Bancaria La Caixa (Down Alzheimer Barcelona Neuroimaging Initiative project), Fundació Catalana Síndrome de Down and Fundació Víctor Grífols i Lucas. Horizon 21 Consortium is partly funded by Jérôme Lejeune Foundation. PREVENT-AD was launched in 2011 as a $13.5 million, 7-year public-private partnership using funds provided by McGill University, the Fonds de Recherche du Québec–Santé, an unrestricted research grant from Pfizer Canada, the J.L. Levesque Foundation, the Lemaire Foundation, the Douglas Hospital Research Centre and Foundation, the Government of Canada, and the Canada Fund for Innovation. Additional funding sources include the Canadian Institutes of Health Research (438655), US National Institutes of Health (R01 AG068563), Alzheimer’s Association, Alzheimer Society of Canada and Brain Canada grants. Dr Blennow is supported by the Swedish Research Council (2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (AF-930351, AF-939721, AF-968270, and AF-994551), Hjärnfonden, Sweden (ALZ2022-0006 and FO2024-0048-TK-130), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (ALFGBG-965240 and ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer, the Kirsten and Freddy Johansen Foundation, and Familjen Rönströms Stiftelse. Dr Teunissen is supported by the European Commission (Marie Curie International Training Network, grant agreement 860197) and TAME, Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking, grant 101034344) and JPND (bPRIDE, CCAD), European Partnership on Metrology, cofinanced from the European Union’s Horizon Europe Research and Innovation Programme and by the participating states (22HLT07 NEuroBioStand). The CANTATE project was funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Michael J Fox Foundation, Health Holland, the Dutch Research Council, Alzheimer Drug Discovery Foundation, the Selfridges Group Foundation, and Alzheimer Netherlands. Dr Teunissen is also a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (73305095007) and Health~Holland, Topsector Life Sciences & Health (LSHM20106), and of TAP-dementia, a ZonMw-funded project (10510032120003) in the context of the Dutch National Dementia Strategy.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Time-encoded ASL reveals lower cerebral blood flow in the early AD continuum

  • Falcón, Carles
  • Minguillón, Carolina
  • Fauria, Karine
  • Cascales Lahoz, Diego
  • Contador, José
  • Fernández-Lebrero, Aida
  • Navalpotro-Gómez, Irene
  • Puig-Pijoan, Albert
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
Introduction: Cerebral blood flow (CBF) is reduced in cognitively impaired (CI) Alzheimer's disease (AD) patients. We checked the sensitivity of time-encoded arterial spin labeling (te-ASL) in measuring CBF alterations in individuals with positive AD biomarkers and associations with relevant biomarkers in cognitively unimpaired (CU) individuals. Methods: We compared te-ASL with single-postlabel delay (PLD) ASL in measuring CBF in 59 adults across the AD continuum, classified as CU amyloid beta (Aβ) negative (-), CU Aβ positive (+), and CI Aβ+. We sought associations of CBF with biomarkers of AD, cerebrovascular disease, synaptic dysfunction, neurodegeneration, and cognition in CU participants. Results: te-ASL was more sensitive at detecting CBF reduction in the CU Aβ+ and CI Aβ+ groups. In CU participants, lower CBF was associated with altered biomarkers of Aβ, tau, synaptic dysfunction, and neurodegeneration. Discussion: CBF reduction occurs early in the AD continuum. te-ASL is more sensitive than single-PLD ASL at detecting CBF changes in AD. Highlights: Lower CBF can be detected in CU subjects in the early AD continuum. te-ASL is more sensitive than single-PLD ASL at detecting CBF alterations in AD. CBF is linked to biomarkers of AD, synaptic dysfunction, and neurodegeneration., We want to express our most sincere gratitude to the ALFA project participants and relatives, without whom this research would not have been possible. We thank Roche Diagnostics International Ltd for providing the NeuroToolKit kits to measure CSF biomarkers, Eli Lilly and Company for providing the measurements of the in-house assay for CSF and plasma p-tau217, and GE Healthcare for providing the doses of [18F] flutemetamol PET. Lastly, we would like to thank Valeria Di Giacomo, PhD, and Allison Clark, from ThePaperMill, for providing writing support, funded by The Fundació Pasqual Maragall. Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through projects PI19/00155 and PI22/00456 (cofunded by the European Union FEDER), the Department of Research and Universities of the Generalitat de Catalunya through the project 2021 SGR 01137, the HNA Foundation through the project PROAD, and the ERA PerMed ERA-NET and the Department of Health of the Generalitat de Catalunya (DS-CAT) through the project SLD077/21/000001. Moreover, Marc receives support from a fellowship provided by “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant agreement No. 847648 (fellowship code LCF/BQ/PR21/11840004). Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (Nos. 2022-01018 and 2019-02397), the European Union's Horizon Europe research and innovation program under Grant agreement No. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (No. 201809-2016862), the AD Strategic Fund and the Alzheimer's Association (Nos. ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant agreement No. 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Oriol Grau-Rivera receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (cofunded by the European Unior FEDER), and the MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I (cofunded by the European Union NextGenerationEU/PRTR).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease

  • Argiris, Georgette
  • Akinci, Muge
  • Peña-Gómez, Cleofé
  • Palpatzis, Eleni
  • Garcia Prat, Marina
  • Shekari, Mahnaz
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Ashton, Nicholas J.
  • Karikari, Thomas K.
  • Brinkmalm-Westman, Ann
  • Lantero Rodriguez, Juan
  • Fauria, Karine
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Background: Cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction, neuroinflammation, and glial response, complementing Alzheimer's disease (AD) core biomarkers, have improved the pathophysiological characterization of the disease. Here, we tested the hypothesis that the co-expression of multiple CSF biomarkers will help the identification of AD-like phenotypes when biomarker positivity thresholds are not met yet. Methods: Two hundred and seventy cognitively unimpaired adults with family history (FH) of sporadic AD (mean age = 60.6 ± 4.85 years, 64.8% women) underwent lumbar puncture, magnetic resonance imaging (n = 266) and positron emission tomography imaging (n = 239) protocols, and clinical evaluations. CSF Aβ42, Aβ40, p-tau181, p-tau217, p-tau231, NfL, neurogranin, sTREM2, YKL40, GFAP, S100, α-Synuclein, SYT1, and SNAP25 were measured. Participants were clustered based on CSF biomarker co-expression with an agglomerative algorithm. The predictive value of the classification against brain and cognitive outcomes was evaluated. Results: Three clusters (C) were identified. Higher Aβ burden and CSF p-tau was the hallmark of C1. The other two clusters showed lower Aβ burden but higher expression of glial (C2) or synaptic markers (C3). Participants in C1 showed an AD-like clinical phenotype, comprising participants with the overall highest percentage of two parent FH and APOE-ε4 carriers, in addition to comprising more females compared to C2. C3 displayed better vascular health compared to C1. C2 were older and comprised a lower percentage of females compared to C3. C1 showed an AD-like gray matter reduction in medial temporal (notably hippocampus) and frontal regions that were not observed in Aβ42/40 + compared with Aβ42/40 - . Furthermore, Aβ42/40 - participants in C1 showed GM reduction in inferior temporal areas compared with Aβ42/40 + participants overall. C1 membership also predicted cognitive decline in executive function, but not memory, beyond Aβ + status, overall suggesting a better prognosis in Aβ42/40 + participants without C1 membership. Additionally, C1 displayed a higher rate of conversion to Aβ + (25%) over time. Conclusions: Our results suggest that examining multiple CSF biomarkers reflecting diverse pathological pathways may complement and/or outperform AD core biomarkers and thresholding approaches to identify individuals showing a clinical and cognitive AD-like phenotype, including higher conversion to Aβ + , GM reductions and cognitive decline. The clinical utility of this approach warrants further investigation and replication in other cohorts., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Support has also been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research (JPND2022-138). E.P is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). GA receives support from the Alzheimer’s Association research fellowship (23AARF-1028873). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation program under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21–831,376-C, #ADSF-21–831,381-C, and #ADSF-21–831,377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Program – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project "PI19/00155″, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Past connectivity but recent inbreeding in cross river gorillas determined using whole genomes from single hairs

  • Alvarez-Estape, Marina
  • Pawar, Harvinder
  • Fontseré Alemany, Clàudia, 1992-
  • Trujillo, Amber E.
  • Gunson, Jessica L.
  • Bergl, Richard A.
  • Bermejo, Magdalena
  • Linder, Joshua M.
  • McFarland, Kelley
  • Oates, John F.
  • Sunderland-Groves, Jacqueline L.
  • Orkin, Joseph D.
  • Higham, James P.
  • Viaud-Martinez, Karine A.
  • Lizano, Esther, 1974-
  • Marquès i Bonet, Tomàs, 1975-
The critically endangered western gorillas (Gorilla gorilla) are divided into two subspecies: the western lowland (G. g. gorilla) and the Cross River (G. g. diehli) gorilla. Given the difficulty in sampling wild great ape populations and the small estimated size of the Cross River gorilla population, only one whole genome of a Cross River gorilla has been sequenced to date, hindering the study of this subspecies at the population level. In this study, we expand the number of whole genomes available for wild western gorillas, generating 41 new genomes (25 belonging to Cross River gorillas) using single shed hairs collected from gorilla nests. By combining these genomes with publicly available wild gorilla genomes, we confirm that Cross River gorillas form three population clusters. We also found little variation in genome-wide heterozygosity among them. Our analyses reveal long runs of homozygosity (>10 Mb), indicating recent inbreeding in Cross River gorillas. This is similar to that seen in mountain gorillas but with a much more recent bottleneck. We also detect past gene flow between two Cross River sites, Afi Mountain Wildlife Sanctuary and the Mbe Mountains. Furthermore, we observe past allele sharing between Cross River gorillas and the northern western lowland gorilla sites, as well as with the eastern gorilla species. This is the first study using single shed hairs from a wild species for whole genome sequencing to date. Taken together, our results highlight the importance of implementing conservation measures to increase connectivity among Cross River gorilla sites., This research was funded by Ministerio de Ciencia, Universidades e Investigación (FPI, PRE2018) (to M.A.-E.), Generalitat de Catalunya (FI_B100131) (to H.P.), European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 864203), PID2021-126004NB-100 (MICIIN/FEDER, UE), “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M), NIH 1R01HG010898-01A1 and Secretaria d’Universitats i Recerca and CERCA Programme del Departament d’Economia i Coneixement de la Generalitat de Catalunya (GRC 2021 SGR 00177) (to T.M.B.). Illumina Inc. provided support for next-generation library sequencing, Beatriu de Pinós postdoctoral programme of the Government of Catalonia’s Secretariat for Universities and Research of the Ministry of Economy and Knowledge 2017 BP 00265 (to J.O.). The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (No 847648. The fellowship code is LCF/BQ/PI20/11760004) (to J.O.).
Repisalud
Publication Artículo científico (JournalArticle)

Genetic characterization of the ALFA study: Uncovering genetic profiles in the Alzheimer's continuum.

  • Vilor-Tejedor, Natalia
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Minguillón, Carolina
  • Sadeghi, Iman
  • González-Escalante, Armand
  • Crous-Bou, Marta
  • Suárez-Calvet, Marc
  • Grau-Rivera, Oriol
  • Brugulat-Serrat, Anna
  • Sánchez-Benavides, Gonzalo
  • Esteller, Manel
  • Fauria, Karine
  • Molinuevo, José Luis
  • Navarro, Arcadi
  • Gispert, Juan Domingo
INTRODUCTION In 2013, the ALzheimer's and FAmilies (ALFA) project was established to investigate pathophysiological changes in preclinical Alzheimer's disease (AD), and to foster research on early detection and preventive interventions. METHODS We conducted a comprehensive genetic characterization of ALFA participants with respect to neurodegenerative/cerebrovascular diseases, AD biomarkers, brain endophenotypes, risk factors and aging biomarkers. We placed particular emphasis on amyloid/tau status and assessed gender differences. Multiple polygenic risk scores were computed to capture different aspects of genetic predisposition. We additionally compared AD risk in ALFA to that across the full disease spectrum from the Alzheimer's Disease Neuroimaging Initiative (ADNI). RESULTS Results show that the ALFA project has been successful at establishing a cohort of cognitively unimpaired individuals at high genetic predisposition of AD. DISCUSSION It is, therefore, well-suited to study early pathophysiological changes in the preclinical AD continuum. Highlights Prevalence of ε4 carriers in ALzheimer and FAmilies (ALFA) is higher than in the general European population The ALFA study is highly enriched in Alzheimer's disease (AD) genetic risk factors beyond APOE AD genetic profiles in ALFA are similar to clinical groups along the continuum ALFA has succeeded in establishing a cohort of cognitively unimpaired individuals at high genetic AD risk ALFA is well suited to study pathogenic events/early pathophysiological changes in AD.
Repisalud
Publication Artículo científico (JournalArticle)

The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study.

  • Cumplido-Mayoral, Irene
  • Brugulat-Serrat, Anna
  • Sánchez-Benavides, Gonzalo
  • González-Escalante, Armand
  • Anastasi, Federica
  • Milà-Alomà, Marta
  • López-Martos, David
  • Akinci, Muge
  • Falcón, Carles
  • Shekari, Mahnaz
  • Cacciaglia, Raffaele
  • Arenaza-Urquijo, Eider M
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Grau-Rivera, Oriol
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
BACKGROUND Neuroimaging-based brain-age delta has been shown to be a mediator linking cardiovascular risk factors to cognitive function. We aimed to assess the mediating role of brain-age delta in the association between modifiable risk factors of dementia and longitudinal cognitive decline in middle-aged and older individuals who are asymptomatic, stratified by Alzheimer's disease pathology. We also explored whether the mediation effect is specific to cognitive domain. METHODS In this cohort study, we included participants from the ALFA+ cohort aged between 45 years and 65 years who were cognitively unimpaired and who had available structural MRI, cerebrospinal fluid β-amyloid (Aβ)42 and Aβ40 measurements obtained within 1 year of each other, modifiable risk factors assessment, and cognitive evaluation over 3 years. Participants were recruited from the Barcelonaβeta Brain Research Center (Barcelona, Spain). Included individuals underwent a first assessment between Oct 25, 2016, and Jan 28, 2020, and a follow-up cognitive assessment 3·28 (SD 0·27) years later. We computed brain-age delta and composites of different cognitive function domains (preclinical Alzheimer's cognitive composite [PACC], attention, executive function, episodic memory, visual processing, and language). We used partial least squares path modelling to explore mediation effects in the associations between modifiable risk factors (including cardiovascular, mental health, mood, metabolic or endocrine history, and alcohol use) and changes in cognitive composites. To assess the role of Alzheimer's disease pathology, we computed separate models for Aβ-negative and Aβ-positive individuals. FINDINGS Of the 419 participants enrolled in ALFA+, 302 met our inclusion criteria, of which 108 participants were classified as Aβ-positive and 194 as Aβ-negative. In Aβ-positive individuals, brain-age delta partially mediated (percent mediation proportion 15·73% [95% CI 14·22-16·66]) the association between modifiable risk factors and decline in overall cognition (across cognitive domains). Brain-age delta fully mediated (mediation proportion 28·03% [26·25-29·21]) the effect of modifiable risk factors on the PACC, wherein increased values for risk factors correlated with an older brain-age delta, and, consequently, an older brain-age delta was linked to greater PACC decline. This effect appears to be primarily driven by memory decline. Mediation was not significant in Aβ-negative individuals (3·52% [0·072-4·17]) on PACC, although path coefficients were not significantly different from those in the Aβ-positive group. INTERPRETATION Our findings suggest that brain-age delta captures the association between modifiable risk factors and longitudinal cognitive decline in middle-aged and older people. In asymptomatic middle-aged and older individuals who are Aβ-positive, the pathology might be the strongest driver of cognitive decline, whereas the effect of risk factors is smaller. Our results highlight the potential of brain-age delta as an objective outcome measure for preventive lifestyle interventions targeting cognitive decline. FUNDING La Caixa Foundation, the TriBEKa Imaging Platform, and the Universities and Research Secretariat of the Catalan Government. TRANSLATION For the Spanish translation of the abstract see Supplementary Materials section.
Repisalud
Publication Artículo científico (JournalArticle)

Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study.

  • Tristão-Pereira, Catarina
  • Fuster, Valentin
  • Oliva, Belen
  • Moreno-Arciniegas, Andrea
  • Garcia-Lunar, Ines
  • Perez-Herreras, Cristina
  • Schöll, Michael
  • Suárez-Calvet, Marc
  • Moro, Maria Angeles
  • Garcia-Alvarez, Ana
  • Fernandez-Ortiz, Antonio
  • Sanchez-Gonzalez, Javier
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Ibáñez, Borja
  • Gispert, Juan D
  • Cortes-Canteli, Marta
BACKGROUND Cardiovascular disease and dementia often coexist at advanced stages. Yet, longitudinal studies examining the interplay between atherosclerosis and its risk factors on brain health in midlife are scarce. We aimed to characterise the longitudinal associations between cerebral glucose metabolism, subclinical atherosclerosis, and cardiovascular risk factors in middle-aged asymptomatic individuals. METHODS The Progression of Early Subclinical Atherosclerosis (PESA) study is a Spanish longitudinal observational cohort study of 4184 asymptomatic individuals aged 40-54 years (NCT01410318). Participants with subclinical atherosclerosis underwent longitudinal cerebral [18F]fluorodeoxyglucose ([18F]FDG)-PET, and annual percentage change in [18F]FDG uptake was assessed (primary outcome). Cardiovascular risk was quantified with SCORE2 and subclinical atherosclerosis with three-dimensional vascular ultrasound (exposures). Multivariate regression and linear mixed effects models were used to assess associations between outcomes and exposures. Additionally, blood-based biomarkers of neuropathology were quantified and mediation analyses were performed. Secondary analyses were corrected for multiple comparisons using the false discovery rate (FDR) approach. FINDINGS This longitudinal study included a PESA subcohort of 370 participants (median age at baseline 49·8 years [IQR 46·1-52·2]; 309 [84%] men, 61 [16%] women; median follow-up 4·7 years [IQR 4·2-5·2]). Baseline scans took place between March 6, 2013, and Jan 21, 2015, and follow-up scans between Nov 24, 2017, and Aug 7, 2019. Persistent high risk of cardiovascular disease was associated with an accelerated decline of cortical [18F]FDG uptake compared with low risk (β=-0·008 [95% CI -0·013 to -0·002]; pFDR=0·040), with plasma neurofilament light chain, a marker of neurodegeneration, mediating this association by 20% (β=0·198 [0·008 to 0·740]; pFDR=0·050). Moreover, progression of subclinical carotid atherosclerosis was associated with an additional decline in [18F]FDG uptake in Alzheimer's disease brain regions, not explained by cardiovascular risk (β=-0·269 [95% CI -0·509 to -0·027]; p=0·029). INTERPRETATION Middle-aged asymptomatic individuals with persistent high risk of cardiovascular disease and subclinical carotid atherosclerosis already present brain metabolic decline, suggesting that maintenance of cardiovascular health during midlife could contribute to reductions in neurodegenerative disease burden later in life. FUNDING Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III, Santander Bank, Pro-CNIC Foundation, BrightFocus Foundation, BBVA Foundation, "la Caixa" Foundation.
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

Quantum gravity phenomenology at the dawn of the multi-messenger era—A review

  • Addazi, A.
  • Illana Calero, José Ignacio|||0000-0003-0622-311X
  • Masip Mellado, Manuel|||0000-0002-7750-2514
  • Navas Concha, Sergio
The exploration of the universe has recently entered a new era thanks to the multimessenger paradigm, characterized by a continuous increase in the quantity and quality of experimental data that is obtained by the detection of the various cosmic messengers (photons, neutrinos, cosmic rays and gravitational waves) from numerous origins. They give us information about their sources in the universe and the properties of the intergalactic medium. Moreover, multi-messenger astronomy opens up the possibility to search for phenomenological signatures of quantum gravity. On the one hand, the most energetic events allow us to test our physical theories at energy regimes which are not directly accessible in accelerators; on the other hand, tiny effects in the propagation of very high energy particles could be amplified by cosmological distances. After decades of merely theoretical investigations, the possibility of obtaining phenomenological indications of Planck-scale effects is a revolutionary step in the quest for a quantum theory of gravity, but it requires cooperation between different communities of physicists (both theoretical and experimental). This review, prepared within the COST Action CA18108 ‘‘Quantum gravity phenomenology in the multi-messenger approach", is aimed at promoting this cooperation by giving a state-of-the art account of the interdisciplinary expertise that is needed in the effective search of quantum gravity footprints in the production, propagation and detection of cosmic messengers., Talent Scientific Research Program of College of Physics, Sichuan University 1082204112427, Fostering Program in Disciplines Possessing Novel Features for Natural Science of Sichuan University 2020SCUNL209, 1000 Talent program of Sichuan province 2021, Xunta de Galicia, European Commission European Union ERDF, "Maria de Maeztu'' Units of Excellence program MDM-2016-0692, Red Tematica Nacional de Astroparticulas RED2018-102661-T, La Caixa Foundation 100010434, European Commission 847648 LCF/BQ/PI21/11830030 754510, Ministry of Education, Science & Technological Development, Serbia 451-03-9/2021-14/200124, FSR Incoming Postdoctoral Fellowship Ministry of Education, Science and Technological Development, Serbia 451-03-9/2021-14/200124, University of Rijeka grant uniri-prirod-18-48, Croatian Science Foundation (HRZZ) IP-2016-06-9782, Villum Fonden 29405 DGA-FSE 2020-E2117R, European Regional Development Fund through the Center of Excellence (TK133) "The Dark Side of the Universe'' European Regional Development Fund (ESIF/ERDF), Ministry of Education, Youth & Sports - Czech Republic CoGraDS-CZ.02.1.01/0.0/0.0/15 003/0000437, Blavatnik grant, Basque Government IT-97916 Basque Foundation for Science (IKERBASQUE), European Space Agency C4000120711 4000132310, FNRS (Belgian Fund for Research), Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT), Universidad Nacional Autonoma de Mexico TA100122, National University of La Plata X909 DICYT 042131GR, National Research, Development & Innovation Office (NRDIO) - Hungary 123996, FQXi, Swiss National Science Foundation (SNSF), European Commission 181461 199307, Netherlands Organization for Scientific Research (NWO) 680-91-119 15MV71, Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT) Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research (KAKENHI) 20H01899 20H05853 JP21F21789, Estonian Research Council PRG356, Julian Schwinger Foundation, Generalitat Valenciana Excellence PROMETEO-II/2017/033 PROMETEO/2018/165, Istituto Nazionale di Fisica Nucleare (INFN), European ITN project HIDDeN H2020-MSCA-ITN-2019//860881-HIDDeN, Swedish Research Council, European Commission 2016-05996 European Research Council (ERC) European Commission 668679, Advanced ERC grant TReX, Ministry of Education, Universities and Research (MIUR) 2017X7X85K, Fonds de la Recherche Scientifique - FNRS 4.4501.18, Ministry of Research, Innovation and Digitization - Romania PN19-030102-INCDFM PN-III-P4ID-PCE-2020-2374, United States Department of Energy (DOE) DE-SC0020262, Ministry of Science, ICT & Future Planning, Republic of Korea 075-15-2020-778, German Academic Scholarship Foundation German Research Foundation (DFG) 408049454 420243324 425333893 445990517 Germany's Excellence Strategy (EXC 2121 "Quantum Universe'') 390833306 390837967 Federal Ministry of Education & Research (BMBF) 05 A20GU2 05 A20PX1, Centro de Excelencia "Severo Ochoa'' SEV-2016-0588, CERCA program of the Generalitat de Catalunya, Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR) Generalitat de Catalunya 2017-SGR-1469 2017-SGR-929 ICCUB CEX2019-000918-M, National Science Centre, Poland 2019/33/B/ST2/00050 2017/27/B/ST2/01902, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) 306414/2020-1, Dicyt-USACH 041931MF, National Science Fund of Bulgaria KP-06-N 38/11 RCN ROMFORSK 302640, Comunidad de Madrid 2018-T1/TIC-10431 2019-T1/TIC-13177 S2018/NMT-4291, UK Research & Innovation (UKRI), Science & Technology Facilities Council (STFC) ST/T000759/1 ST/P000258/1 ST/T000732/1 ST/V005596/1, Portuguese Foundation for Science and Technology UIDB/00618/2020 UIDB/00777/2020 UIDP/00777/2020 CERN/FIS-PAR/0004/2019 PTDC/FIS-PAR/29436/2017 PTDC/FISPAR/31938/2017 PTDC/FIS-OUT/29048/2017 SFRH/BD/137127/2018, Centre National de la Recherche Scientifique (CNRS), LabEx UnivEarthS ANR-10-LABX-0023 ANR18-IDEX-0001, Junta de Andalucia European Commission A-FQM-053-UGR18, Natural Sciences and Engineering Research Council of Canada (NSERC) RGPIN-2021-03644, National Science Centre Poland Sonata Bis 2019/33/B/ST2/00050 DEC-2017/26/E/ST2/00763, Natural Sciences and Engineering Research Council of Canada (NSERC) DGIID-DGA 2015-E24/2, Spanish Research State Agency and Ministerio de Ciencia e Innovacion MCIN/AEI PID2019-104114RB-C32 PID2019-105544GB-I00 PID2019-105614GB-C21 PID2019106515GB-I00 PID2019-106802GB-I00 PID2019-107394GB-I00 PID2019-107844GB-C21 PID2019-107847RB-C41 MCIN/AEI PGC2018-095328-B-I00 PGC2018-094856-B-I00 PGC2018-096663-B-C41 PGC2018-096663-B-C44 PGC2018-094626-BC21 PGC2018-101858-B-I00 FPA2017-84543-P FPA2016-76005-C2-1-P, Spanish 'Ministerio de Universidades' BG20/00228 Spanish Government PID2020-115845GBI00 Generalitat de Catalunya Comunidad de Madrid S2018/NMT-4291 Spanish Government PID2019-105544GB-I00, Perimeter Institute for Theoretical Physics, Government of Canada through the Department of Innovation, Science and Economic Development, Province of Ontario through the Ministry of Colleges and Universities, Istituto Nazionale di Fisica Nucleare (INFN), Centre National de la Recherche Scientifique (CNRS), Netherlands Organization for Scientific Research (NWO), Fundamental Questions Institute (FQXi), European Cooperation in Science and Technology (COST) CA18108, Research Council of University of Guilan, Iniziativa Specifica TEONGRAV Iniziativa Specifica QGSKY Iniziativa Specifica QUAGRAP Iniziativa Specifica GeoSymQFT, the Spanish Research State Agency and Ministerio de Ciencia e Innovacion MCIN/AEI PID2020-115845GBI00 PID2019-108485GB-I00 PID2020-113334GB-I00 PID2020-113701GB-I00 PID2020-113775GB-I00 PID2020-118159GB-C41 PID2020-118159GA-C42 PRE2019-089024, Rothchild grant UID/MAT/00212/2020 FPU18/04571
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Subnanokelvin thermometry of an interacting d-dimensional homogeneous Bose gas

  • Miskeen Khan, Muhammad
  • Mehboudi, Mohammad
  • Terças, Hugo
  • Lewenstein, Maciej
  • Garcia March, Miguel Angel|||0000-0001-7092-838X
[EN] We propose experimentally feasible means for nondestructive thermometry of homogeneous Bose-Einstein condensates in different spatial dimensions (d is an element of {1 , 2, 3}). Our impurity-based protocol suggests that the fundamental error bound on thermometry at the subnanokelvin domain depends highly on the dimension, in that the higher the dimension the better the precision. Furthermore, suboptimal thermometry of the condensates by using measurements that are experimentally feasible is explored. We specifically focus on measuring position and momentum of the impurity that belong to the family of Gaussian measurements. We show that, generally, experimentally feasible measurements are far from optimal, except in one dimension, where position measurements are indeed optimal. This makes realistic experiments perform very well at few nanokelvin temperatures for all dimensions, and at subnanokelvin temperatures in the one-dimensional scenario. These results take a significant step towards experimental realization of probe-based quantum thermometry of Bose-Einstein condensates, as it deals with them in one, two, and three dimensions and uses feasible measurements applicable in current experimental setups., M.M.K. acknowledges support from Fundacao para a Ciencia e a Tecnologia (FCT-Portugal) through Grant No. PD/BD/114335/2016. H.T. acknowledges Fundacao para a Ciencia e a Tecnologia (FCT Portugal) through Con-tract No CEECIND/00401/2018, and the financial support through the Quantum Flagship Grant PhoQus (Grant No. 820392) of the European Union. M.A.G.M. acknowledges funding from the Spanish Ministry of Education and Vocational Training (MEFP) through the Beatriz Galindo program 2018 (BEAGAL18/00203) . ICFO group acknowl-edges support from: ERC AdG NOQIA; Agencia Estatal de Investigacion (R&D project CEX2019-000910-S, funded by MCIN/AEI/10.13039/501100011033, Plan Na-tional FIDEUA PID2019-106901GB-I00, FPI, QUANTERA MAQS PCI2019-111828-2, Proyectos de I+D+I ?Retos Co-laboraci?n? QUSPIN RTC2019-007196-7) ; Fundacio Cellex; Fundacio Mir-Puig; Generalitat de Catalunya through the European Social Fund FEDER and CERCA program (AGAUR Grant No. 2017 SGR 134, QuantumCAT \ U16-011424, co-funded by ERDF Operational Program of Catalonia 2014-2020) ; EU Horizon 2020 FET-OPEN OPTOlogic (Grant No 899794) ; National Science Centre, Poland (Symfonia Grant No. 2016/20/W/ST4/00314) ; European Union?s Horizon 2020 research and innova-tion programme under the Marie-Sk?odowska-Curie Grant Agreement No. 101029393 (STREDCH) and No. 847648 (?La Caixa? Junior Leaders fellowships ID100010434: LCF/BQ/PI19/11690013, LCF/BQ/PI20/11760031, LCF/BQ/PR20/11770012, LCF/BQ/PR21/11840013) . M.M. acknowl-edges financial support from the Swiss National Science Foundation (NCCR SwissMAP) . M.M.K. acknowledges Rey group at JILA for the hospitality and for providing the work-ing conditions.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Population annealing with topological defect driven nonlocal updates for spin systems with quenched disorder

  • Cirauqui, David
  • Saavedra, J.R.M.
  • Lewenstein, Maciej
  • Grzybowski, Przemyslaw R.
  • Garcia March, Miguel Angel|||0000-0001-7092-838X
[EN] Population annealing, one of the currently state-of-the-art algorithms for solving spin -glass systems, sometimes finds hard disorder instances for which its equilibration quality at each temperature step is severely damaged. In such cases, therefore, one cannot be sure about having reached the true ground state without vastly increasing the computational resources. In this work, we seek to overcome this problem by proposing a quantum -inspired modification of population annealing. Here we focus on the three-dimensional random plaquette gauge model, whose ground -state energy problem seems to be much harder to solve than that of the standard spin -glass Edwards -Anderson model. In analogy to the toric code, by allowing single bond flips we let the system explore nonphysical states, effectively expanding the configurational space by introducing topological defects that are then annealed through an additional field parameter. The dynamics of these defects allow for the effective realization of nonlocal cluster moves, potentially easing the equilibration process. We study the performance of this method in three-dimensional random plaquette gauge model lattices of various sizes, and we compare it against population annealing. With that we conclude that the newly introduced nonlocal moves are able to improve the equilibration of the lattices, in some cases being superior to a normal population annealing algorithm with a computational resource investment that is 16 times higher., D.C. and P.R.G. would like to thank H. Katzgraber and J. Machta for illuminating discussion and comments that helped to improve the manuscript. D.C. acknowledges funding from Generalitat de Catalunya (AGAUR Doctorats Industrials 2019, 2n termini) . ICFO group acknowledges support from ERC AdG NOQIA; Ministerio de Ciencia y Innovation Agencia Estatal de Investigaciones (PGC2018-097027-B-I00/10.13039/501100011033, CEX2019-000910-S/10.13039/501100011033, Plan National FIDEUA PID2019-106901GB-I00, FPI, QUANTERA MAQS PCI2019-111828-2, QUANTERA DYNAMITE PCI2022-132919, Proyectos de I + D + I "Retos Colabo-racion" QUSPIN RTC2019-007196-7) ; MICIIN with funding from European Union NextGenerationEU (PRTR-C17.I1) and by Generalitat de Catalunya; Fundacio Cellex; Fundacio Mir-Puig; Generalitat de Catalunya (European Social Fund FEDER and CERCA program, AGAUR Grant No. 2021 SGR 01452, QuantumCAT U16-011424, cofunded by ERDF Operational Program of Catalonia 2014-2020) ; Barcelona Supercomputing Center MareNostrum (FI-2023-1-0013) ; EU (PASQuanS2.1, 101113690) ; EU Horizon 2020 FET-OPEN OPTOlogic (Grant No. 899794) ; EU Horizon Europe Program (Grant Agreement No. 101080086-NeQST) , National Science Centre, Poland (Symfonia Grant No. 2016/20/W/ST4/00314) ; ICFO Internal "QuantumGaudi" project; European Union's Horizon 2020 research and innovation program under the Marie-Sklodowska-Curie Grant Agreement No. 101029393 (STREDCH) and No. 847648 ("La Caixa" Junior Leaders fellowships ID 100010434: LCF/BQ/PI19/11690013, LCF/BQ/PI20/11760031, LCF/BQ/PR20/11770012, LCF/BQ/PR21/11840013) . Views and opinions expressed are, however, those of the author (s) only and do not necessarily reflect those of the European Union, European Commission, European Climate, Infrastructure and Environment Executive Agency (CINEA) , nor any other granting authority. Neither the European Union nor any granting authority can be held responsible for them. M.& Aacute;.G.-M. acknowledges funding from the Spanish Ministry of Education and Professional Training (MEFP) through the Beatriz Galindo program 2018 (BEAGAL18/00203) , QuantERA II Cofund 2021 PCI2022-133004, Projects of MCIN with funding from European Union NextGenerationEU (PRTR-C17.I1) and by Generalitat Valenciana, with Ref. 20220883 (PerovsQuTe) and COMCUANTICA/007 (QuanTwin) , and Red Tematica RED2022-134391-T.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Gravitational-wave parameter inference with the Newman-Penrose scalar

  • Calderón Bustillo, Juan
  • Wong, Isaac C. F.
  • Sanchís Gual, Nicolás
  • Leong, Samson H. W.
  • Torres Forné, Alejandro
  • Chandra, Koustav
  • Font, José A.
  • Herdeiro, Carlos
  • Radu, Eugen
  • Li, Tjonnie G. F.
Detection and parameter inference of gravitational-wave signals from compact mergers rely on the comparison of the incoming detector strain data 𝑑⁡(𝑡) to waveform templates for the gravitational-wave strain ℎ⁡(𝑡) that ultimately rely on the resolution of Einstein’s equations via numerical relativity simulations. These, however, commonly output a quantity known as the Newman-Penrose scalar 𝜓4⁡(𝑡) which, under the Bondi gauge, is related to the gravitational-wave strain by 𝜓4⁡(𝑡) =𝑑2⁢ℎ⁡(𝑡)/𝑑⁢𝑡2. Therefore, obtaining strain templates involves an integration process that introduces artifacts that need to be treated in a rather manual way. By taking second-order finite differences on the detector data and inferring the corresponding background noise distribution, we develop a framework to perform gravitational-wave data analysis directly using 𝜓4⁡(𝑡) templates. We first demonstrate this formalism, and the impact of integration artifacts in strain templates, through the recovery of numerically simulated signals from head-on collisions of Proca stars injected in Advanced LIGO noise. Next, we reanalyze the event GW190521 under the hypothesis of a Proca-star merger, obtaining results equivalent to those previously published [Phys. Rev. Lett. 126, 081101 (2021)], where we used the classical strain framework. We find, however, that integration errors would strongly impact our analysis if GW190521 was 4 times louder. Finally, we show that our framework fixes significant biases in the interpretation of the high-mass gravitational-wave trigger S200114f arising from the usage of strain templates. We remove the need to obtain strain waveforms from numerical relativity simulations, avoiding the associated systematic errors
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis

  • Martínez García de la Torre, Raquel A.
  • Ayuso García, Paula
  • Varela Rey, Marta María
  • Woodhoo, Ashwin
  • Sancho-Bru, Pau
Defining the trajectory of cells during differentiation and disease is key for uncovering the mechanisms driving cell fate and identity. However, trajectories of human cells remain largely unexplored due to the challenges of studying them with human samples. In this study, we investigate the proteome trajectory of iPSCs differentiation to hepatic stellate cells (diHSCs) and identify RORA as a key transcription factor governing the metabolic reprogramming of HSCs necessary for diHSCs’ commitment, identity, and activation. Using RORA deficient iPSCs and pharmacologic interventions, we show that RORA is required for early differentiation and prevents diHSCs activation by reducing the high energetic state of the cells. While RORA knockout mice have enhanced fibrosis, RORA agonists rescue multi-organ fibrosis in in vivo models. Notably, RORA expression correlates negatively with liver fibrosis and HSCs activation markers in patients with liver disease. This study reveals that RORA regulates cell metabolic plasticity, important for mesoderm differentiation, pericyte quiescence, and fibrosis, influencing cell commitment and disease.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Mapping the Universe Expansion: Enabling Percent-level Measurements of the Hubble Constant with a Single Binary Neutron-star Merger Detection

  • Calderón Bustillo, Juan
  • Leong, Samson H. W.
  • Dietrich, Tim
  • Lasky, Paul D.
The joint observation of the gravitational-wave (GW) and electromagnetic (EM) signal from the binary neutron-star merger GW170817 allowed for a new independent measurement of the Hubble constant H0, albeit with an uncertainty of about 15% at 1σ. Observations of similar sources with a network of future detectors will allow for more precise measurements of H0. These, however, are currently largely limited by the intrinsic degeneracy between the luminosity distance and the inclination of the source in the GW signal. We show that the higher-order modes in gravitational waves can be used to break this degeneracy in astrophysical parameter estimation in both the inspiral and post-merger phases of a neutron star merger. We show that for systems at distances similar to GW170817, this method enables percent-level measurements of H0 with a single detection. This would permit the study of time variations and spatial anisotropies of H0 with unprecedented precision. We investigate how different network configurations affect measurements of H0, and discuss the implications in terms of science drivers for the proposed 2.5- and third-generation GW detectors. Finally, we show that the precision of H0 measured with these future observatories will be solely limited by redshift measurements of EM counterparts.
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Trajectories of antidepressant use and 6-year change in body weight: a prospective population-based cohort study

  • Lassale, Camille
  • Lugon, Gabriela
  • Hernáez, Álvaro
  • Frank, Philipp
  • Marrugat, Jaume
  • Ramos, Rafel
  • Garre-Olmo, Josep
  • Elosua, Roberto
Background: Antidepressant drug treatment may be associated with weight gain, but long-term studies are lacking. Methods: We included 3,127 adults (1,701 women) from the REGICOR study, aged 55.6 (SD = 11.6) years on average in 2003–2006, living in the northeast of Spain. They had data at two time points (baseline and a median of 6.3 years later) on self-reported antidepressant use, body weight and height, and on baseline smoking, physical activity, diet quality, education, civil status, and depressive symptoms assessed with the Patient Health Questionnaire (PHQ-9) at follow-up. We defined four trajectories of antidepressant use as follows: never use, new use at follow-up, initial use discontinued, repeated use at both time points. We used multivariable linear models to estimate the association of these trajectories with the percentage of weight change. In people without obesity at baseline (n = 2,404), we also estimated the association with obesity incidence at follow-up. Results: The average 6-year weight gain was 0.53 kg (1.01% body weight), and 24.5% of the participants gained >5% of body weight. The majority (83.6%) of participants did not report any use of antidepressants, 6.2% initiated during follow-up, 5.1% discontinued it, and 5.1% reported their use at both time points. In multivariable analyses, compared to never users, all trajectories were associated with greater weight gain: +1.78% (0.57, 2.98) for initial use discontinued, +2.08% (0.97, 3.19) for new use at follow-up, and +1.98% (95% CI: 0.75, 3.20) for repeated use. In non-obese participants at baseline (n = 2,404), the odds ratio for becoming obese was 2.06 (1.03, 3.96) for repeated use and non-statistically significant for the other trajectories. Conclusions: In a population-based adult cohort, repeated use of antidepressants was strongly associated with weight gain. New and discontinued use was associated with weight gain, but non-significantly to obesity incidence. Given the global obesity epidemic and the widespread use of antidepressants, weight management and metabolic monitoring should be encouraged and integrated into depression follow-up guidelines alongside antidepressant prescriptions., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

BrainBike peptidomimetic enables efficient transport of proteins across brain endothelium

  • Lucana, Maria C.
  • Lucchi, Roberta
  • Gosselet, Fabien
  • Díaz-Perlas, Cristina
  • Oller-Salvia, Benjamí
Protein therapeutics cannot reach the brain in sufficient amounts because of their low permeability across the blood–brain barrier. Here we report a new family of bicyclic peptide shuttles, BrainBikes, capable of increasing transport of proteins, including antibody derivatives, in a human cell-based model of the blood–brain barrier., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Association between different diet quality scores and depression risk: the REGICOR population-based cohort study

  • Lugon, Gabriela
  • Hernáez, Álvaro
  • Jacka, Felice
  • Marrugat, Jaume
  • Ramos , Rafel
  • Garre-Olmo, Josep
  • Elosua Llanos, Roberto
  • Lassale, Camille
Background Our aim was to determine the association between diet quality and depression incidence in the population-based REGICOR cohort study, Catalonia, Spain. Methods Prospective observational study using participants’ baseline (2003–2006), follow-up (2007–2013) and clinical records data. Five diet quality scores were derived from a food frequency questionnaire (FFQ) at baseline: the relative Mediterranean Diet Score (rMED), the Modified Mediterranean Diet Score (ModMDS), a Dietary Approaches to Stop Hypertension (DASH) score, a Healthful Plant-based Diet Index (HPDI) and the World Health Organization Healthy Diet Indicator (WHO-HDI). Participants using pharmacological antidepressant treatment were excluded as a proxy for presence of depression at baseline. At follow-up, the Patient Health Questionnaire (PHQ-9) was applied to assess depressive symptoms (≥ 10 defining depressive disorder). A secondary outcome was depression diagnosis assessed through clinical records. Logistic regression and Cox proportional hazards models were used. Results Main analysis included 3046 adults (50.3% women) with a mean age of 54.7 (SD = 11.6) years. After 6-years follow-up, 184 (6.04%) cases of depressive disorder were identified. There was 16% lower odds of depressive disorder per 1SD increase of rMED (OR = 0.84; 95%CI = 0.71–0.98). Secondary outcome analysis (n = 4789) identified 261 (5.45%) incident cases of clinical depression diagnosis over 12 years follow-up, and 19% lower risk of clinical depression was observed with the WHO-HDI (HR = 0.81; 95%CI = 0.70–0.93). Adjusting for BMI did not attenuate the findings. Conclusions A significant inverse association between diet quality and depression incidence was found in this population-based cohort study, independent of sociodemographic, health and lifestyle. Adherence to a healthy diet could be a complementary intervention for the prevention of depression., info:eu-repo/semantics/publishedVersion
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Force-dependent elasticity of nucleic acids

  • Luengo Márquez, Juan
  • Juan, Zalvide Pombo
  • Pérez Pérez, Rubén
  • Salvatore, Assenza
The functioning of double-stranded (ds) nucleic acids (NAs) in cellular processes is strongly mediated by their elastic response. These processes involve proteins that interact with dsDNA or dsRNA and distort their structures. The perturbation of the elasticity of NAs arising from these deformations is not properly considered by most theoretical frameworks. In this work, we introduce a novel method to assess the impact of mechanical stress on the elastic response of dsDNA and dsRNA through the analysis of the fluctuations of the double helix. Application of this approach to atomistic simulations reveals qualitative differences in the force dependence of the mechanical properties of dsDNA with respect to those of dsRNA, which we relate to structural features of these molecules by means of physically-sound minimalistic models, The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement no. 847648. The fellowship code is LCF/BQ/PI20/ 11760019. We acknowledge support from the Ministerio de Ciencia e Innovación (MICINN) through the project PID2020-115864RB-I00 and the “María de Maeztu” Programme for Units of Excellence in R&D (grant no. CEX2018-000805-M). We thank Laura R. Arriaga for helpful discussion
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Shape and size tunability of sheets of interlocked ring copolymers

  • Luengo Márquez, Juan
  • Assenza, Salvatore
  • Micheletti, Cristian
Mechanically bonded membranes of interlocked ring polymers are a significant generalization of conventional elastic sheets, where connectivity is provided by covalent bonding, and represent a promising class of topological meta-materials. In this context, two open questions regard the large-scale reverberations of the heterogeneous composition of the rings and the inequivalent modes of interlocking neighboring rings. We address these questions with Langevin dynamics simulations of chainmails with honeycomb-lattice connectivity, where the rings are block copolymers with two segments of different rigidity. We considered various combinations of the relative lengths of the two segments and the patterns of the over- and under-passes linking neighboring rings. We find that varying ring composition and linking patterns have independent and complementary effects. While the former sets the overall size of the chainmail, the latter defines the shape, enabling the selection of starkly different conformation types. Notably, one of the considered linking patterns favors saddle-shaped membranes, providing a first example of spontaneous negative Gaussian curvature in mechanically bonded sheets. The results help establish the extent to which mechanically bonded membranes can differ from conventional elastic ones, particularly for the achievable shape and size tunability, The project that gave rise to these results received the support of a fellowship from the ‘‘la Caixa’’ Foundation (ID 100010434) and from the European Unions Horizon research and innovation programme under Marie Skłodowska Curie grant agreement no. 847648. The fellowship code is LCF/BQ/PI20/11760019. S. A. acknowledges support from a Ramón y Cajal Fellowship (ref. RYC2022-037744-I), funded by MICIU/AEI/10.13039/501100011033 and FSE+. C. M. acknowledges support by the European Union– NextGenerationEU, in the framework of the PRIN Project ‘‘The Physics of Chromosome Folding’’ (code: 2022R8YXMR, CUP: G53D23000820006) and by PNRR Mission 4, Component 2, Investment 1.4_CN_00000013_CN-HPC: National Centre for HPC, Big Data and Quantum Computing– spoke 7 (CUP: G93C22000600001)
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Spontaneous scattering of Raman photons from cavity-QED systems in the ultrastrong coupling regime

  • Macrì, Vincenzo
  • Mercurio, Alberto
  • Nori, Franco
  • Savasta, Salvatore
  • Sánchez Muñoz, Carlos
We show that spontaneous Raman scattering of incident radiation can be observed in cavity-QED systems without external enhancement or coupling to any vibrational degree of freedom. Raman scattering processes can be evidenced as resonances in the emission spectrum, which become clearly visible as the cavity-QED system approaches the ultrastrong coupling regime. We provide a quantum mechanical description of the effect, and show that ultrastrong light-matter coupling is a necessary condition for the observation of Raman scattering. This effect, and its strong sensitivity to the system parameters, opens new avenues for the characterization of cavity QED setups and the generation of quantum states of light, C. S. M. acknowledges that the project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 847648, with fellowship code LCF/BQ/PI20/11760026, and financial support from the Proyecto Sinérgico CAM 2020 Y2020/TCS-6545 (NanoQuCo-CM). F. N. is supported in part by Nippon Telegraph and Telephone Corporation (NTT) Research, the Japan Science and Technology Agency (JST) [via the Quantum Leap Flagship Program (Q-LEAP) program, and the Moonshot R&D Grant No. JPMJMS2061], the Japan Society for the Promotion of Science (JSPS) [via the Grants-in-Aid for Scientific Research (KAKENHI) Grant No. JP20H00134], the Army Research Office (ARO) (Grant No. W911NF-18-1-0358), the Asian Office of Aerospace Research and Development (AOARD) (via Grant No. FA2386-20-1-4069), and the Foundational Questions Institute Fund (FQXi) via Grant No. FQXiIAF19-06. S. S. acknowledges the Army Research Office (ARO) (Grant No. W911NF1910065)
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Quantum metrology of two-photon absorption

Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Language statistical learning responds to reinforcement learning principles rooted in the striatum

  • Orpella, Joan
  • Mas-Herrero, Ernest
  • Ripollés, Pablo
  • Marco Pallarés, Josep
  • Diego Balaguer, Ruth de
Statistical learning (SL) is the ability to extract regularities from the environment. In the domain of language, this ability is fundamental in the learning of words and structural rules. In lack of reliable online measures, statistical word and rule learning have been primarily investigated using offline (post-familiarization) tests, which gives limited insights into the dynamics of SL and its neural basis. Here, we capitalize on a novel task that tracks the online SL of simple syntactic structures combined with computational modeling to show that online SL responds to reinforcement learning principles rooted in striatal function. Specifically, we demonstrate-on 2 different cohorts-that a temporal difference model, which relies on prediction errors, accounts for participants' online learning behavior. We then show that the trial-by-trial development of predictions through learning strongly correlates with activity in both ventral and dorsal striatum. Our results thus provide a detailed mechanistic account of language-related SL and an explanation for the oft-cited implication of the striatum in SL tasks. This work, therefore, bridges the long-standing gap between language learning and reinforcement learning phenomena.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

An ultra-short-period transiting super-Earth orbiting the M3 dwarf TOI-1685

  • Bluhm, P.
  • Amado, Pedro J.
Full list of authors: Bluhm, P.; Pallé, E.; Molaverdikhani, K.; Kemmer, J.; Hatzes, A. P.; Kossakowski, D.; Stock, S.; Caballero, J. A.; Lillo-Box, J.; Béjar, V. J. S.; Soto, M. G.; Amado, P. J.; Brown, P.; Cadieux, C.; Cloutier, R.; Collins, K. A.; Collins, K. I.; Cortés-Contreras, M.; Doyon, R.; Dreizler, S.; Espinoza, N.; Fukui, A.; González-Álvarez, E.; Henning, Th.; Horne, K.; Jeffers, S. V.; Jenkins, J. M.; Jensen, E. L. N.; Kaminski, A.; Kielkopf, J. F.; Kusakabe, N.; Kürster, M.; Lafrenière, D.; Luque, R.; Murgas, F.; Montes, D.; Morales, J. C.; Narita, N.; Passegger, V. M.; Quirrenbach, A.; Schöfer, P.; Reffert, S.; Reiners, A.; Ribas, I.; Ricker, G. R.; Seager, S.; Schweitzer, A.; Schwarz, R. P.; Tamura, M.; Trifonov, T.; Vanderspek, R.; Winn, J.; Zechmeister, M.; Zapatero Osorio, M. R., Dynamical histories of planetary systems, as well as the atmospheric evolution of highly irradiated planets, can be studied by characterizing the ultra-short-period planet population, which the TESS mission is particularly well suited to discover. Here, we report on the follow-up of a transit signal detected in the TESS sector 19 photometric time series of the M3.0 V star TOI-1685 (2MASS J04342248+4302148). We confirm the planetary nature of the transit signal, which has a period of Pb = 0.6691403-0.0000021+0.0000023 d, using precise radial velocity measurements taken with the CARMENES spectrograph. From the joint photometry and radial velocity analysis, we estimate the following parameters for TOI-1685 b: a mass of Mb = 3.78-0.63+0.63 M? , a radius of Rb = 1.70-0.07+0.07 R? , which together result in a bulk density of ρb = 4.21-0.82+0.95 g cm-3, and an equilibrium temperature of Teq = 1069-16+16 K. TOI-1685 b is the least dense ultra-short-period planet around an M dwarf known to date. TOI-1685 b is also one of the hottest transiting super-Earth planets with accurate dynamical mass measurements, which makes it a particularly attractive target for thermal emission spectroscopy. Additionally, we report with moderate evidence an additional non-transiting planet candidate in the system, TOI-1685 [c], which has an orbital period of Pc = 9.02-0.12+0.10 d. © ESO 2021., CARMENES is an instrument at the Centro Astronómico Hispano-Alemán (CAHA) at Calar Alto (Almería, Spain), operated jointly by the Junta de Andalucía and the Instituto de Astrofísica de Andalucía (CSIC). CARMENES was funded by the Max-Planck-Gesellschaft (MPG), the Consejo Superior de Investigaciones Científicas (CSIC), the Ministerio de Economía y Competitividad (MINECO) and the European Regional Development Fund (ERDF) through projects FICTS-2011-02, ICTS-2017-07-CAHA-4, and CAHA16-CE-3978, and the members of the CARMENES Consortium (Max-Planck-Institut für Astronomie, Instituto de Astrofísica de Andalucía, Landessternwarte Königstuhl, Institut de Ciències de l’Espai, Institut für Astrophysik Göttingen, Universidad Complutense de Madrid, Thüringer Landessternwarte Tautenburg, Instituto de Astrofísica de Canarias, Hamburger Sternwarte, Cen tro de Astrobiología and Centro Astronómico Hispano-Alemán), with additional contributions by the MINECO, the Deutsche Forschungsgemeinschaft through the Major Research Instrumentation Programme and Research Unit FOR2544 “Blue Planets around Red Stars”, the Klaus Tschira Stiftung, the states of Baden-Württemberg and Niedersachsen, and by the Junta de Andalucía. We acknowledge financial support from the Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades and the ERDF through projects PID2019-109522GB- C5[1:4]/AEI/10.13039/501100011033, PGC2018-098153-B-C33, and the Centre of Excellence “Severo Ochoa” and “María de Maeztu” awards to the Instituto de Astrofísica de Canarias (SEV-2015-0548), Instituto de Astrofísica de Andalucía (SEV-2017-0709), and Centro de Astro biología (MDM-2017-0737), the Generalitat de Catalunya/CERCA programme,“la Caixa” Foundation (100010434), European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agree ment No. 847 648 (LCF/BQ/PI20/11760023), a University Research Support Grant from the National Astronomical Observatory of Japan, JSPS KAKENHI (JP15H02063, JP18H01265, JP18H05439, JP18H05442, and JP22000005), JST PRESTO (JPMJPR1775), UK Science and Technology Facilities Council (ST/R000824/1), and NASA (NNX17AG24G) This article is based on obser vations made with the MuSCAT2 instrument, developed by ABC, at Telescopio Carlos Sánchez operated on the island of Tenerife by the IAC in the Spanish Observatorio del Teide, with the Observatoire du Mont-Mégantic, financed by Université de Montréal, Université Laval, the National Sciences and Engineer ing Council of Canada, the Fonds québécois de la recherche sur la Nature et les technologies, and the Canada Economic Development program, and with the LCOGT network. LCOGT telescope time was granted by NOIRLab through the Mid-Scale Innovations Program , which is funded by NSF. Funding for the TESS mission is provided by NASA’s Science Mission Directorate. We acknowledge the use of public TESS data from pipelines at the TESS Science Office and at the TESS Science Processing Operations Center. This research has made use of the Exoplanet Follow-up Observation Program website, which is operated by the California Institute of Technology, under contract with the National Aeronau tics and Space Administration under the Exoplanet Exploration Program. This research also made use of AstroImageJ, and TAPIR, and the SIMBAD database, operated at CDS, Strasbourg, France., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The Diversity of Primates: From Biomedicine to Conservation Genomics

  • Orkin, Joseph D.
  • Kuderna, Lukas F. K.
  • Marqués-Bonet, Tomàs
Until now, the field of primate genomics has focused on two major themes: understanding human evolution and advancing biomedical research. We propose that it is now time for a third theme to receive attention: conservation genomics. As a result of anthropogenic effects, the majority of primate species have become threatened with extinction. A more robust primate conservation genomics will allow for genetically informed population management. Thanks to a steady decline in the cost of sequencing, it has now become feasible to sequence whole primate genomes at the population level. Furthermore, technological advances in noninvasive genomic methods have made it possible to acquire genome-scale data from noninvasive biomaterials. Here, we review recent advances in the analysis of primate diversity, with a focus on genomic data sets across the radiation., J.D.O. is supported by the Beatriu de Pinós postdoctoral program of the Government of Catalonia's Secretariat for Universities and Research of the Ministry of Economy and Knowledge. The project that gave rise to these results received the support of a fellowship from La Caixa Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement 847648 to J.D.O. L.F.K.K. is supported by a Formación de Personal Investigador fellowship associated to BFU2014-55090-P (MINECO/FEDER, UE) and by a European Molecular Biology Organization short-term fellowship STF-8286. T.M.-B. is supported by funding from the European Research Council under the European Union's Horizon 2020 research and innovation program (grant agreement 864203); BFU2017-86471-P (MINECO/FEDER, UE); Unidad de Excelencia María de Maeztu, funded by the Agencia Estatal de Investigacíon (CEX2018-000792-M); Howard Hughes International Early Career Award; and Obra Social La Caixa and Secretaria d'Universitats i Recerca and CERCA Program del Departament d'Economia i Coneixement de la Generalitat de Catalunya (GRC 2017 SGR 880)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2018-000792-M).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Supramolecular systems chemistry through advanced analytical techniques

  • Jain, Ankit
  • Calò, Annalisa
  • Barceló, Damià
  • Kumar, Mohit
Supramolecular chemistry is the quintessential backbone of all biological processes. It encompasses a wide range from the metabolic network to the self-assembled cytoskeletal network. Combining the chemical diversity with the plethora of functional depth that biological systems possess is a daunting task for synthetic chemists to emulate. The only route for approaching such a challenge lies in understanding the complex and dynamic systems through advanced analytical techniques. The supramolecular complexity that can be successfully generated and analyzed is directly dependent on the analytical treatment of the system parameters. In this review, we illustrate advanced analytical techniques that have been used to investigate various supramolecular systems including complex mixtures, dynamic self-assembly, and functional nanomaterials. The underlying theme of such an overview is not only the exceeding detail with which traditional experiments can be probed but also the fact that complex experiments can now be attempted owing to the analytical techniques that can resolve an ensemble in astounding detail. Furthermore, the review critically analyzes the current state of the art analytical techniques and suggests the direction of future development. Finally, we envision that integrating multiple analytical methods into a common platform will open completely new possibilities for developing functional chemical systems., This project was funded by a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648. The fellowship code is “LCF/BQ/PI21/11830035.” AC received the Ajut a la Recerca Transversal project from IN2UB (ART2020)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Wounding response in Porifera (sponges) activates ancestral signaling cascades involved in animal healing, regeneration, and cancer

  • Wu, Yu-Chen
  • Franzenburg, Sören
  • Ribes, Marta
  • Pita, Lucía
13 pages, 5 figures, supplementary information https://doi.org/10.1038/s41598-022-05230-x.-- This is a contribution from the Marine Biogeochemistry and Global Change group from the Generalitat de Catalunya (2017SGR1011), Upon injury, the homeostatic balance that ensures tissue function is disrupted. Wound-induced signaling triggers the recovery of tissue integrity and offers a context to understand the molecular mechanisms for restoring tissue homeostasis upon disturbances. Marine sessile animals are particularly vulnerable to chronic wounds caused by grazers that can compromise prey’s health. Yet, in comparison to other stressors like warming or acidification, we know little on how marine animals respond to grazing. Marine sponges (Phylum Porifera) are among the earliest-diverging animals and play key roles in the ecosystem; but they remain largely understudied. Here, we investigated the transcriptomic responses to injury caused by a specialist spongivorous opisthobranch (i.e., grazing treatment) or by clipping with a scalpel (i.e., mechanical damage treatment), in comparison to control sponges. We collected samples 3 h, 1 d, and 6 d post-treatment for differential gene expression analysis on RNA-seq data. Both grazing and mechanical damage activated a similar transcriptomic response, including a clotting-like cascade (e.g., with genes annotated as transglutaminases, metalloproteases, and integrins), calcium signaling, and Wnt and mitogen-activated protein kinase signaling pathways. Wound-induced gene expression signature in sponges resembles the initial steps of whole-body regeneration in other animals. Also, the set of genes responding to wounding in sponges included putative orthologs of cancer-related human genes. Further insights can be gained from taking sponge wound healing as an experimental system to understand how ancient genes and regulatory networks determine healthy animal tissues, Open Access funding enabled and organized by Projekt DEAL. LP was awarded a postdoctoral fellowship from Alexander von Humboldt Foundation, which was sponsored by The Future Ocean Cluster of Excellence. LP is currently at the Institute of Marine Science (ICM-CSIC) thanks to a fellowship supported by “la Caixa” Foundation (ID 10010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie gran agreement No 847648), fellowship code is 104855. Financial support was provided by the Spanish Government through the Grant (RTI2018-094187-B-100) and the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000928-S) to MR, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

An episodically variable stellar wind in the planetary nebula IC 4997

  • Miranda, Luis F.
  • Torrelles, José M.
  • Lillo-Box, Jorge
IC 4997 is a planetary nebula well known by its variability. We present high-resolution spectra of IC 4997 obtained in 1993, 2019, and 2020 that reveal changes in the Hα and [N » II] emission line profiles, which had never been reported for this object. The Hα P Cygni emission profile observed in 1993 changed to a single-peaked profile in 2019-2020, implying that the stellar wind has largely weakened. The very broad Hα emission wings narrowed by a factor of ∼2 between 1993 and 2019-2020, indicating that the efficiency of the Rayleigh-Raman scattering has noticeably decreased. A high-velocity [N » II] nebular component detected in 1993 is missing in 2019 and 2020, probably due to a decrease in its electron density. A correlation exists between the strength of the stellar wind and the episodic (∼50-60 yr) variation in the [O » III]λ4363/Hγ line intensity ratio, suggesting that an episodic, smoothly variable stellar wind is the main cause of the variability of IC 4997. Monitoring of that intensity ratio and of the Hα emission line profile in the coming years and new multiwavelength observations are key to unveiling the ongoing processes in IC 4997 and constraining the origin of the wind variability. © ESO 2022., We thank Calar Alto Observatory for allocation of director’s discretionary time to this programme. LFM is partially supported by MCIU grant AYA2017-84390-C2-1-R (co-funded by FEDER) and PID2020-114461GB-I00 of AEI (10.13039/501100011033), and acknowledges financial support from the State Agency for Research of the Spanish MCIU through the “Center of Excellence Severo Ochoa” award for the Instituto de Astrofísica de Andalucía (SEV-2017-0709). J.M.T. acknowledges partial support from the PID2020-117710GB-I00 grant funded by MCIN/AEI/10.13039/501100011033. J.L.-B. acknowledges financial support received from “la Caixa” Foundation (ID 100010434) and from the European Unions Horizon 2020 research and innovation programme under the Marie Slodowska-Curie grant agreement No 847648, with fellowship code LCF/BQ/PI20/11760023. This research has also been partly funded by the Spanish State Research Agency (AEI) Projects No.ESP2017-87676-C5-1-R and No. MDM-2017-0737 Unidad de Excelencia “María de Maeztu”- Centro de Astrobiología (INTA-CSIC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Discovery and mass measurement of the hot, transiting, Earth-sized planet, GJ 3929 b

  • Kemmer, J.
  • Caballero, J. A.
  • Amado, Pedro J.
  • Herrero, Enrique
  • Lillo-Box, Jorge
  • Ribas, Ignasi
  • Rodríguez Martínez, Eloy
  • Aceituno, Francisco José
  • Cifuentes, C.
  • Cortés-Contreras, M.
  • López González, Maria J.
  • Lafarga, M.
  • Luque, Rafael
  • Morales, Juan Carlos
  • Sota Ballano, Alfredo
  • Zechmeister, Mathias
Full list of authors: Kemmer, J.; Dreizler, S.; Kossakowski, D.; Stock, S.; Quirrenbach, A.; Caballero, J. A.; Amado, P. J.; Collins, K. A.; Espinoza, N.; Herrero, E.; Jenkins, J. M.; Latham, D. W.; Lillo-Box, J.; Narita, N.; Pallé, E.; Reiners, A.; Ribas, I.; Ricker, G.; Rodríguez, E.; Seager, S.; Vanderspek, R.; Wells, R.; Winn, J.; Aceituno, F. J.; Béjar, V. J. S.; Barclay, T.; Bluhm, P.; Chaturvedi, P.; Cifuentes, C.; Collins, K. I.; Cortés-Contreras, M.; Demory, B. -O.; Fausnaugh, M. M.; Fukui, A.; Gómez Maqueo Chew, Y.; Galadí-Enríquez, D.; Gan, T.; Gillon, M.; Golovin, A.; Hatzes, A. P.; Henning, Th.; Huang, C.; Jeffers, S. V.; Kaminski, A.; Kunimoto, M.; Kürster, M.; López-González, M. J.; Lafarga, M.; Luque, R.; McCormac, J.; Molaverdikhani, K.; Montes, D.; Morales, J. C.; Passegger, V. M.; Reffert, S.; Sabin, L.; Schöfer, P.; Schanche, N.; Schlecker, M.; Schroffenegger, U.; Schwarz, R. P.; Schweitzer, A.; Sota, A.; Tenenbaum, P.; Trifonov, T.; Vanaverbeke, S.; Zechmeister, M., We report the discovery of GJ 3929 b, a hot Earth-sized planet orbiting the nearby M3.5 V dwarf star, GJ 3929 (G 180-18, TOI-2013). Joint modelling of photometric observations from TESS sectors 24 and 25 together with 73 spectroscopic observations from CARMENES and follow-up transit observations from SAINT-EX, LCOGT, and OSN yields a planet radius of Rb = 1.150 ± 0.040 R⊕, a mass of Mb = 1.21 ± 0.42 M⊕, and an orbital period of Pb = 2.6162745 ± 0.0000030 d. The resulting density of ρb = 4.4 ± 1.6 g cm−3 is compatible with the Earth’s mean density of about 5.5 g cm−3. Due to the apparent brightness of the host star (J = 8.7 mag) and its small size, GJ 3929 b is a promising target for atmospheric characterisation with the JWST. Additionally, the radial velocity data show evidence for another planet candidate with P[c] = 14.303 ± 0.035 d, which is likely unrelated to the stellar rotation period, Prot = 122 ± 13 d, which we determined from archival HATNet and ASAS-SN photometry combined with newly obtained TJO data. © ESO 2022., This paper is based on observations made with the MuSCAT3 instrument, developed by the Astrobiology Center and under financial supports by JSPS KAKENHI (JP18H05439) and JST PRESTO (JPMJPR1775), at Faulkes Telescope North on Maui, HI, operated by the Las Cumbres Observatory. This work includes observationscarried out at the Observatorio Astronómico Nacional on the Sierra de San Pedro Mártir (OAN-SPM), Baja California, México. We acknowledge financial support from the Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades and the ERDF through projects PID2019-109522GB-C5[1:4], PID2019-107061GB-C64, PID2019-110689RB-100, ESP2017-87676-C5-1-R, and the Centre of Excellence “Severo Ochoa” and “María de Maeztu” awards to the Instituto de Astrofísica de Canarias (CEX2019-000920-S), Instituto de Astrofísica de Andalucía (SEV-2017-0709), and Centro de Astrobiología (MDM-2017-0737), the Swiss National Science Foundation (PP00P2-163967 and PP00P2-190080), the Centre for Space and Habitability of the University of Bern, the National Centre for Competence in Research PlanetS, supported by the Swiss National Science Foundation, the Deutsche Forschungsgemeinschaft priority program SPP 1992 “Exploring the Diversity of Extrasolar Planets” (JE 701/5-1), the Excellence Cluster ORIGINS, which is funded by the Deutsche Forschungsgemeinschaft under Germany’s Excellence Strategy (EXC-2094 – 390783311), NASA (NNX17AG24G), JSPS KAKENHI Grant Number JP18H05439, JST CREST Grant Number JPMJCR1761, the Astrobiology Center of National Institutes of Natural Sciences (NINS) (Grant Number AB031010), the UNAM-DGAPA PAPIIT (BG-101321), the “la Caixa” Foundation (100010434), the European Union Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie (No. 847648, fellowship code LCF/BQ/PI20/11760023), and the Generalitat de Catalunya/CERCA programme. Data were partly collected with the 90-cm telescope at Observatorio de Sierra Nevada (OSN), operated by the Instituto de Astrofísica de Andalucí a (IAA, CSIC). We deeply acknowledge the OSN telescope operators for their very appreciable support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A high-quality, long-read genome assembly of the endangered ring-tailed lemur (Lemur catta)

  • Palmada-Flores, Marc
  • Orkin, Joseph D.
  • Haase, Bettina
  • Mountcastle, Jacquelyn
  • Bertelsen, Mads F.
  • Fedrigo, Olivier
  • Kuderna, Lukas F. K.
  • Jarvis, Erich D.
  • Marqués-Bonet, Tomàs
Background: The ring-tailed lemur (Lemur catta) is a charismatic strepsirrhine primate endemic to Madagascar. These lemurs are of particular interest, given their status as a flagship species and widespread publicity in the popular media. Unfortunately, a recent population decline has resulted in the census population decreasing to <2,500 individuals in the wild, and the species's classification as an endangered species by the IUCN. As is the case for most strepsirrhine primates, only a limited amount of genomic research has been conducted on L. catta, in part owing to the lack of genomic resources. Results: We generated a new high-quality reference genome assembly for L. catta (mLemCat1) that conforms to the standards of the Vertebrate Genomes Project. This new long-read assembly is composed of Pacific Biosciences continuous long reads (CLR data), Optical Mapping Bionano reads, Arima HiC data, and 10X linked reads. The contiguity and completeness of the assembly are extremely high, with scaffold and contig N50 values of 90.982 and 10.570 Mb, respectively. Additionally, when compared to other high-quality primate assemblies, L. catta has the lowest reported number of Alu elements, which results predominantly from a lack of AluS and AluY elements. Conclusions: mLemCat1 is an excellent genomic resource not only for the ring-tailed lemur community, but also for other members of the Lemuridae family, and is the first very long read assembly for a strepsirrhine., The project that gave rise to these results received the support of 2 fellowships from "la Caixa" Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 847648. The fellowship codes are LCF/BQ/PI20/11760004 and LCF/BQ/DR20/11790032. T.M.B. is supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. 864203), BFU2017-86471-P (MINECO/FEDER, UE), “Unidad de Excelencia María de Maeztu,” funded by the AEI (CEX2018-000792-M), Howard Hughes International Early Career, NIH 1R01HG010898-01A1, and Secretaria d'Universitats i Recerca and CERCA Programme del Departament d'Economia i Coneixement de la Generalitat de Catalunya (GRC 2017 SGR 880)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Phase Diagram of 1+1 D Abelian-Higgs Model and Its Critical Point

  • Chanda, Titas
  • Lewenstein, Maciej
  • Zakrzewski, Jakub
  • Tagliacozzo, Luca
6 pags., 3 figs., We determine the phase diagram of the Abelian-Higgs model in one spatial dimension and time (1+1D) on a lattice. We identify a line of first order phase transitions separating the Higgs region from the confined one. This line terminates in a quantum critical point above which the two regions are connected by a smooth crossover. We analyze the critical point and find compelling evidence for its description as the product of two noninteracting systems: a massless free fermion and a massless free boson. However, we find also some surprising results that cannot be explained by our simple picture, suggesting this newly discovered critical point is an unusual one., The numerical computations have been possible thanks to PL-Grid Infrastructure. The works of T. C. and J. Z have been realized within the QuantERA grant QTFLAG, financed by National Science Centre (Poland) via Grant 2017/25/Z/ST2/03029. M. L. acknowledges support from ERC AdG NOQIA; Agencia Estatal de Investigacion (R&D project CEX2019-000910-S, funded by MCIN/ AEI/10.13039/501100011033, Plan National FIDEUA PID2019-106901GB-I00, FPI, QUANTERA MAQS PCI2019-111828-2, Proyectos de I+D+I “Retos Colaboracion” RTC2019-007196-7); Fundacio Cellex; Fundacio Mir-Puig; Generalitat de Catalunya through the CERCA program, AGAUR Grant No. 2017 SGR 134, QuantumCAT U16-011424, co-funded by ERDF Operational Program of Catalonia 2014-2020; EU Horizon 2020 FET-OPEN OPTOLogic (Grant No 899794); National Science Centre, Poland (Symfonia Grant No. 2016/20/W/ST4/00314); Marie SkłodowskaCurie grant STREDCH No. 101029393; “La Caixa” Junior Leaders fellowships (ID100010434) and EU Horizon 2020 under Marie Skłodowska-Curie grant agreement No. 847648 (LCF/BQ/PI19/11690013, LCF/BQ/ PI20/11760031, LCF/BQ/PR20/11770012, LCF/BQ/ PR21/11840013). L. T. acknowledges support from the Ramón y Cajal program RYC-2016-20594, the “Plan Nacional Generación de Conocimiento” PGC2018- 095862-B-C22, the State Agency for Research of the Spanish Ministry of Science and Innovation through the “Unit of Excellence María de Maeztu 2020-2023” award to the Institute of Cosmos Sciences (CEX2019-000918-M), and the European Union Regional Development Fund within the ERDF Operational Program of Catalunya, Spain (project QUASICAT/QuantumCat, ref. 001-P001644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

OCCASO, IV. Radial velocities and open cluster kinematics

  • Carrera, Ricardo
  • Casamiquela, Laia
  • Carbajo-Hijarrubia, J.
  • Balaguer-Nuñez, Lola
  • Jordi, Carme
  • Romero-Gómez, Mercè
  • Blanco-Cuaresma, S.
  • Cantat-Gaudin, Tristan
  • Lillo-Box, Jorge
  • Masana, Eduard
  • Pancino, E.
[Context] Open clusters (OCs) are widely used as test particles to investigate a variety of astrophysical phenomena, from stellar evolution to Galactic evolution. Gaia and the complementary massive spectroscopic surveys are providing an unprecedented wealth of information about these systems. [Aims] The Open Cluster Chemical Abundances from Spanish Observatories (OCCASO) survey aims to complement all this work by determining OCs' accurate radial velocities and chemical abundances from high-resolution, R ≥ 60 000, spectra. [Methods] Radial velocities were obtained by cross-correlating the observed spectra with a library of synthetic spectra that covers early M to A spectral types. [Results] We provide radial velocities for 336 stars including several Gaia benchmark stars and objects belonging to 51 open clusters. The internal uncertainties of the derived radial velocities go from 10ms-1 to 21ms-1 as a function of the instrumental configuration used. The derived radial velocities, together with the Gaia proper motions, were used to investigate the cluster membership of the observed stars. After this careful membership analysis, we obtained average velocities for 47 open clusters. To our knowledge, this is the first radial velocity determination for five of these clusters. Finally, the radial velocities, proper motions, distances and ages were used to investigate the kinematics of the observed clusters and in the integration of their orbits., This work was partially supported by the Spanish Ministry of Science, Innovation and University (MICIU/FEDER, UE) through grant RTI2018-095076-B-C21, and the Institute of Cosmos Sciences University of Barcelona (ICCUB, Unidad de Excelencia ‘María de Maeztu’) through grant CEX2019-000918-M. J.L.-B. acknowledges financial support received from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648, with fellowship code LCF/BQ/PI20/11760023. This research has also been partly funded by the Spanish State Research Agency (AEI) Projects No. ESP2017-87676-C5-1-R and No. MDM-2017-0737 Unidad de Excelencia “María de Maeztu”- Centro de Astrobiología (INTA-CSIC).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

High-harmonic spectroscopy of quantum phase transitions in a high-Tc superconductor

  • Alcalà, Jordi
  • Bhattacharya, Utso
  • Biegert, Jens
  • Ciappina, Marcelo
  • Elu, Ugaitz
  • Grass, Tobias
  • Grochowski, Piotr T.
  • Lewenstein, Maciej
  • Palau, Anna
  • Sidiropoulos, Themistoklis P. H.
  • Steinle, Tobias
  • Tyulnev, Igor
We report on the nonlinear optical signatures of quantum phase transitions in the high-temperature superconductor YBCO, observed through high harmonic generation. While the linear optical response of the material is largely unchanged when cooling across the phase transitions, the nonlinear optical response sensitively imprints two critical points, one at the critical temperature of the cuprate with the exponential growth of the surface harmonic yield in the superconducting phase and another critical point, which marks the transition from strange metal to pseudogap phase. To reveal the underlying microscopic quantum dynamics, a strong-field quasi-Hubbard model was developed, which describes the measured optical response dependent on the formation of Cooper pairs. Further, the theory provides insight into the carrier scattering dynamics and allows us to differentiate between the superconducting, pseudogap, and strange metal phases. The direct connection between nonlinear optical response and microscopic dynamics provides a powerful methodology to study quantum phase transitions in correlated materials. Further implications are light wave control over intricate quantum phases, light-matter hybrids, and application for optical quantum computing., We thank V. Kunets from MMR Technologies and X. Menino at Institut de Ciencies Fotoniques for technical support and Dr. K. Dewhurst and Dr. S. Sharma for help with the ELK code. J.B., U.E., T.P.H.S., T.S., and I.T. acknowledge financial support from the European Research Council (ERC) for ERC Advanced Grant “TRANSFORMER” (grant 788218) and ERC Proof of Concept Grant “miniX” (grant 840010). J.B. and group acknowledge support from FET -OPEN “PETACom” (grant 829153), FET-OPEN “OPTOlogic” (grant 899794), EIC-2021-PATHFINDEROPEN “TwistedNano” (grant 101046424), Laserlab-Europe (grant 654148), Marie Sklodowska-Curie ITN “smart-X” (grant 860553), Plan Nacional PID-PID2020-112664GB-I00-210901, AGAUR for 2017 SGR 1639, “Severo Ochoa” (grant SEV-2015-0522), Fundació Cellex Barcelona, the CERCA Programme/Generalitat de Catalunya, and the Alexander von Humboldt Foundation for the Friedrich Wilhelm Bessel Prize. U.B., T.G., P.T.G., and M.L. acknowledge funding from the ERC for ERC Advanced Grant NOQIA; Agencia Estatal de Investigación (R&D project CEX2019-000910-S, funded by MCIN/AEI/10.13039/501100011033, Plan National FIDEUA PID2019-106901GB-I00, FPI, QUANTERA MAQS PCI2019-111828-2, Proyectos de I+D+I “Retos Colaboración” RTC2019-007196-7); Fundació Cellex; Fundació Mir-Puig; Generalitat de Catalunya through the CERCA program; AGAUR grant 2017 SGR 134; QuantumCAT U16-011424, cofunded by ERDF Operational Program of Catalonia grant 2014-2020; EU Horizon 2020 FET-OPEN OPTOLogic (grant 899794); National Science Centre, Poland (Symfonia grant 2016/20/W/ST4/00314); Marie Skłodowska-Curie grant STREDCH 101029393; “La Caixa” Junior Leaders fellowships (ID100010434); and EU Horizon 2020 under Marie Skłodowska-Curie grant agreement 847648 (LCF/BQ/PI19/11690013, LCF/BQ/PI20/11760031, LCF/BQ/PR20/11770012, and LCF/BQ/PR21/11840013). P.T.G. acknowledges the Polish National Science Center grants 2018/31/N/ST2/01429 and 2020/36/T/ST2/00065 and is supported by the Foundation for Polish Science. Center for Theoretical Physics of the Polish Academy of Sciences is a member of the National Laboratory of Atomic, Molecular and Optical Physics. A.P. and J.A. acknowledge support from the Spanish Ministry of Economy and Competitiveness through the “Severo Ochoa” Programme for Centres of Excellence in R&D (grant SEV-2015-0496), SuMaTe project (RTI2018-095853-B-C21) cofinanced by the European Regional Development Fund, and the Catalan Government grant 2017-SGR-1519. This work was supported by EU COST action NANOCOHYBRI CA16218. M.C. acknowledges financial support from the Guangdong Province Science and Technology Major Project (Future functional materials under extreme conditions - 2021B0301030005)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Distribution and export of particulate organic carbon in East Antarctic coastal polynyas

  • Ratnarajah, Lavenia
  • Puigcorbé, Viena
  • Moreau, Sebastien
  • Roca-Martí, Montserrat
  • Janssens, Julie
  • Corkill, Matthew
  • Duprat, Luis
  • Genovese, Cristina
  • Lieser, Jan
  • Masqué, Pere
  • Lannuzel, Delphine
14 pages, 11 figures, 2 tables, supplementary data https://doi.org/10.1016/j.dsr.2022.103899.-- Data availability: Data presented in this study can be sourced from https://metadata.imas.utas.edu.au/geonetwork/srv/eng/metadata.show?uuid=02364e10-ebc0-463a-b690-2c4ed643733c, Polynyas represent regions of enhanced primary production because of the low, or absent, sea-ice cover coupled with the proximity of nutrient sources. However, studies throughout the Southern Ocean suggest elevated primary production does not necessarily result in increased carbon export. Three coastal polynyas in East Antarctica and an off-shelf region were visited during the austral summer from December 2016 to January 2017 to examine the vertical distribution and concentration of particulate organic carbon (POC). Carbon export was also examined using thorium-234 (234Th) as a proxy at two of the polynyas. Our results show that concentrations and integrated POC stocks were higher within the polynyas compared to the off-shelf sites. Within the polynyas, vertical POC concentrations were higher in the Mertz and Ninnis polynyas compared to the Dalton polynya. Similarly, higher carbon export was measured in the diatom-dominated Mertz polynya, where large particles (>53 μm) represented a significant fraction of the particulate 234Th and POC (average 50% and 39%, respectively), compared to the small flagellate-dominated Dalton polynya, where almost all the particulate 234Th and POC were found in the smaller size fraction (1–53 μm). The POC to Chlorophyll-a ratios suggest that organic matter below the mixed layer in the polynyas consisted largely of fresh phytoplankton at this time of the year. In combination with a parallel study on phytoplankton production at these sites, we find that increased primary production at these polynyas does lead to greater concentrations and export of POC and a higher POC export efficiency, This study was supported by the Australian Government's Cooperative Research Centres through the Antarctic Climate and Ecosystem Cooperative Research Centre, the Australian Antarctic Division research projects AAS 4131 and 4291, and the Institute for Marine and Antarctic Studies, University of Tasmania. L. Ratnarajah also received support from BYONIC (ERC award number 724289). D. Lannuzel was supported by an Australian Research Council Future Fellowship (Project ID L0026677). S. Moreau and C. Genovese were supported by the Australian Research Council's Special Research Initiative for Antarctic Gateway Partnership (Project ID SR140300001). V. Puigcorbé was supported by Edith Cowan University through an Early Career Researcher Grant (G1003456) and an ECU-Collaboration Enhancement Scheme grant (G1003362). V. Puigcorbé received the support of a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code 105183). M. Roca-Martí was supported by funding from the Woods Hole Oceanographic Institution's Ocean Twilight Zone study and the Ocean Frontier Institute. [...] This work acknowledges the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000928-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Unconventional mechanism of virtual-state population through dissipation

  • Vivas-Viaña, A.
  • González-Tudela, A.
  • Sánchez-Muñoz, C.
11 pags., 6 figs., 3 apps., Virtual states are a central concept in quantum mechanics. By definition, the probability of finding a quantum system in a virtual state should be vanishingly small at all times. In contrast to this notion, we report a phenomenon occurring in open quantum systems by which virtual states can acquire a sizable population in the long-time limit, even if they are not directly coupled to any dissipative channel. This means that the situation in which the virtual state remains unpopulated can be metastable. We describe this effect by introducing a two-step adiabatic elimination method, which we termed hierarchical adiabatic elimination, that allows one to obtain analytical expressions of the timescale of metastability in general open quantum systems. We show how these results can be relevant for practical questions such as the generation of stable and metastable entangled states in dissipative systems of interacting qubits., C.S.M. acknowledges that the project that gave rise to these results received the support of a fellowship from la Caixa Foundation (ID 100010434), from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie Grant Agreement No. 847648, with fellowship code LCF/BQ/PI20/11760026. A.G.T. acknowledges support from CSIC Research Platform on Quantum Technologies PTI-001 and from Spanish project PGC2018-094792-B-100(MCIU/AEI/FEDER, EU). All authors acknowledge financial support from Proyecto Sinérgico CAM 2020 Y2020/TCS-6545 (NanoQuCo-CM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Stability of a dominant sponge-symbiont in spite of antibiotic-induced microbiome disturbance

  • Schmittmann, Lara
  • Rahn, Tanja
  • Busch, Kathrin
  • Fraune, Sebastian
  • Pita, Lucía
  • Hentschel, Ute
19 pages, 4 figures, 1 table, supporting information https://doi.org/10.1111/1462-2920.16249.-- Data Availability Statement: All 16 S rRNA gene amplicon reads and the sample metadata and attributes are available in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA): PRJNA786895; BioSample accessions: SAMN23732322- SAMN23732615, Marine sponges are known for their complex and stable microbiomes. However, the lack of a gnotobiotic sponge-model and experimental methods to manipulate both the host and the microbial symbionts currently limit our mechanistic understanding of sponge-microbial symbioses. We have used the North Atlantic sponge species Halichondria panicea to evaluate the use of antibiotics to generate gnotobiotic sponges. We further asked whether the microbiome can be reestablished via recolonization with the natural microbiome. Experiments were performed in marine gnotobiotic facilities equipped with a custom-made, sterile, flow-through aquarium system. Bacterial abundance dynamics were monitored qualitatively and quantitatively by 16 S rRNA gene amplicon sequencing and qPCR, respectively. Antibiotics induced dysbiosis by favouring an increase of opportunistic, antibiotic-resistant bacteria, resulting in more complex, but less specific bacteria-bacteria interactions than in untreated sponges. The abundance of the dominant symbiont, Candidatus Halichondribacter symbioticus, remained overall unchanged, reflecting its obligately symbiotic nature. Recolonization with the natural microbiome could not reverse antibiotic-induced dysbiosis. However, single bacterial taxa that were transferred, successfully recolonized the sponge and affected bacteria-bacteria interactions. By experimentally manipulating microbiome composition, we could show the stability of a sponge-symbiont clade despite microbiome dysbiosis. This study contributes to understanding both host-bacteria and bacteria-bacteria interactions in the sponge holobiont, This project is supported by funding of the DFG (“Origin and Function of Metaorganisms”, CRC1182-TP B01) and the Gordon and Betty Moore Foundation (“Symbiosis in Aquatic Systems Initiative”, GBMF9352) to UH. LS is further supported by the International Max Planck Research School for Evolutionary Biology, and LP receives funding by the DFG (‘IMMUBASE’, 417,981,041) and is currently supported by ‘la Caixa’ Foundation (ID 10010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grand agreement No 847648, fellowship code is 104855, With the institutional support of the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000928-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Diazotrophs are overlooked contributors to carbon and nitrogen export to the deep ocean

  • Bonnet, Sophie
  • Benavides, Mar
  • Le Moigne, Frédéric
  • Camps, Mercedes
  • Torremocha, Antoine
  • Grosso, Olivier
  • Dimier, Céline
  • Spungin, Dina
  • Berman-Frank, Ilana
  • Garczarek, Laurence
  • Cornejo-Castillo, Francisco M.
12 pages, 6 figures, supplementary information https://doi.org/10.1038/s41396-022-01319-3.-- Data availability: Data are available in the main text or the supplementary materials. Sequences have been deposited to NCBI with accession numbers SAMN24579080-SAMN24579145, Diazotrophs are widespread microorganisms that alleviate nitrogen limitation in 60% of our oceans, thereby regulating marine productivity. Yet, the group-specific contribution of diazotrophs to organic matter export has not been quantified, which so far has impeded an accurate assessment of their impact on the biological carbon pump. Here, we examine the fate of five groups of globally-distributed diazotrophs by using an original combination of mesopelagic particle sampling devices across the subtropical South Pacific Ocean. We demonstrate that cyanobacterial and non-cyanobacterial diazotrophs are exported down to 1000 m depth. Surprisingly, group-specific export turnover rates point to a more efficient export of small unicellular cyanobacterial diazotrophs (UCYN) relative to the larger and filamentous Trichodesmium. Phycoerythrin-containing UCYN-B and UCYN-C-like cells were recurrently found embedded in large (>50 µm) organic aggregates or organized into clusters of tens to hundreds of cells linked by an extracellular matrix, presumably facilitating their export. Beyond the South Pacific, our data are supported by analysis of the Tara Oceans metagenomes collected in other ocean basins, extending the scope of our results globally. We show that, when diazotrophs are found in the euphotic zone, they are also systematically present in mesopelagic waters, suggesting their transport to the deep ocean. We thus conclude that diazotrophs are a significant part of the carbon sequestered in the deep ocean and, therefore, they need to be accounted in regional and global estimates of export, This research is a contribution of the TONGA project (Shallow hydroThermal sOurces of trace elemeNts: potential impacts on biological productivity and the bioloGicAl carbon pump; TONGA cruise https://doi.org/10.17600/18000884) funded by the Agence Nationale de la Recherche (grant TONGA ANR-18- CE01-0016 and grant CINNAMON ANR-17-CE2-0014-01), the LEFE-CyBER program (CNRS-INSU), the A-Midex foundation, the Institut de Recherche pour le Développement (IRD). FMCC and LG acknowledge funding from the European Union’s Horizon 2020 research programme under the Marie Sklodowska-Curie grant agreement No. 749380 (UCYN2PLAST). FMCC has also received the support of a fellowship (grant no. 105090) from”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648”, and acknowledges funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000928-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Histone post-translational modifications — cause and consequence of genome function

  • Millán-Zambrano, Gonzalo
  • Burton, Adam
  • Bannister, Andrew J.
  • Schneider, Robert
Much has been learned since the early 1960s about histone post-translational modifications (PTMs) and how they affect DNA-templated processes at the molecular level. This understanding has been bolstered in the past decade by the identification of new types of histone PTM, the advent of new genome-wide mapping approaches and methods to deposit or remove PTMs in a locally and temporally controlled manner. Now, with the availability of vast amounts of data across various biological systems, the functional role of PTMs in important processes (such as transcription, recombination, replication, DNA repair and the modulation of genomic architecture) is slowly emerging. This Review explores the contribution of histone PTMs to the regulation of genome function by discussing when these modifications play a causative (or instructive) role in DNA-templated processes and when they are deposited as a consequence of such processes, to reinforce and record the event. Important advances in the field showing that histone PTMs can exert both direct and indirect effects on genome function are also presented., The R.S. laboratory is supported by the German Research Foundation (DFG) through SFB 1064 (Project-ID 213249687) and SFB 1309 (Project-ID 325871075), as well as the Helmholtz Gesellschaft. A.J.B is supported by grants from Cancer Research UK (RG96894 and C6946/A24843) and the Wellcome Trust (WT203144). G.M.-Z. is supported by a Juan de la Cierva postdoctoral contract (IJC2019-039988) from the Spanish Ministry of Science and Innovation and a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement No. 847648. The fellowship code is LCF/BQ/PR21/11840007. A.B. is supported by the DFG through SFB 1064 (Project-ID 213249687) as well as the Helmholtz Gesellschaft. The authors apologize to colleagues whose important studies they were unable to cite owing to space constraints.